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Most  theories  concerning  the  primary  cause  of  Crohn’s  disease  focus  on  over­
activation of the  immune response.  Paradoxically,  the defect may  instead relate  to 
diminished acute  inflammation.  Neutrophil  accumulation to sites of dermal  trauma 
has been shown to be  reduced.  Were the  same phenomenon to occur in the  gut,  it 
might impair bacterial clearance thus provoking granuloma formation.
In  this  thesis,  a  novel  technique  demonstrated  attenuated  neutrophil 
accumulation  following  trauma  to  the  bowel.  A  modified  skin  window  technique 
linked  this  failure  of migration  to  defective  IL-8  production.  Polymorphisms  in 
CARDI5,  associated  with  susceptibility  to  Crohn’s  disease,  compounded  the 
problem by abrogating the normal pro-inflammatory action of the protein but did not 
underlie  the  basic  phenotype.  Consequently,  the  response  of macrophages  to  other 
inflammatory agonists was examined. IL-8 production was also impaired in Crohn’s 
disease after stimulation with wound fluid, C5a or TNF-a.
The response of Crohn’s patients to gut bacteria was assessed directly in vivo 
by subcutaneous  injection of killed Escherichia coli.  This elicited substantial  local 
inflammation  in  controls,  manifested  by  an  NO-mediated  increase  in  blood  flow. 
The  response  was  considerably  lower  in  Crohn’s  patients,  particular  those  with 
colonic  disease.  In  contrast,  acute  phase  reactants  were  highest  in  the  latter, 
supporting the hypothesis that an impaired local response can drive a systemic pro- 
inflammatory state.
The demonstration of attenuated acute inflammation in Crohn’s disease may 
have  important  implications  for understanding  its pathogenesis and targeting novel 
therapies.Contents
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13Chapter 1: Introduction
1.1 Clinical features of Crohn’s disease
1.1.1 Crohn's disease manifests as a granulomatous enterocolitis
Crohn’s  disease  is  a  chronic  inflammatory  granulomatous  disorder  primarily 
affecting  the  gastrointestinal  tract  and  associated  with  considerable  lifelong 
morbidity.  The  first  description  has  been  ascribed  to  Giovanni  Battista  Morgagni 
(1682-1771),  who  reported  a 20-year-old  man  suffering  from  protracted  diarrhoea 
and colicky abdominal pain and who later died from a perforated ileum \  Subsequent 
patients were described in Sweden by John Berg in  1898 and in Warsaw by Antoni 
Lesniowski in  1903^. In  1913, Dalziel published the first case series of nine patients 
with disseminated thickening of the terminal ileum, some of whom also had colonic 
involvement^. The disease reached prominence in  1932, when Crohn and colleagues 
published their case series of 14 patients with regional ileitis"^.
The incidence of Crohn’s disease rose substantially during the latter part of 
the twentieth century^  for reasons that remain poorly understood, although this has 
now  become  relatively  constant.  The  prevalence  varies  geographically,  with  rates 
highest in northern Europe and North America, approaching  100/100,000 people^. It 
affects females slightly more frequently than males. Although it can develop at any 
time of life, onset typically occurs between the ages of 20-29, with a second smaller 
peak  between  60-79  years  of  age.  Of  the  various  environmental  risk  factors 
examined  to  date,  cigarette  smoking  remains  the  strongest,  conferring  a  five-fold 
increase in susceptibility and a higher incidence of exacerbations^.
14Patients present with inflammation that can occur at any point throughout the 
alimentary  canal.  The  majority  of  lesions  develop  in  the  terminal  ileum 
(approximately 40%), colon (30%) or both (30%), with relative sparing of the upper 
gastrointestinal tract and rectum*.  These  manifest symptomatically with abdominal 
pain,  diarrhoea,  intestinal  bleeding  and  malnutrition,  resulting  in  considerable 
morbidity.  Other organs can also be affected, producing the extraintestinal  features 
associated  with  this  disease.  These  include  inflammation  in  the  eyes  (uveitis  and 
episcleritis),  skin  (erythema  nodosum  and  pyoderma  gangrenosum),  joints 
(peripheral  arthritis,  sacroiliitis  and  ankylosing  spondylitis),  peri-anal  region 
(abscesses  and  fistulae)  and the  hepatobiliary  system  (sclerosing  cholangitis).  The 
natural  history  of Crohn’s  disease  typically  follows  a  relapsing-remitting  course, 
with  intermittent  flares  disrupting  periods  of  inactivity.  Mortality  appears  only 
slightly  greater  than  that  of  the  general  population,  with  a  reduction  in  life 
expectancy  of approximately  five  years’.  This  small  excess  seems  to  relate  to  the 
increased  requirements  for  surgery  and  the  modestly  raised  (approximately  five­
fold'^) risk of colorectal cancer.
At endoscopy, the earliest visible  features include erythema and oedema of 
the intestinal mucosa, with the formation of multiple aphthous ulcers (Fig.  1.1 A) that 
can  coalesce  into  confluent  serpiginous  longitudinal  tracks"  (Fig.  I.IB). 
Inflammation often occurs  in  multiple  discrete,  well-demarcated patches  separated 
by  areas  of normal  mucosa,  producing  skip  lesions  and  a  cobblestone  appearance 
(Fig.  I.IC).  Prolonged  active  disease  can  lead  to  the  development  of  strictures 
through  extensive  fibrosis  (Fig.  I.ID)  and  fistula  formation  by  extension  of 
inflammation through the serosa.
15Microscopic  features of biopsy specimens recovered from  areas of affected 
mucosa  include  a  transmural  inflammatory  infiltrate  (Fig.  1.2A,B);  occasional 
fibrosis  or  Assuring  (Fig.  1.2C);  lymphoid  hyperplasia  and  frequently  granuloma 
formation*’  (Fig.  1  2D); and distortion of crypt architecture in longstanding disease 
(Fig.  1.2E). A granuloma comprises a collection of macrophages with a surrounding 
mantle  of lymphocytes.  These  typically  form  in  response  to  the  presence  of non- 
digestible  foreign material’^.  In some  diseases,  such as  tuberculosis,  the  offending 
antigen is known. In other conditions, the provoking stimulus remains unidentified: 
these include sarcoidosis, Wegener’s granulomatosis and Crohn’s disease. Although 
most  reports  in  the  literature  suggest  that  granulomata  develop  in  only  50%  of 
patients’^, this may be an underestimate. These numbers are based on clinical studies 
with tissue obtained for diagnostic purposes, in which usually no more than twelve 
biopsies are taken from the small and large bowel combined; this is probably greatly 
underpowered. A study in which resected intestines from Crohn’s patients were step- 
sectioned showed that granulomata were present throughout the tract,  including  in 
areas of otherwise apparently normal mucosa’" * . The potential for a type I error due 
to sampling is therefore high, due to both obtaining tissue from the wrong location 
or at the wrong time, since granulomata are dynamic structures’^.
In active disease, therefore, histology reveals substantial inflammation. Both 
mononuclear and  polymorphonuclear  leukocytes  infiltrate  the  mucosa  (Fig.  1.2E), 
driven  by  local  production  of  inflammatory  mediators.  Inflamed  bowel  shows 
increased  production  of  many  pro-inflammatory  cytokines,  including
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Figure 1.1 Typical macroscopic appearances of Crohn's lesions. (A) Ulcer in the 
colon  (B) Linear ulcers. (C) Cobblestone mucosa. (D) Barium follow -through showing 
separation of bowel wall loops (indicating bowel wall oedema) and stricturing (arrows).
Figure 1.2 Typical microscopic appearances of Crohn's lesions  (A,B) Transmural 
inflammation. (C) Fissure fonnation (arrow). (D) Granulomata (arrows). (E) Cry ptitis 
w ith a mixed leukoc\ tic infiltrate.
17interleukin-ip  (IL-ip),  interleukin-6  (IL-6 ),  interleukin-8  (IL-8)  and  tumour 
necrosis factor-a (TNF-a)*^. More specifically, the cytokine pattern corresponds 
to a Thl  immunological reaction, with raised concentrations of interleukin-2 (IL- 
2), interleukin-12 (IL-12) and interferon-y (IFN-y)'^.
1.1.2  Immunosuppression provides the mainstay of treatment 
Whilst  management  of Crohn’s  disease  requires  a  multidisciplinary  approach, 
drugs  that  suppress  the  immune  system  play  a  central  role.  Corticosteroids 
remain  the  most  effective  pharmacological  agents  for  active  disease**.  These 
bind  to  intracellular  receptors  leading  to  a  number  of  potentially  beneficial 
effects, including reduced leukocyte activation and survival; decreased activation 
of the typically pro-inflammatory transcription factor nuclear factor-KB (NF-kB); 
and attenuated induction of pro-inflammatory mediators including cytokines and 
eicosanoids*^.
Unfortunately  corticosteroids  carry  a  heavy  burden  of  side  effects, 
particularly with chronic use. In view both of this and the paucity of evidence for 
their  efficacy  in  the  maintenance  of remission^**,  alternative  agents  have  been 
developed  for  long-term  management.  The  5-aminosalicylate  (5-ASA) 
derivatives, such as sulfasalazine (Fig.  1.3A) and mesalazine (Fig.  1.3B), appear 
moderately  effective  for  active  disease,  although  the  evidence  for  benefit  in 
relapse  prevention  remains  equivocal^*.  Chemical  modifications  allow 
preferential release in the small or large bowel. Whilst less potent, they possess a 
similar spectrum of anti-inflammatory actions to corticosteroids.
Azathioprine (Fig.  1.3C) and its metabolite 6 -mercaptopurine (Fig.  1.3D) 
are  used  principally  in  disease  otherwise  dependent  on  or  refractory  to
18B
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Figure 1.3 Chemical stnictiires of therapeutic drugs. (A) sulfasalazine, (B) mesalazine, 
(C) azathioprine and (D) 6-mercaptopurine.
19corticosteroids^^.  The  proposed  mechanism  of action  relates  to  their  ability  as 
purine  analogues  to  inhibit  DNA  synthesis  and  thus  lymphocyte  proliferation, 
although  modulation  of neutrophil  function  has  also  been  documented.  Other 
immunosuppressive  agents,  including  methotrexate  and  cyclosporine,  are 
employed far less frequently.
Antibodies  that  recognize  TNF-a  comprise  a  recent  addition  to  the 
pharmacological repertoire for Crohn’s disease. These were initially investigated 
under the hypothesis that pro-inflammatory TNF-a plays a central role in driving 
chronic  inflammation,  and  that  its  neutralization  might  prove  therapeutically 
beneficial^^.  Clinical  trials  with  a  chimeric  antibody  (Infliximab)  and  more 
recently a fully humanized antibody (Adalimumab) have demonstrated efficacy, 
particularly  in  patients  with  fistulating  or otherwise  refractory  disease^"*.  Their 
mechanism  of  action,  however,  does  not  appear  straightforward.  TNF-a 
blockade was originally pioneered  for the treatment of chronic  inflammation in 
rheumatoid  arthritis.  Two  classes  of drug  were  developed:  antibodies  against 
TNF-a and recombinant TNF-a receptors (Etanercept and Onercept). Both bind 
TNF-a  with  similar  efficacy  and  both  ameliorate  inflammation  in  rheumatoid 
arthritis^^.  In  contrast,  the  receptors  have  proven  ineffective  for  Crohn’s 
disease^"*’^^,  suggesting  that  simple  blockade  of TNF-a  is  insufficient  in  this 
condition.  The  true  mechanism  of action  appears  to  relate  to  the  ability  of the 
antibodies  to  bind  and  cross-link  membrane-bound  TNF-a  on  the  surface  of 
lymphocytes, initiating apoptosis as well as complement-mediated and antibody- 
dependent cytotoxicity^^.
Whilst effective at suppressing inflammation, none of these therapies are 
curative.  All  have  side  effects,  and  none  guarantee  prevention  of relapse.  The
20same  is  true  of surgical  removal  of affected  bowel:  around  50%  of patients 
develop symptomatic recurrence and more than 90% exhibit endoscopic features 
of active disease at the anastomosis within 1  year of operation^^. Such procedures 
are  thus  usually  reserved  to  treat  secondary  complications  of Crohn’s  disease: 
typical  indications  include  disease  refractory  to  medical  management;  the 
presence  of  persistent  intestinal  obstruction  or  fistulae;  or  emergency 
complications  such  as  bowel  perforation.  Despite  its  temporary  efficacy, 
however,  approximately 60% of patients require  surgery  at some point  in their 
lives^*.
1.1.3  Alternative inflammatory enteritides
Crohn’s disease comprises only one of the inflammatory enteritides.  Ulcerative 
colitis remains the most significant other idiopathic inflammatory bowel disease. 
Although it can produce similar symptoms, the pathology differs with restriction 
of inflammation to  the  large  bowel  (although  a  backwash  ileitis  can occur),  in 
continuous  segments  usually  starting  at  the  rectum  without  intervening 
unaffected mucosa^^. Leukocytes infiltrate only superficially into the epithelium, 
accompanied by marked goblet cell depletion but not granuloma formation. The 
immunological  pattern  varies  from  Crohn’s  disease:  the  process  appears  Th2- 
driven  with  high  levels  of  interleukin-4  (IL-4),  interleukin-5  (IL-5)  and 
interleukin-13 (IL-13)^^. The study of ulcerative colitis as a control inflammatory 
disorder is crucial,  in that  it allows  distinction of factors  related  specifically to 
Crohn’s  disease  compared  to  those  secondary  to  any  chronic  inflammation 
affecting the gastrointestinal tract.
21Other, rarer idiopathic inflammatory bowel diseases include lymphocytic, 
eosinophilic, microscopic and collagenous colitis, the latter often associated with 
use  of non-steroidal  anti-inflammatory drugs  (NSAID)^\  These exhibit distinct 
pathological  features and almost certainly represent discrete disease entities.  In 
approximately  15%  of  patients,  pathological  investigations  reveal  only  non­
specific inflammatory changes consistent with more than one of these enteritides 
or  another  cause  such  as  infection^^.  This  indeterminate  colitis  has  been 
interpreted by some to indicate a spectrum of disease with Crohn’s disease and 
ulcerative colitis at either end but an underlying unifying pathogenesis. A failure 
to arrive at a definitive diagnosis may, however, simply reflect sampling error in 
obtaining pathological specimens from the bowel.
1.2  Mucosal immunology
1.2.1  The aetiology of Crohn’ s disease remains unclear
The  exuberant  inflammatory  reaction  in  the  gastrointestinal  tract  underlies  the 
generation  of symptoms  and  morbidity  in  Crohn’s  disease.  The  driving  force 
behind  this  inflammation  remains  unknown.  Most  research  has  focused  on  the 
immunological characteristics of established lesions and drawn inferences about 
their initiation. The aetiological factors responsible for disease onset and relapse 
could be very different from those underlying persistence.
A major difficulty in defining the cause of Crohn’s disease stems from its 
heterogeneity  amongst  patients,  as  evidenced  by  the  different  sites  of bowel 
involvement,  disease  behaviours  and  associated  clinical  features.  It is probable 
that  multiple  genetic  and  environmental  factors,  which  differ  between
22individuals, give rise to a common syndrome. Such mechanistic differences may 
contribute to the well-established variations in clinical phenotype.
A wealth of experimental data indicates that Crohn’s disease results from 
an  abnormal  interaction  between  the  intestinal  luminal  contents,  the  mucosal 
surface  and  submucosal  immune  system*^.  The  identity  of  the  primary 
pathogenic factors remains highly contentious: some studies implicate abnormal 
infectious or particulate material within the bowel  lumen, others a dysregulated 
innate  or  adaptive  immune  response.  Compromise  theories  propose  that  a 
combination  of  these  factors  may  ultimately  prove  important,  with  altered 
luminal  contents  acting  on  a  susceptible  immunological  background.  The 
relationship between the gastrointestinal flora and the mucosal immune system is 
explored  below,  together  with  the  aberrations  documented  in  Crohn’s  disease 
that may elicit bowel inflammation.
1.2.2  Commensal enteric flora
Microorganisms heavily colonize the adult bowel, with the numbers of bacteria 
constituting the normal gastrointestinal flora estimated as  10-fold greater than the 
number of other cells in the human body^^. More than 500 different species have 
been reported to date,  although recent genetic  analyses  of their complement of 
16S ribosomal RNA genes in the distal intestine suggest that many more have yet 
to be cultured^"*.
The  neonate  intestine  remains  sterile  until  shortly  after  birth,  when  it 
acquires  a microbial  flora within  hours.  In adults, the concentration of bacteria 
increases,  with  greatest  numbers  distally.  The  stomach  and  duodenum  possess 
approximately  10"*  organisms/ml,  predominantly  Lactobacilli^^.  In  the  distal
23ileum,  the  concentration  rises  to  10^  organisms/ml,  with  the  introduction  of 
Streptococci. On reaching the caecum, numbers increase to  10*^ organisms/gram 
of faecal  material.  This  is  largely due to the  introduction of a major anaerobic 
component including Bacteroides, Clostridia and Enterobacteriaceae, but also a 
significant  aerobic  population  of  which  Escherichia  coli  forms  a  principal 
constituent.  These  organisms  are  not  normally  pathogenic.  Instead  they 
participate  in a symbiotic  relationship with the  host,  playing  important roles  in 
the  establishment and  maintenance  of mucosal  structure  and  host  defence,  and 
the metabolism of certain vitamins and bile  salts.  The  importance of the  faecal 
flora in the pathogenesis of Crohn’s disease is discussed later (see 1.3).
1.2.3  The epithelial barrier
The  gastrointestinal  tract  constitutes  the  major  portal  of  entry  of  exogenous 
material  into  the  body.  The  mucosal  immune  system,  of which  the  epithelial 
barrier forms an important component, requires precise regulation so as to allow 
uptake of beneficial nutrients, not to overreact to the commensal bowel flora, and 
to  eliminate  potentially  pathogenic  microorganisms.  Intestinal  epithelial  cells 
generally form a relatively impermeable physical barrier to the luminal contents, 
facilitated  by  tight junctions  that  impede  paracellular  transport^^.  Its  integrity 
remains  critical  for  preventing  infiltration  by  luminal  contents  and  subsequent 
inflammation,  as  illustrated  by  the  spontaneous  development  of inflammatory 
bowel disease  in transgenic  mice expressing a dominant-negative mutant of the 
junctional adhesion protein cadherin^^.
In  the  small  intestine,  enterocytes  project  microvilli  from  their  apical 
surface  with  a  filamentous  brush  border;  this  anatomy  further  impedes
24penetration by luminal contents^^. Epithelial cells can also express proteins that 
recognize  bacteria,  including  Toll-like  receptors^*,  and  present  antigens  to 
mucosal  leukocytes  (see  1.2.5\  such  as  MHC-Il  molecules^^’" ^ ® .  Additionally, 
they  can  participate  in  the  orchestration  of  the  inflammatory  response  by 
producing  cytokines  such  as  IL-8^'.  In  order  not  to  overreact  to  the  normal 
intestinal flora, many of the pathogen receptors exhibit low or absent expression 
under  basal  conditions,  with  up-regulation  when  required.  These  include  the 
peptidoglycan-responsive  Toll-like  receptor-2  (TLR2)  and  the  LPS  receptor 
complex of CD 14, Toll-like receptor-4 (TLR4) and MD-2"*^.
The epithelium  also  secretes a variety of compounds with antimicrobial 
actions into the bowel lumen. These derive from two principal cell types: goblet 
cells'*^, which produce mucins and trefoil proteins, and Paneth cells'*"*.  Intestinal 
mucus forms a gel layer over the epithelium, acting as a semi-permeable barrier; 
its properties depend on the mucin content. Mucins are extremely large (up to 20 
X   10^  kDa),  filamentous polypeptides that are heavily glycosylated (60-80% by 
mass), sulphated and sialated. This confers a highly negative surface charge and 
hydrophobicity"*^"*^.  They  can  be  functionally  subdivided  into  secretory  (gel- 
forming),  membrane-bound and soluble  forms.  As  well  as physically  impeding 
microbial  translocation,  they  also  mimic  pathogen  adhesion  sites'*^"**  and  store 
IgA,  enhancing  mucosal  protection"*^.  Trefoils  constitute  a  group  of  small, 
cysteine-rich  peptides  expressed  in a  site-specific  fashion  in the  intestine,  with 
trefoil  factor-3  production in the  small  and large  intestines^®.  These both cross­
link  mucins  to  stabilise  the  mucus  barrier^',  and  stimulate  epithelial  restitution 
following injury^^.
25The  integrity  of the  mucus  barrier  appears  vital  for  limiting  bacterial 
ingress.  In  rat  ileum  in  which  this  layer  had  been  depleted,  in  vitro  bacterial 
passage rose from 33.3% in controls to  100% in treated small bowel despite an 
intact  epithelium^^.  Mice  lacking  mucin  Muc2^^  or  trefoil  factor-3^'*  proved 
extremely  susceptible  to  dextran  sodium  sulfate-induced  (DSS)  colitis  (see 
1.8.1); the phenotype in the latter was reversible on exogenous supplementation 
of this factor.
Paneth  cells  are  generally  restricted  to  the  base  of  the  crypts  of 
Lieberkiihn in the small  intestine, although under inflammatory conditions they 
can arise  in the  oesophagus,  stomach,  pancreas  and colon^^.  They synthesize  a 
number of antibacterial  molecules,  including lysozyme, DNAse and a-defensin 
(cryptdin)^^.  The  defensins  are  small,  3-4  kDa  cationic  peptides,  produced  by 
Paneth  and  myeloid  cells^^.  Their  antimicrobial  action  derives  from  their 
insertion  into  bacterial  membranes  to  form  pores  of  approximately  20  Â 
diameter; these dissipate electrochemical gradients leading to cell death^*. Paneth 
cells  release  the  contents  of their  secretory  vesicles  into  the  crypt  lumen  in 
response to a number of stimuli; these include whole bacteria, LPS, lipoteichoic 
acid, lipid A and muramyl dipeptide {see 1.6.Sf^.
The  epithelium  does  not constitute  an entirely continuous  barrier to  the 
luminal contents:  food proteins can normally be detected in plasma^^ and a few 
gut bacteria within mesenteric  lymph nodes^'.  Specialized M cells interrupt the 
enterocyte  layer  at  regular  intervals^^.  Their  apical  surface  is  thrown  into 
microfolds,  interspersed  with  clathrin-coated  microdomains  that  mediate 
endocytosis  of luminal  particles^^’^^.  Larger  particles  can  also  be  engulfed  by 
extension of cellular processes.  These cells therefore mediate the transepithelial
26transport of microbes,  macromolecules and other foreign material.  A  pocket in 
their  basolateral  membrane  protrudes  against  the  apical  surface,  creating  a 
docking  site  for  subepithelial  lymphocytes^.  This  assembly  constitutes  the 
follicle-associated epithelium (FAE),  designed for the continuous sampling and 
surveillance  of  luminal  contents  by  mucosal  leukocytes  (Fig.  1.4).  The  gut 
epithelium  therefore  merely  limits  but  does  not exclude  luminal  material  from 
entering the tissues.
1.2.4  IgA
Numerous  mononuclear  leukocytes  reside  within  the  intestinal  mucosa: 
principally  macrophages,  dendritic  cells,  lymphocytes  and  plasma  cells.  The 
latter  secrete  IgA,  accounting  for  approximately  70%  of all  immunoglobulin 
production  in  the  body^^.  Dendritic  cells  induce  class  switching  to  IgA 
production  by  B  cells^.  The  latter  then  mature  and  re-circulate  through  the 
lymphatic system and blood stream^^, returning to the mucosa where they secrete 
IgA into the bowel lumen^*’^^.
Whilst IgA plays an important role in neutralizing many enteric viruses^®, 
its  antibacterial  function  remains  less  well  defined.  It  coats  the  majority  of 
commensal  bacteria^',  limiting  their  non-specific  ingress  across  the  epithelial 
barrier^^^^ and blocking the action of potentially noxious microbial products^'^’^^. 
It also enhances their recognition and uptake by mucosal leukocytes.
Passive  immunization  with  purified  IgA  can  protect  against  mucosal 
bacterial  infection^^.  Mice deficient  in the  polymeric  immunoglobulin receptor, 
which  transports  both  IgA  and  IgM  across  the  enterocyte  layer,  develop  an 
enteropathy  secondary  to  damage  to  the  paracellular  permeability  barrier^^.  In
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Figure 1.4 Follicle-associated epithelium. Specialized M cells endoc> tose luminal bacteria 
and pass them to lymphocy tes sitting in a pocket in their basolateral membrane; these then 
migrate to lymphoid follicles. Dendritic cells reside superficially in the mucosa and extend 
processes through the epithelial cell barrier that continuously sample the luminal contents
28activation-induced cytidine deaminase knockout mice, which lack  IgA but also 
other  class-switched  isotypes  and  affinity-matured  IgM^*,  luminal  densities  of 
commensal  organisms  rise.  Antibody-deficient  germ-ffee  mice  also  exhibit  a 
more persistent leak of these organisms through the mucosa on introduction of an 
intestinal  fiora^^'^^.  These  strains,  however,  subsequently  adapt  to  terminate 
bacterial translocation^^, developing IgG recognizing the commensal flora*®.
IgA  deficiency  remains  the  commonest  humoral  immunodeficiency  in 
humans,  affecting  up  to  1   in  500-2,000  people*\  Most  develop  no  illness*^, 
perhaps partly related to compensatory up-regulation of IgM and IgG*‘, although 
they  exhibit  some  variation  in  their  bowel  flora  constituents*^.  Rare  cases  of 
Crohn’s disease arising in IgA-deficient individuals have been reported*"*'*^, but 
given the prevalence  of both disorders this  may  be coincidental.  These  studies 
therefore  demonstrate  that  IgA  contributes  to  mucosal  protection  but  is  not 
essential.
1.2.5  Mucosal leukocytes and the gut-associated lymphoid tissue 
In non-infiamed bowel, macrophages and dendritic cells probably constitute the 
first leukocytes to interact directly with opsonized microorganisms. Macrophages 
can express a number of pathogen recognition receptors that allow detection of 
bacteria. As with epithelial cells, many of these show minimal expression under 
resting conditions*^ but are up-regulated following bacterial  invasion.  Dendritic 
cells  occupy  a  privileged  position  in  which  they  extend  processes  through  the 
epithelium**  (Fig.  1.4).  It  has  been  suggested  that  this  permits  sampling  and 
constant surveillance of soluble proteins and antigens within the lumen*^, and of 
the  commensal  flora,  although  direct  evidence  remains  lacking.  On  detecting
29potentially pathogenic material, macrophages and dendritic cells  instigate acute 
inflammation by releasing cytokines that recruit and activate phagocytes from the 
surrounding microcirculation^, and present antigen to lymphocytes initiating the 
adaptive immune response.
The  gut-associated  lymphoid  tissue  (GALT)  consists  of  mucosal 
lymphocytes  that  tend  to  cluster.  These  aggregates  are  most  prevalent  in  the 
small  intestine  where,  in  conjunction  with  other  antigen-presenting  cells,  they 
form  the  Peyer’s patches  (numbering approximately  200  in adults)^'.  A  further 
10^  smaller  follicles  line  the  remainder  of  the  small  intestine  and  colon^^. 
Following  antigen  presentation,  lymphocytes  undergo  clonal  proliferation  and 
differentiation. Naïve  lymphocytes migrate to regional mesenteric  lymph nodes 
where they undergo affinity maturation and, in the case of B cells, antibody class 
switching.  Subsequently,  lymphocytes that were  activated in the  GALT have  a 
propensity  to  home  back  to  the  lamina  propria,  where  they  participate  in  the 
inflammatory response^^.  Helper CD4^ T cells (Th) continue to present antigen 
and  secrete  cytokines.  These  augment  the  recruitment  and  response  of other 
leukocytes,  including  cytotoxic  CD8^  T  cells  (Tc)  that  can  directly  eliminate 
infected  host  cells,  and  B  cells  and  plasma  cells.  The  latter cells  both  present 
antigen and secrete antibodies to optimize the recognition and removal of foreign 
material.  A  third  population  of  CD4^  suppressor  T  cells  (Th3,  Treg)  exert  a 
negative, regulatory  influence by secreting anti-inflammatory cytokines  such as 
interleukin-10 (lL-10) and transforming growth factor-p  (TGE-p)^"*.  These  limit 
the extent of inflammation and encourage resolution and healing (see 1.5.6).
301.2.6  Commensal flora support mucosal immunity
The relationship between the normal gut flora and host immune system is closely 
regulated,  since the  former does  not usually trigger a substantial  inflammatory 
response.  The  anergy of mucosal  leukocytes  arises partly  from  intrinsic  down- 
regulation of pathogen  recognition  receptors*^,  but can  also  be  induced  by  the 
microorganisms  themselves.  For  example,  many  bacteria  secrete  proteins  that 
interact with epithelial cells and  leukocytes to  inhibit NF-kB  and consequently 
cytokine release^^.
Far from exerting a detrimental  influence,  commensal  organisms play a 
vital  role  in  establishing  optimal  mucosal  immunity.  Mice  raised  in  germ-free 
environments  possess  very  small  Peyer’s  patches,  and  in  human  neonates  the 
latter  contain  only  poorly  developed  primary  B  cell  follicles  with  few 
lymphocytes  or  plasma  cells^^.  Furthermore,  recognition  of the  normal  flora 
through Toll-like receptors actually limits the extent of inflammation induced in 
the DSS model of colitis (see l.S.lf^.
Gut  bacteria  often  breach  the  epithelial  barrier:  they  can  routinely  be 
detected in dendritic cells, within the Peyer’s patches and local lymph nodes^*. In 
contrast,  they  rarely  spread past the  mesenteric  lymph  nodes  into  the  systemic 
circulation, due to prior removal by phagocytosis (see 1.5.2). As discussed below 
(see  1.3.1),  the  breakdown  of some  aspect  of this  homeostasis  is  believed  to 
underlie the generation of Crohn’s lesions.
311.3  Potential infective causes of Crohn’s disease
1.3.1  Mucosal inflammation in Crohn's disease requires the luminal contents 
Strong evidence supports a critical role for luminal constituents as environmental 
determinants  of Crohn’s  disease.  Inflammation  most  frequently  occurs  in  the 
ileocaecal  region  and  colon,  both  of which  possess  extremely  high  bacterial 
loads^\  Furthermore,  germ-ffee  animals  appear  highly  resistant  to  enteric 
inflammation^,  and possess minimal  gut-associated  lymphoid tissue  or soluble 
IgA (see 1.2.4 and 1.2.5)^^.
An  elegant  series  of experiments  demonstrate  the  requirement  for  the 
luminal  contents  in  the  generation  of Crohn’s  lesions.  In  patients  who  have 
undergone  an  intestinal  resection with stoma formation,  inflammation does  not 
arise in the distal de-functioned bowelIn  o n e  study5   Crohn’s patients 
had  an  ileal  resection  with  an  ileocolonic  anastomosis;  a  proximal  diverting 
ileostomy was then constructed excluding all distal bowel from intestinal transit. 
Six months later, biopsies were taken from the ileocolon then full transit restored. 
Six  months  after  re-anastomosis,  further  biopsies  were  taken.  None  of the  5 
patients  demonstrated  any  inflammation  whilst  the  faecal  stream  remained 
diverted;  however,  all  developed  endoscopic  and  histological  recurrence 
following  its  réintroduction.  In  a  control  group  of  75  patients  with  one-step 
surgery without diversion, 53 showed endoscopic recurrence in the neo-terminal 
ileum within six months of surgery.
Relapse  can  also  be  induced  by  experimental  introduction  of effluent 
from  the  ileostomyIn  three  patients  who  had  undergone  an  ileocolonic 
resection  and  anastomosis  with temporary proximal  ileostomy,  intestinal  fluids 
were instilled into the distal bowel for 8 days. Prior to this insult, the mucosa was
32macroscopically and microscopically normal. Introduction of the faecal material 
induced focal infiltration of mononuclear cells, eosinophils and neutrophils into 
the mucosa, and up-regulation of molecular cell markers reflective of leukocyte 
activation  and  epithelioid  macrophage  transformation.  The  effects  of  the 
ileostomy  effluent  could  be  abrogated  by  prior  passage  through  a  0.22  pm 
filter’^, which removes large particles and bacteria.
A number of effective treatments for Crohn’s disease reduce the numbers 
of  enteric  bacteria  and  their  fermentation  products,  as  well  as  other  dietary 
antigens. Metronidazole, an antibiotic with activity against anaerobes, has proven 
efficacious  particularly  in  patients  with  peri-anal  lesions  Elemental  diets 
consisting of amino acid feeds also reduce bacterial load.  Several clinical trials 
demonstrate that these ameliorate disease activity, in some series as effectively as 
corticosteroids*^'*^*.  Surgical  bypass  of  affected  bowel  is  a  recognized 
treatment, though rarely employed***^. Modification of the bowel flora may also 
exert therapeutic effects as illustrated by the use of probiotics (living organisms 
that exert beneficial effects beyond basic nutrition)****.
1.3.2  The enteric flora dijfers in Crohn's disease
Many  have  proposed  a  specific  infectious  origin  for Crohn’s disease,  although 
unequivocal proof of transmissibility in humans has yet to be provided. The best 
evidence  derives  from  inoculation  of homogenates  of affected  Crohn’s  bowel 
into mice, which elicit a similar granulomatous reaction'**; this can be prevented 
by pre-treatment of the tissues by autoclaving, storage at -20°C or irradiation**^. 
This  reaction  is  consistent  with  the  substantial  rate  of  Kveim  test  positivity 
reported in Crohn’s disease**^.
33The most prevalent bacteria at the  sites  of predilection for lesions have 
been detailed above (see 1.2.2). Differential representation of commensal species 
has been reported in Crohn’s disease**'^, and perhaps more remain undiscovered 
due  to  limitations  in  culture  techniques.  In  active  disease,  the  numbers  of 
Escherichia coli (of which an adherent-invasive  subspecies has attracted recent 
interest**^), Bacteroides vulgatus. Mycoplasma pneumoniae and L-phase bacteria 
appear  increased,  and  those  of Bifidobacteria  and  Lactobacilli  reduced'
Two organisms have received particular attention as potential causal pathogens: 
Mycobacterium avium paratuberculosis (see 1.3.3) and measles virus (see 1.3.4).
Changes  in  commensal  populations  could,  however,  occur  as  a 
consequence  of disease  and  not  relate  to  the  primary  pathogenesis.  Increased 
bowel  transit  due  to  diarrhoea  and  the  use  of medications  with  antibacterial 
properties  could  modify  the  resident  flora.  Furthermore,  the  distribution  of 
bacteria within the bowel  lumen may not reflect the  population adjacent to the 
mucosa. Although anaerobes outnumber aerobes in the colonic faecal matter by 
1,000-fold, they exist in equal proportions at the epithelial barrier'^''. Given their 
proximity to the  mucosal  immune  system,  these  adherent bacteria are  likely to 
prove most important for the generation of Crohn’s lesions;  greater numbers of 
these have been reported in inflammatory bowel disease patients'^''.
1.3.3  Mycobacterium avium paratuberculosis
The  suggestion  that  Mycobacterium  avium  paratuberculosis  (MAP)  infection 
underlies Crohn’s disease accompanied the first case series of the syndrome^. In 
ruminants it causes Johne’s disease, a granulomatous ileocolitis that many regard 
as  the  animal  equivalent  of Crohn’s  disease'^'.  MAP  persists  within  meat  and
34milk  from these animals, providing a potential  route of transmission.  Although 
conventional  histochemical  techniques  fail  to  reveal  mycobacteria  in  Crohn’s 
tissues,  specialized  culture  of  these  samples  can  grow  cell-wall  deficient 
organisms termed  spheroplasts.  These  later develop Ziehl-Neelsen-positive  cell 
walls and contain a MAP genomeInoculation of animals with these isolates 
elicits  variable  phenotypes.  Mice  generate  hepatic  and  splenic  granulomata, 
many  other  species  exhibit  no  detectable  responsebut,  most  impressively, 
goats develop a granulomatous ileitis following oral inoculation'^'*.
Case-control  studies  have  examined  the  disease  specificity  of  MAP, 
principally by comparing detection rates of its IS900 DNA insertion element or 
serum antibodies in patients and controls. The results proved highly variable, not 
least due to methodological differences between studiesThose that detected 
MAP  DNA  in  Crohn’s  patients  frequently  reported  similar  rates  in  ulcerative 
colitis  controls,  and  a  significant  incidence  in  healthy  individuals 
Organisms isolated  from  Crohn’s patients, however,  exhibit greater viability  in 
long-term culture ' ^  .
Conclusive evidence for MAP pathogenicity in humans remains lacking. 
A  frequently  cited  case  report  describes  a  7-year-old  boy  who  presented  with 
granulomatous cervical lymphadenopathy, positive for MAP DNA, who 5 years 
later  developed  terminal  ileitis  consistent  with  Crohn’s  diseaseWhilst  this 
story  appears  compelling,  it warrants  a proviso  that the  histological  finding  of 
caseating  granulomata  in  the  lymph  node  implicates  Mycobacterium 
scrofulaceum  (untested)  as  the  causative  pathogen.  Subsequent  inflammatory 
bowel disease could have arisen coincidentally,  or the patient may have had an 
underlying immunodeficiency syndrome (see 1.5.5).
35Under  the  MAP  hypothesis,  anti-mycobacterial  treatment  should 
represent  a  cure.  Early  trials  showed  no  efficacy*^^'*^^,  but  these  may  have 
administered inappropriate agents or continued for an insufficient duration. More 
recent trials have  included macrolide  antibiotics  but whilst these have reported 
some successthey were conducted as uncontrolled, open label studies. As 
such,  they  do  not  allow  strong  conclusions  concerning  treatment  efficacy 
compared  to  spontaneous  remission  and  placebo  effects,  or  the  long-term 
sustainability of benefits; nor did they comment on changes in the presence and 
viability of MAP.
A  number  of  concerns  have  arisen  concerning  MAP  as  a  candidate 
organism. Many have criticized Johne’s disease as a modelAffected animals 
develop  neither  the  intestinal  strictures  or  fistulae  nor  the  extra-intestinal 
manifestations  frequently  observed  in  Crohn’s  disease.  MAP  can  be  directly 
visualized  in  Johne’s  disease  tissue*'^®.  No  documented  evidence  of  zoonotic 
transmission existsnor do the  geographical distributions of the two diseases 
correspondAlterations in immunological background in Crohn’s disease also 
argue against its pathogenicity. In patients treated with Infliximab, an inhibitor of 
TNF-a, or those who develop AIDS, the risk of reactivation of Mycobacterium 
tuberculosis  and  other  atypical  mycobacteria  rises  substantially;  conversely 
bowel inflammation often remits''^^’*'^^.
Although MAP may persist abnormally  in Crohn’s disease, the case  for 
causality remains weak.  Any hypothesis  invoking this as the  primary aetiology 
needs  to  explain  why  carriage  in  healthy  individuals  does  not  lead  to  disease, 
accepting that Mycobacterium tuberculosis induces pathology only in a minority 
of  those  infected.  This  requires  postulation  of  a  susceptible  immunological
36background.  Additionally,  the  failure  to  detect MAP  in  every patient  indicates 
alternative explanations in these individuals.
1.3.4 Measles virus
The  measles  hypothesis  of  Crohn’s  disease  arose  following  morphological 
studies  that  suggested  a  central  role  for  a  vasculitic  process  associated  with 
paramyxoma-like  particles,  cellular  inclusion  bodies,  and  the  detection  of 
measles virus within lesions*'^’*'*^. Subsequent epidemiological studies appeared, 
claiming  increased  susceptibility to  Crohn’s  disease  in  individuals  bom  within 
three  months  of  measles  epidemics’"* ^,  with  maternal  infection  during 
pregnancy’"*^, and with measles vaccination’"* * .
Unfortunately, many of these results do not withstand close scrutiny. The 
morphological  abnormalities  actually  closely  resemble  normal  cellular 
structures’"* ^. Several attempts to replicate the detection of measles have failed’^’’*  
and  the  original  methodology  proven  inadequate’^ "* .  The  epidemiological 
work contains severe ascertainment and selection biases that critically undermine 
its  interpretation’^^.  More  rigorously  designed  studies  refute  any association’^^' 
and the hypothesis is now discredited’^^.
In conclusion, there is little evidence to support a primary pathogenic role 
for  any  single  microorganism.  The  origin  of Crohn’s  disease  is  unlikely  to  be 
fundamentally infectious. The more probable explanation remains an underlying 
abnormality in host defence on which the normal gut flora acts.
371.4  The adaptive immune system
1.4.1  Immune tolerance to normal gut contents
Lymphocytes  usually  react  on  encountering  antigens  recognized  by  their 
receptors, either membrane-bound immunoglobulin for B cells or T cell receptors 
for T cells.  Tolerance is the mechanism by which the  immune system prevents 
pathologic autoreactivity against self proteinsThe first stage occurs centrally 
within  the  thymus,  which  contains  cells  that  express  a  variety  of self antigens 
found in the periphery. T lymphocytes displaying too great an affinity for these 
epitopes are negatively selected and eliminated through apoptosis; the exception 
are a population of CD4^CD25^ Treg cells
Despite  the  efficacy  of  thymic  selection,  a  number  of  potentially 
autoreactive effector cells escape into the systemic circulation. These are usually 
then  restrained  by  a  number  of  peripheral  tolerogenic  mechanisms*^.  These 
include  homeostatic  regulation  by  cytokines;  T cell  clonal  anergy  or apoptotic 
deletion in the absence  of co-stimulatory  signals  from  antigen-presenting  cells; 
diversion  of effector  T  cell  phenotype  towards  an  immature  state  (ThO);  and 
suppression by Treg cells through the release of IL-10 and TGF-p. Oral tolerance 
is  a  further  phenomenon  of unique  immunological  importance,  in  which  oral 
exposure  to  antigenic  peptides  or  proteins  induces  immunological  anergy  on 
subsequent re-challenge’^^. The means through which this occurs depends on the 
dose of antigen administered:  low doses lead to active regulation by other cells, 
high doses to clonal deletionThe mechanisms employed are similar to those 
of endogenous peripheral tolerance.
There  have  been  claims  that  tolerance  is  broken  in  Crohn’s  disease.  T 
cells  isolated  from  the  mucosa  of  healthy  individuals  react  only  against
38heterologous bowel flora from different individuals; those from Crohn’s patients 
appear  to  react  to  autologous  floraOthers  have  reported  enhanced  T  cell 
proliferation following exposure to Staphylococcus aureus or LPS*^* and T cell 
resistance to apoptosis, associated with an increased ratio of Bcl-2:Bax*^^. These 
differences may, however, arise as a consequence of chronic inflammation, since 
the majority of cells were isolated from sites of active disease.
1.4.2  The case for autoimmunity
Many  believe  that  Crohn’s  disease  has  an  autoimmune  origin,  related  to  self­
reactive  T  cells  or  autoantibodies.  This  is  largely  based  on  the  observation  of 
extensive T cell infiltration and activation within established lesions. In general, 
autoimmunity can arise through a number of mechanisms. Central tolerance can 
prove inadequate, for example, if antigens expressed in thymus are subjected to 
different  post-translational  modifications  in  the  periphery  generating  neo­
epitopes with the potential to drive T cell activation*^. The inherent randomness 
of  somatic  mutation  and  gene  rearrangement  of  recognition  motifs  in 
lymphocytes in secondary lymphoid organs entails a risk of creating autoreactive 
cells.  Defects  in  autoantigen  clearance  or  Treg  function  have  also  been 
postulated  Finally,  neo-antigens  can  arise  through  the  release  of previously 
sequestered  proteins,  by  molecular  mimicry  (antigen-specific)  or  bystander 
activation (cytokine driven and not antigen-specific),  leading to expansion of a 
population of low affinity autoreactive cells that have escaped negative selection. 
An infective influence is frequently implicated but rarely proven in initiating the 
latter two mechanisms.
39Although reviews in the literature frequently refer to Crohn’s disease as 
an  autoimmune  disorder,  it  is  not  at  all  clear  that  this  is  the  case  under  the 
strictest  definitionsThese  include  the  positive  criteria  that  patients  should 
possess  pathogenic  autoreactive  T  cells  or  autoantibodies,  a  human  leukocyte 
antigen (HLA) association, and that there should be a convincing animal model 
of the disease (see 1.8). The negative criterion of no alternative explanation also 
applies.
1.4.3  Antibodies
The  role  of  antibodies  in  establishing  Crohn’s  lesions  remains  similarly 
unresolved.  Abnormalities  in  immunoglobulin  production  have  been 
documented, including an increase in serum IgG subtypes*^*. Antibodies against 
Saccharomyces cerevisiae are associated with Crohn’s diseaseand segregate 
with disease concordance in monozygotic twinsThese could, however, arise 
from raised exposure to bowel contents consequent to increased permeability of 
the  bowel  wall  occurring  as  a  result  of active  inflammation.  Their  pathogenic 
capacity  remains  dubious,  although  in  theory  they  could  cross-react  with  host 
antigens or lead to autoreactivity through epitope spreading.
It is possible that some of the extra-intestinal manifestations of Crohn’s 
disease, most notably the arthritides'^'*, are secondary to induced autoantibodies 
arising  following  increased  exposure  to  gastrointestinal  microbes  that  have 
translocated  across  the  mucosal  barrier.  Again,  these  could  be  directed  against 
previously sequestered antigens, neo-antigens created by a microbial  hapten, or 
cross-reacting self-antigens.
401.4.4  The hygiene hypothesis
The hygiene hypothesis is often invoked to explain the increase in incidence  in 
Crohn’s  disease  over  the  last  few  decades  of  the  previous  century^,  its 
predominance  in  the  Western  world  and  its  scarcity  in  the  tropics  and  other 
regions  with  high  rates  of endemic  intestinal  infection  and  infestation*^^.  In 
general  terms,  the  hypothesis  proposes  that  naturally  occurring  microbial 
exposures,  particularly  in  childhood,  immunize  against  future  development  of 
allergy  and  autoimmune  disease,  and  that  increased  standards  of  cleanliness 
impair this protection*^^.
The rise  in Crohn’s disease  in particular has been temporally correlated 
with the widespread introduction of domestic  refrigeration*^^ and was  found to 
associate  with  the  presence  of  better  household  amenities  in  infancy*^*. 
Appendectomy  has  also  been  identified  as  a risk  factor*although the  theory 
that  this  results  in  impaired  peripheral  T  cell  suppression  remains  speculative. 
Finally,  this  could  explain  the  beneficial  therapeutic  effects  of  helminths  in 
Crohn’s  disease  reported  in  early  clinical  trials****.  No  cause  and  effect 
relationship, however, has been established for any disease, and interpretation is 
limited in view of the many potential confounding influences. Whilst the hygiene 
hypothesis remains attractive, it should not be accepted uncritically.
In  summary,  although  established  Crohn’s  lesions  are  characterised  by 
substantial activation of cells of the adaptive immune system, the direct evidence 
for  causality  remains  weak  and  rather  circumstantial.  The  involvement  of 
lymphocytes could be secondary to alternative underlying processes.
411.5  The innate immune system
1.5.1  Mucosal integrity is reduced in Crohn ’5  disease
The normal  intestinal mucosa does not constitute a complete barrier to  luminal 
contents:  M  cells  interrupt  the  enterocyte  layer  and  pass  luminal  contents  to 
leukocytes  in  the  submucosa  (see  1.2.3),  thereby  permitting  limited  entry  of 
luminal  contents  into  the  bowel  wall.  Whether  the  bowel  in  Crohn’s  patients 
allows  greater  permeation  has  come  under  scrutiny.  Studies  of  intestinal 
permeability  typically  rely  on  oral  administration  of test  probes  in  vivo  and 
subsequent measurement of their secretion in urine’*’. Compounds employed are 
typically molecules with minimal uptake or metabolism in normal bowel, usually 
poorly  digested  carbohydrates  or  radiolabeled  chelators.  Although  many  early 
studies  relied  on  a  single  test  probe,  this  remains  suboptimal  as  urinary 
accumulation depends  not only on  intestinal  uptake but also the  rate of gastric 
emptying,  luminal  degradation,  volume  of  distribution  and  renal  function. 
Studies  with  an  improved  design  also  examined  the  ratio  between  probes  of 
differing permeabilities,  which  should  be  affected  identically  by extra-mucosal 
factors.
Most studies of intestinal permeability have demonstrated some increase 
in  Crohn’s  patients  to  probes  such  as  polyethyleneglycol  (PEG)’*^ 
lactulose/mannitol’*^,  [^ ’ Cr]-ethylenediaminetetraacetic  acid  (EDTA)’*'’  and 
[99rnTc]_diethylenetriaminopentaacetic  acid  (DTPA)’*^,  although  a  few  have 
failed to replicate these findings’*^.  Permeability was increased even in patients 
with  quiescent  disease  and  macroscopically  normal  bowelbut  more  so  in 
those with active inflammation.  There was no difference between subjects with 
small or large bowel involvement, and some enhancement was also observed in
42ulcerative  colitis.  One case report describes  an increase  in a healthy individual 
with a macroscopically normal; they manifested Crohn’s disease 8 years later***.
Permeability  was  also  found  to  provide  an  excellent  predicator  of 
relapse**^.  Interestingly,  a parallel  increase  in pulmonary mucosa absorption of 
[99mTc]_DTPA  has  been  documented  in  Crohn’s  patients*^  as  has  a  similarly 
increased intestinal PEG uptake in their unaffected relatives*^*. Although others 
have  failed to confirm the  latter finding  many of the  negative  studies  do 
show a non-significant  rise  and  may  have  been  underpowered to  detect  a true 
abnormality***. These last observations, in conjugation with the defect occurring 
in  inactive  disease,  argue  that  this  phenomenon  may  play  a  primary  role  in 
disease pathogenesis that becomes compounded by active inflammation.
The same phenomenon has also been assessed in vitro in resected mucosa 
by  determining  the  transmucosal  permeation  of  fluorescent  ovalbumin  and 
dextran using confocal microscopy*Ovalbumin uptake was increased in non­
inflamed specimens from Crohn’s subjects compared to cancer patient controls, 
although dextran permeation was equivalent between the two groups. Ovalbumin 
translocated via both the transcellular and paracellular routes; dextran only by the 
former.  This  implies  a  derangement  in  intercellular  tight  junctions,  which 
conforms  with previous  observations  in  non-inflamed  Crohn’s  bowel  in which 
the protein filaments comprising these structures were fragmented and disarrayed 
into  irregularly  distributed  strands*^.  Crohn’s  bowel  is  also  more  sensitive  to 
increases  in  permeability  induced  by  photo-activated  CIO,  an  agent  known  to 
disrupt tight junctions*^^. This correlated with increased paracellular permeability 
to  [^*Cr]-EDTA,  tight  junction  dilatation  on  electron  microscopy  and  more 
pronounced disassembly of peri-junctional F-actin.
43Alterations  in  the  mucus  barrier  have  also  been  implicated. 
Polymorphisms  in  the  MUC3A  gene  may  increase  susceptibility  to  Crohn’s 
disease’^*. The expression of several other mucin genes has been suggested to be 
altered  in  both  normal  and  diseased  tissuesas  have  the  post-translation 
modifications of the proteins^^^, altering both the quantity^^^ and consistency of 
the gel  layer.  A reduction in mucosal  integrity, as highlighted by these  studies, 
could predispose to increased ingress of bacteria and other luminal constituents 
into the bowel  wall,  as  occurs  in the  cadherin dominant-negative  mouse^^  (see 
1.2.3). This would place the mucosal immune system under greater stress to clear 
the exogenous material.
1.5.2  Acute inflammation is required to remove debris from the bowel wall 
Any debris that accumulates  in the bowel  wall  must be removed to prevent its 
accumulation and, in the case of microorganisms, collateral spread and infection. 
This  is  largely  achieved  by  phagocytosis.  Tissue  macrophages  are  highly 
phagocytic  but  their  respiratory  burst  capacity  (see  1.5.3)  undergoes  down- 
regulation^^. Neutrophils remain the most efficient phagocytes, and provide an 
early  defence  after  bacteria,  fungi  or  other  organic  debris  have  breached  the 
mucosal  barrier^®^.  They  have  a  short  lifespan  and  are  normally  sparse  in  the 
intestinal  lamina  propria;  hence  they  must  be  recruited  from  the  surrounding 
microcirculation.  Microbial  invasion  provokes  the  release  of  cytokines  and 
vasoactive factors by resident mucosal leukocytes, eliciting influx of neutrophils 
and further mononuclear cells.
Mice in which both the gp91  component of the NADPH oxidase enzyme 
complex  and  inducible  nitric  oxide  synthase  (iNOS)  have  been  knocked  out
44demonstrate that neutrophils are critical  for homeostasis  in this manner^^.  The 
bactericidal  capacity  of these  phagocytes  is  almost  completely  abrogated.  The 
most  apparent  phenotype  is  the  development  of  multiple  abscesses, 
predominantly  abdominal,  containing  organisms  derived  from  the  normal  gut 
flora.
Furthermore, despite its proposed central role in driving Crohn’s disease, 
evidence  from  murine  models  suggests  that  TNF-a  may  protect  against 
prolonged  intestinal  inflammation.  In  the  DSS  model  (see  1.8.1),  blockade  of 
TNF-a  aggravated  the  development  of  acute  colitis,  whilst  ameliorating 
inflammation  when  administered  at  a  chronic  established  stage^®^.  This  is 
reminiscent of two case-reports in which arthritis patients started on Etanercept 
(see 1.1.2) developed Crohn’s disease^®**^®^. Additionally, mice deficient in TNF- 
a  appear more  susceptible  to  acute  colitis  induced  by  DSS,  with a 60%  7-day 
mortality compared to 0% in wild type animals^*®, similar to the TLR-4 knockout 
animals^^ (see  1.2.6).  These studies suggest that activation of pro-inflammatory 
mechanisms early after mucosal  insult  is  essential  to remove potential  noxious 
agents and prevent the development of a chronic inflammatory state.
1.5.3  Colitis in chronic granulomatous disease
The  key  importance  of neutrophils  in  mucosal  immunity  is  underscored  by  a 
number  of  congenital  diseases  characterised  by  compromised  neutrophil 
ftmction,  of  which  chronic  granulomatous  disease  (CGD)  represents  the 
prototype. CGD is a rare genetic disorder, with a prevalence of approximately  1  
in  250,000^*’,  caused  by  mutations  in  proteins  that  form  or  interact  with  the 
NADPH oxidase enzyme complex^The ability of neutrophils to kill and digest
45bacteria depends critically on the respiratory burst, which is defective  in CGD. 
This  process  consumes  oxygen  by  reducing  it  to  O2  within  the  phagocytic 
vacuole, mediated by the import of electrons by NADPH oxidase.
It was commonly thought that reactive oxygen species (ROS) generated 
in  this  way  are  directly  bactericidal,  although  this  theory  has  recently  been 
questioned^During  the  respiratory  burst,  cytoplasmic  granules  containing 
digestive  proteases  discharge their contents  into  the  vacuole.  Mice  deficient  in 
these enzymes but with intact free radical generation show a major impairment in 
microbial killing.
Patients with CGD have an absent or greatly attenuated respiratory burst, 
with  consequent  impairment  in  innate  immunity.  They  present  with  recurrent, 
severe bacterial and fungal infections, and chronic granulomatous inflammation 
involving  many  organs,  but  most  frequently  in  the  bowel  and  cervical  lymph 
nodes^*"*.  The  majority  of patients  are  diagnosed  in  infancy.  Until  thirty  years 
ago, death during childhood was common. Now, due to increased awareness of 
the disease and prophylaxis with antibiotics^'*, a higher prevalence of its chronic 
sequelae has emerged.
The bowel disease found in CGD is remarkably similar to that of Crohn’s 
disease; indeed a significant proportion are mistakenly diagnosed as such before 
the recognition of multiple infections^In both, chronic enteritis occurs, usually 
separated by skip lesions of normal mucosa. Ulceration extends to the submucosa 
with frequent fissuring and  fistulation, and peri-anal disease  is often present^ 
Gastrointestinal manifestations reported in a recent review of the US registry of 
CGD patients included peri-anal abscess formation in  13% of patients, colitis in 
17%, and granulomatous  obstruction at the  gastric pylorus or cardia in  15%^".
46Even  higher  levels  of bowel  involvement  have  been  described  in  other  case 
series^*'*. These might still be underestimates: no study has examined the rates of 
endoscopic disease, and subclinical small intestinal malabsorption may occur in 
the  majority of patients^The reasons behind the phenotypic  heterogeneity of 
the  bowel  disease  remain  largely  unresolved,  although  polymorphisms  in  the 
myeloperoxidase gene have been associated with peri-anal involvement^**.
Macroscopic  and  histological  features  of  CGD  colitis  appear  largely 
comparable  to  Crohn’s  disease^Microscopic  characteristics  include 
ulceration of the colon with the formation of granulomata, comprised of sharply 
defined  aggregates  of  epithelioid  histiocytes  surrounded  by  a  dense  cuff  of 
lymphocytes^*^. Subtle differences have been identified, such as the nature of the 
histiocytes  (which  are  lightly  pigmented  and  lipid-laden),  a  paucity  of 
neutrophils, and multiple degranulating eosinophils within the crypts^^®.
Clinical therapeutic trials for CGD enteritis are limited due to the rarity of 
the  disease.  In a double-blind,  placebo-controlled  study involving  128  patients, 
recombinant human IFN-y was effective, although the study was underpowered 
to  determine  its  prophylactic  capacity^^*.  Recombinant  human  G-CSF 
administration has been associated with colitis remission^^^. Non-myeloablative, 
matched  bone  marrow transplantation  can  successfully  reduce  the  incidence  of 
gastrointestinal  granulomata^^^,  and  exogenous  neutrophil  transfusion  has  been 
used  in  CGD  to  treat  life-threatening  infections^^"*.  As  with  Crohn’s  disease, 
immunosuppressive  agents  (including  5-aminosalicylate  drugs,  steroids, 
azathioprine and Infliximab) also relieve symptoms^*^.
The  important  principle  established  by  CGD  enteritis  is  that  the 
pathological picture observed in Crohn’s disease  can develop as a consequence
47of impaired digestion by neutrophils.  This  may  not only inform  on pathogenic 
mechanisms but also point to novel therapeutic approaches.
1.5.4  Defects in neutrophil recruitment in Crohn’ s disease 
Although  Crohn’s  disease  presents  as  a  condition  characterised  by  excessive 
inflammation, mounting evidence suggests that these patients in fact possess an 
impaired  acute  inflammatory  response.  The  proposition  is  that  clearance  of 
bacteria  and  other  organic  debris  from  the  bowel  wall  is  consequently 
suboptimal, leading to its persistence (Fig.  1.5). The latter could elicit granuloma 
formation  as  a  protective  response,  to  limit  collateral  spread  of  potentially 
pathogenic material.  Since the granuloma consist of activated macrophages and 
lymphocytes,  subsequent release of pro-inflammatory cytokines such as TNF-a 
could drive the secondary, chronic inflammation found in active disease.
This  theory  could  explain  the  relative  organ  specificity  of  Crohn’s 
disease,  predominating  in  the  gut  due  to  its  high  bacterial  load.  It  could 
potentially  account  for the  increased  incidences  of various  bacteria reported  in 
this condition (see  1.3.2), resulting not from higher infection rates but impaired 
clearance. The similar pathology that occurs in CGD enteritis (see  1.5.3) sets an 
important precedent for such a mechanism, as do the colitides also described in 
other  neutrophil  disorders  including  glycogen  storage  disease-Ib^^^,  leukocyte 
adhesion  deficiency^^^,  Chediak-Higashi  syndrome^^^,  and  a  variety  of 
neutropaenias^^*'^^ '.
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Figure 1.5 Flowchart illustrating the l^pothesis of defective neutrophil recruitment. This process is 
normally required to remove exogenous material from the bowel wall. Its impairment may lead to 
Crohn's disease through the persistence of debris and a granulomatous reaction. The documented 
changes in the intestinal flora and epithelial permeability (dotted arrows) and CARD 15 
polymorphisms may feed into this scheme by further stressing the system.
49Neutrophil  biology  in Crohn’s  disease  has  previously been  investigated 
under this hypothesis. A significant abnormality was discovered, in that Crohn’s 
patients exhibited markedly delayed recruitment of neutrophils in vivo to the sites 
of breaches in an epithelial layer, as demonstrated in the skin window model of 
acute  inflammation^^^.  This  defect  did  not  occur  in  inflammatory  disease 
controls, nor did it relate to disease activity or use of medication. The neutrophils 
responded  normally  under  in  vitro  assays  of chemotaxis^^^’^^"*,  suggesting  an 
alteration in the inflammatory milieu rather than an intrinsic failure of leukocyte 
motility. A circulating inhibitor of inflammation has been postulated on the basis 
of ex vivo experiments^^^: serum from inflammatory bowel disease patients (in a 
non-disease specific manner) inhibited in vitro chemotaxis to casein to a greater 
degree than that from healthy controls. The inhibitory factor was never formally 
identified,  although  its  biochemical  properties  promote  immunoglobulins  as 
probable candidates. This abnormality, however, remains unproven as the cause 
of depressed neutrophil chemotaxis in vivo in Crohn’s disease.
Defects  have  also  been  reported  in  other  areas  of neutrophil  biology, 
although the data are less consistent. These include a reduced ability to generate 
superoxide in both active and quiescent disease^^^, and attenuated phagocytic and 
bactericidal capacities^^^.
Granulocyte/macrophage-colony  stimulating  factor  (GM-CSF)  activates 
neutrophils  and  augments  their  production  and  release  from  bone  marrow.  A 
double-blind,  randomized  control  trial  of  GM-CSF  in  124  patients  with 
moderately to severely active Crohn’s disease found some evidence of treatment 
benefit^^*. This may, however, have studied a suboptimal patient group, as such
50agents may be more suited to maintenance of remission. The therapeutic efficacy 
of elemental diets, which might reduce intestinal bacterial  loads, and helminths 
could also be explained under this hypothesis (see 1.4.4). The effects of the latter 
are  usually  attributed  to  their augmentation  of Th2  responses  that reciprocally 
suppress the Thl  inflammation observed in active Crohn’s lesions; instead they 
could prime the innate immune system for subsequent mucosal breach.
1.5.5 Mononuclear phagocytes in active Crohn's disease
The  function of monocytes  and  macrophages  remains  less  well  investigated  in 
Crohn’s disease. Macrophages are activated in established lesions^^^’^ "* ® , although 
this may represent a secondary process unrelated to their generation. Monocytes 
from patients contain increased concentrations of lysozyme^"*\ and may exhibit 
increased respiratory burst activity^'*^’^'^^ and increased antigen presentation to T 
cells^'^'*,  but  these  results  directly  correlate  with  disease  activity.  Any  future 
investigation of their function will require careful  controls to delineate primary 
defects  from  those  due  to  an  active  systemic  acute  phase  response  or  use  of 
medication.  There  is  an  increasing  realisation  that  mononuclear  phagocytes 
might play a central role in the disease pathogenesis following the discovery that 
polymorphisms  in  CARD 15  (see  7.6),  expressed  in  these  cells,  predispose  to 
Crohn’s disease.
1.5.6 Resolution of inflammation
The  termination  of  an  inflammatory  reaction  requires  that  pro-inflammatory 
signals are discontinued and wound healing, for example of an ulcerated mucosal 
surface, commences^"*^'^"*^. The previous view that inflammation simply switches
51off, possibly due to catabolism of the driving stimuli, is over-simplistic. Some of 
the  regulatory  cells  and  cytokines  involved  in  negative  regulation  have  been 
discussed  previously  (see  1.2.5).  Indeed,  a  murine  model  of  colitis  can  be 
prevented  or  cured  by  the  adoptive  transfer  of CD4^CD25^  Treg  lymphocytes, 
through mechanisms involving IL-10 and
A number of novel mechanisms involved in the control of inflammation 
are  currently  being  elucidated.  These  include  a  family  of  lipid  mediators 
generated  by  an alternative  metabolic  pathway  downstream  of cyclooxygenase 
(COX) and lipooxygenase (LOX), the enzymes responsible  for the synthesis of 
pro-inflammatory prostaglandins and leukotrienes^"^^. The lipoxins are generated 
by  transcellular  metabolism  of  arachidonic  acid,  requiring  intercellular 
conversion of intermediary lipids^'*^'^^^. The resolvins are produced by the action 
of  COX  and  LOX  on  alternative  substrates,  eicosapentaenoic  and 
docosahexaenoic acids^^'. These compounds have a number of anti-inflammatory 
effects,  including  inhibiting  leukocyte  trafficking^^^  and  pro-inflammatory 
cytokine release^^^.
Another recent discovery  concerns NF-kB, previously  assumed to exert 
only  a  pro-inflammatory  influence.  NF-kB  is  a  generic  term  for  a  family  of 
dimeric  transcription  factors  formed  by  heterodimerization  or  homomeric 
associations  of the  5  members  of the  Rel  family^^^.  In the  early  stages  of the 
inflammatory  response,  the  principal  NF-kB  isoform  consists  of the  c-Rel-p50 
heterodimer^^"*,  which  promotes  the  transcription  of  many  pro-inflammatory 
genes  including  TNF-a,  IFN-y^^^,  and  iNOS^^^.  In  resolution,  the  predominant 
form changes to p50-p50 homodimers that possess distinct DNA-binding sites^^^;
52these  induce  anti-inflammatory  cytokines,  including  TGF-P,  and  pro-apoptotic 
caspases^^^.
Recruited macrophages also play a critical role in resolution: they remove 
apoptotic neutrophils by phagocytosis^^* and secrete metalloproteinases and other 
mediators  that  stimulate  remodelling  of the  extracellular  matrix,  promoted  by 
factors such as epidermal growth factor (EGF) and TGF-P^"^^. The latter, secreted 
in  part  by  neutrophils,  also  attracts  myofibroblasts  that  produce  collagen, 
fibronectin and other extracellular matrix components. Capillary endothelial cells 
then migrate into the region to provide a new blood supply.
Studies of tissue repair in Crohn’s disease remain at a preliminary stage. 
Impaired wound healing has been reported post-operatively^^^, and these patients 
develop intestinal fibrosis and fistulae indicative of such a problem. Fibroblasts 
from  Crohn’s  strictures  preferentially  secrete  TGF-pi^^^,  an  isoform  thought 
inefficient  in  promoting  wound  repair  perhaps  by  producing  excess  type  III 
collagen, although its significance is still unclear.
1.6  CARD15
1.6.1  Hereditary susceptibility to Crohn’ s disease
A  hereditary  component  to  Crohn’s  disease  has  long  been  recognised*^: 
monozygotic twins show approximately 50% disease concordance, the condition 
can  cluster  in  families,  and  about  15%  of patients  have  an  affected  relative. 
Pedigree analyses suggest polygenic inheritance with a significant environmental 
input acting upon a susceptible genetic background.
531.6.2  CARD 15 polymorphisms predispose to ileal Crohn's disease 
In  1996,  a  genome-wide  linkage  screen  for  inflammatory  bowel  disease 
susceptibility  loci  highlighted  the  IBDl  region  on  chromosome  16ql2^^\  a 
finding supported in subsequent linkage studies^^^’^^^.  Over the next five years, 
the same group progressively refined linkage maps to the region.  In 2001, they 
tracked  down  single  nucleotide  polymorphisms  (SNPs)  in  the  CARD15  gene 
(originally named NOD2), which accounted for the majority of this linkage^^. At 
the same time, a second group also identified CARD15 as the IBDl susceptibility 
gene using a candidate gene approach^^^.
Three  polymorphisms  in  CARD15  predispose  to  Crohn’s  disease:  two 
missense  substitutions  (R702W,  G908R)  and  a  single  base-pair  insertion 
(L3020fmsC)^^.  In  Caucasian  populations,  approximately  30%  of  Crohn’s 
patients  carry  one  of these  variants  on  a  single  allele  (compared  to  15%  of 
healthy  controls;  odds  ratio  ~  3;  Fig.  1.6).  In  contrast,  approximately  15%  of 
Crohn’s patients are homozygous or compound heterozygous for these variants 
(odds  ratio  ~  40),  whereas  it  is  rare  for  healthy  individuals  to  carry  two 
polymorphisms although some individuals have been reported^^^.  In addition to 
these polymorphisms, a number of other rare mutations in CARD15 co-segregate 
with  Crohn’s disease  in  individual  families^^^, but do  not achieve  a population 
frequency of 1% required for definition as a polymorphism.  CARD 15 seems to 
play a role  mainly in Caucasian populations,  in which the association has been 
widely replicated although frequencies show some variability^^*’^^^; the variants 
are rarely seen in Chinese^^^ or Japanese^^"* patients.
Several studies have attempted to define the impact of CARD15 variants 
on  clinical  phenotype.  The  only  consistent  finding  is  that  patients  with  these
54CARD15 Polymorphisms
HC 
I  CD 
UC
WT SH
Genotype
CH/HZ
Figure 1.6 CARD 15 polymorphisms. These are more prevalent in patients with Crohn's 
disease (CD) than in healthy controls (HC) or patients with ulcerative colitis (UC). Carriage 
of two polymorphisms strongly, but not inevitably, predisposes to CD. Graph adapted
from data in ref. 264.
WT: wild type: SH: simple heterozygous: CH: compound heterozygous: HZ: homozygous
55polymorphisms almost exclusively develop disease  involving the  ileum^^^.  The 
mechanism  behind  this  localisation  remains  poorly  understood.  Some  studies 
have  reported  a  predisposition  to  fibrostenotic  disease  with  a  younger  age  of 
onset^^^’^^^,  although  this  is  not  universally  replicated*’^^*  and  was  not 
independent  of  ileal  location.  Differences  may  also  occur  because  of  other 
confounders in the populations studied, such as duration of disease or alternative 
treatment protocols  in the various  centres.  The  polymorphisms do  not  seem  to 
occur  more  frequently  in  patients  with  a  positive  family  history  of  Crohn’s 
disease or in those reported to have granulomata on biopsy^^^’^^*.
1.6.3  CARD  15 responds to bacterial cell wall products
CARD 15  is  normally  expressed  predominantly  in  monocytes  and 
macrophages^^^’^*® .  It has also been reported in neutrophils^*’, intestinal Paneth 
cells^*^ and, under inflammatory conditions, within intestinal epithelial cells^*’’. It 
encodes  a  cytoplasmic  protein,  whose  structural  domains  include  two  caspase- 
recruitment  domains  (CARDs),  which  mediate  protein-protein  interactions;  a 
central  nucleotide-binding  domain  (NBD)  important  for activation;  and  ten  C- 
terminal  leucine-rich  repeats  (LRR)  thought  to  bind  ligands^^^  (Fig.  1.7).  All 
polymorphisms associated with Crohn’s disease  occur within or near the  LRR; 
the  L3020fmsC  change  produces  a  premature  STOP  codon  and  a  truncated 
protein^^^.
CARD 15  was  discovered  through  database  searches  for  proteins  with 
homology  to  Apaf-1  (the  basic  subunit  of the  apoptosome)  and  CARD4  (see 
y.7.2)^^^. The crystal structure and molecular mechanism of activation of Apaf-1 
is well described^*^.  It possesses one N-terminal CARD, a central NBD, and C-
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Figure 1.7 Schematic diagram of the structure of CARD 15. The protein contains two 
N-terminal Caspase-Recruitment Domains (CARDs), a central Nucleotide-Binding 
Domain (NBD). and C-terminal Leucine Rich Repeats (LRRs). The polymorphisms 
associated w ith Crohn's disease occur in or near the LRR.
57terminal  WD-40  repeats.  The  latter  acts  as  a  recognition  domain  for 
mitochondrial  damage  through  the  binding  of  cytochrome  c^^^.  Under  basal 
conditions,  these  repeats  exert  an  inhibitory  influence  on  the  rest  of  the 
protein^*^. This is released on ligand binding, leading to Apaf-1  oligomerization 
to  form  the  heptameric  complex  that comprises  the  apoptosome^*^.  This  binds 
procaspase-9  through  homophilic  interactions  between  the  CARDs  of  the 
respective proteins. The induced proximity then leads to proteolytic activation of 
procaspase-9, initiating the caspase cascade and programmed cell death.
In contrast to Apaf-1, CARD4 was found not to contribute significantly to 
apoptosis but potentially to act as a pathogen recognition receptor,^*^ based partly 
on its homology to R proteins important in plant immunity^*^. It was originally 
suggested that CARD 15  could act in a similar manner by binding LPS^^^.  This 
was an attractive proposal in view of the proximity of Crohn’s lesions to areas of 
the  gut  with  the  highest  bacterial  colonization.  Transfection  of HEK293  cells 
with wild type CARD15 conferred responsiveness to LPS, resulting in activation 
of  NF-kB^^^  and  IL-lp  transcription.  Subsequent  purification  of  the  LPS 
preparation  revealed  that  this  activation  actually  derived  from  contaminating 
muramyl  dipeptide  (MDP),  a  component  of  bacterial  cell  wall 
peptidoglycan^**’^*^.
To  determine  the  role  of the  various  domains  of CARD 15,  cells  were 
transfected  with  a  panel  of  mutants^^^.  NF-kB  activation  was  enhanced  by 
deletion of the whole LRR, consistent with an auto-inhibitory function similar to 
the WD-40 repeats of Apaf-1, which is removed on ligand binding. Deletion of 
either CARD was sufficient to abrogate activity,  suggesting these  represent the 
effector domains, which bind and activate the CARD-containing serine/threonine
58kinase  RIP-like  interacting  CLARP  kinase  (RICK,  also  called  R1P2  or 
CARDIAK).
Whereas  cells  with  wild  type  CARD 15  activate  NF-kB  on  stimulation, 
those  transfected  instead  with  a  gene  containing  mutations  associated  with 
Crohn’s  disease  showed  a  greatly  attenuated  response^^^’ ^**.  This  presents  a 
paradox, as leukocytes in active Crohn’s lesions exhibit markedly increased NF- 
kB  activity^^^’ ^^,  and  preliminary  evidence  suggests  that  inhibitors  of  this 
transcription factor might ameliorate the inflammation^^*.
Four principal hypotheses have therefore arisen to explain how CARD15 
polymorphisms confer susceptibility to Crohn’s disease:
■   That exposure to MDP fails to activate anti-inflammatory mediators^^^;
■   That  failure  to  respond  normally  to  MDP  leads  to  an  exaggerated 
adaptive immune response^^^;
■   That  loss  of  CARD 15  in  the  gastrointestinal  tract  leads  to  deranged 
mucosal immune homeostasis^*^; or
■   That there is a toxic gain of function^^^.
There  is  some  evidence  to  support  each  of  these  theories.  Stimulation  of 
macrophages  with  MDP  does  induce  anti-inflammatory  lL-10  secretion^^^. 
CARD 15 has been reported to negatively regulate NF-kB signalling in response 
to  Toll-like  Receptor-2  (TLR2)  activation^^"*,  although  this  has  not  been 
universally  replicable^^^.  CARD 15  has  also  been  documented  in  the  intestine 
within epithelial cells and in particular within Paneth cells^*^,  in which patients 
carrying  the  polymorphisms  exhibit  diminished  expression  of  a-defensins^^^.
59This  might  be  predicted  to  lead  to  expansion  of the  bacterial  flora,  with  the 
caveat that direct evidence remains lacking^^^ and mice deficient for all mature 
Paneth  cell  defensins  exhibit  no  overt  intestinal  pathology  or  microbial 
overgrowth^^*. Alternatively, intestinal epithelial cells transfected with wild type 
CARD15  show  enhanced  containment  of  Salmonella  typhimurium  infection 
compared to those transfected with mutant genes^^^. Finally, a gain of function is 
supported by a recent mouse model (see 1.6.4Ÿ^^.
One  last hypothesis proposes that CARD 15  interacts through its CARD 
domain  with  members  of the  caspase  cascade^®^.  Many  of these  proteins  are 
involved in apoptosis, and failure to initiate programmed cell death could result 
in the accumulation of activated leukocytes within the bowel wall. Others, such 
as  caspase-1,  form  part  of  the  inflammasome.  This  intracellular  complex 
processes  and  activates  cytokines  including  IL-lp^^\  and  could  be  aberrant  in 
Crohn’s disease.  Experimental evidence  is  still required to assess the  merits of 
these last theories.
J.6.4 CARD15 murine models
The murine homologue of CARD15 is encoded on chromosome  8^^^. It displays 
78% sequence homology with the human gene, and possesses similar structural 
motifs.  As  with  the  human  gene,  predominant  expression  occurs  in  peripheral 
blood leukocytes  and resident tissue  macrophages,  with  lower levels  in  spleen, 
granulocytes and dendritic cells.  When the  wild type  gene was transfected  into 
HEK293 cells, MDP exposure activated of NF-kB. The nucleic acid sequences at 
the equivalents of two of the human polymorphic sites, G908R and L3020finsC, 
are conserved in the mouse^®^.
60Mice  have  been  generated  in  which  CARD 15  has  either  been  knocked 
out^^^,  or  contains  G881R  or  L980finsC  variants  that  correspond  to  human 
G908R or L3020finsC  respectively^®^.  All  demonstrate  an absent or attenuated 
response  to  MDP,  but  not  other  bacterial  derivatives.  In  mice  carrying  the 
L980finsC, mutant protein expression is lower but not sufficiently to explain the 
degree  of  reduced  activity.  None  of these  animals  spontaneously  developed 
intestinal pathology.
To  attempt  to  elicit  a  phenotype,  the  knockout  mice  were  exposed  to 
various bacteria or their products^^^. There was no difference in the response to 
an  endotoxic  shock  model,  apart  from  when the  mice  were  first  sensitized  by 
injection  with  MDP,  in which  case  the  knockout  animals  exhibited  a  survival 
advantage.  Immunization  of  the  mice  with  intra-peritoneal  MDP  led  to 
considerable IgGl  generation in wild type animals but not in the knockouts; this 
was  highlighted  as  providing a  link to  the  adaptive  immune  system.  The  mice 
were  then  challenged  with  the  intracellular  gram-negative  bacterium  Listeria 
monocytogenes.  There was no discernable difference with intravenous or intra- 
peritoneal  inoculation,  although  knockout  animals  were  more  susceptible 
following  intra-gastric  exposure.  This  was  suggested to  indicate  that  CARD 15 
plays  a specific  and pivotal  role  in protecting against bacterial  infection  in the 
intestine,  with  possible  mechanisms  including  recognition  of  bacteria  by 
enterocytes, Paneth cell function and production of a-defensins.
A  transgenic  mouse  was  recently  generated  carrying  a  mutation  in 
CARD!5  that  results  in  a  truncated  protein  lacking  the  last  33  amino  acids, 
similar to the human L3020fmsC variant^^^. In contrast to data from humans and 
transfected cells lines, macrophages from these mice demonstrated elevated NF-
61kB  and  IL-ip  activation  on  stimulation  with  MDP.  These  mice  also  failed  to 
develop spontaneous intestinal inflammation, but in the DSS model (see  1.8.1), 
they  demonstrated  increased  weight  loss  and  mortality,  with  more  extensive 
inflammatory  lesions  in  the  colon  and  higher  NF-kB  activation  and  cytokine 
expression.  Oral  antibiotics  protected  against  this  phenotype.  Although  these 
mice  display  an  abnormally  exuberant  inflammatory  response,  they  present  a 
quandary  since  the  functional  effects  of  the  mutations  are  in  the  opposite 
direction to those that predispose to Crohn’s disease in humans. This controversy 
has yet to be resolved, although it is possible that it relates to the strain of mouse 
used or that the structural effects of the generated mutation do not correspond to 
the human variant as closely as predicted.
1.7  Alternative susceptibility genes
1.7.1  Loci identified by genome-wide linkage analysis
A  number of other potential  susceptibility  loci  for human  inflammatory  bowel 
disease have been identified by genome-wide linkage analyses. The IBD2 locus 
on  12pl3.2-12q24.1^^ predisposes specifically to ulcerative colitis^®^. The HLA 
region  on  6p  contributes  susceptibility  to  IBD3^^,  with  several  haplotypes 
potentially increasing the risk of Crohn’s disease and HLA-B27 associated with 
the  co-occurrence  of ankylosing  spondylitis^®^.  The  only  other  chromosomal 
location originally described by linkage  for which the gene has been  identified 
remains  the  IBD5  locus  (see  1.7.4).  Other  regions  still  under  investigation 
include  1BD4  on  14ql l-ql2^®*,  IBD6 on  19plsT   IBD7 on  lp36^‘® ,  IBD8 on 
16p^'*  and  IBD9  on  3p26^’^.  The  majority  of  the  remaining  potential 
susceptibility genes reported were chosen based on a candidate gene approach.
621.7.2 CARD4
Given the association between polymorphisms in CARD15 and Crohn’s disease, 
CARD4 (originally named NODI) presented an obvious candidate gene.  This is 
located on chromosome  7pl4.3^*^,  a region of known  linkage to  inflammatory 
bowel disease^^. Although an early study found no associations^a more recent 
investigation  reported  a  complex  deletion  allele  called  NDi+32656*l  that  co­
segregated  with  Crohn’s  disease^This  was  weakly  associated  with  the 
presence of extraintestinal manifestations but no other disease feature.
CARD4 was also originally found on the basis of homology to Apaf-1^*^. 
It  possesses  a  single  N-terminal  CARD,  a  central  NBD,  and  ten  C-terminal 
LRRs.  It  encodes  a  cytosolic  protein,  expressed  ubiquitously  rather  than 
predominantly  in  myeloid  cells.  As  with  the  CARD 15  protein,  it was  initially 
believed  to  bind  LPS  and  activate  RICK, NF-kB  and  IL-ip  production^*^,  but 
this too was mediated by a peptidoglycan contaminant, N-acetylglucosamine-N- 
acetylmuramic  acid^’^.  The  mechanism  by  which  the  CARD4  mutation 
predisposes  to  Crohn’s  disease  likewise  remains  unresolved,  though  similar 
suggestions have been put forward. Evidence remains minimal, however, except 
that the wild type protein confers some protection against invasive intracellular 
bacteria such as Shigella flexeneri^^^.
1.7.3 Other pathogen recognition receptors
A  number of other receptors are  involved  in the  sensing of pathogens, both on 
leukocytes  and  epithelial  cells.  The  detection  of LPS  requires  its  dissociation 
from bacterial cells walls by serum lipopolysaccharide-binding protein (LBP)^'*,
63which also augments its presentation to the CD 14 receptor on the external aspect 
of the  plasma  membrane^CD 14  has  no  transmembrane  domain  and  must 
associate with TLR4^^° and an accessory molecule MD-2 ^^* in order to transduce 
the  signal  to  the  cytoplasm.  Here,  the  MyD8 8  adaptor  protein  initiates  an 
intracellular signalling cascade^^^.
Polymorphisms  in  genes  encoding  two  of  these  proteins  have  been 
associated  with  Crohn’s  disease:  a  T/C  promoter  variant  at  position  -159  in 
CD 14^^^  and  a  D299G  coding  change  in  TLR4^^^  that  impairs  the  LPS 
response^^^, although the  latter occurs at similar frequencies in Crohn’s disease 
and  ulcerative  colitis.  Neither  gene  corresponds  well  with  regions  previously 
identified by linkage analysis.
A number of other Toll-like receptors have been investigated for variants 
that  may  predispose  to  inflammatory  bowel  disease  but  so  far  preliminary 
positive  data exist only  for Toll-like  receptor-9  {TLR9\  which detects  double­
stranded CpG-rich bacterial and viral DNA^^^.
1.7.4  The IBD5 locus
Considerable  excited  was  generated  by  the  discovery  of the  IBD5  locus  on 
chromosome  5q31^^^,  due  to  its  proximity  to  a  cytokine  gene  cluster^^*.  The 
underlying  genes,  however,  have  recently  been  identified  and  encode  not 
inflammatory  mediators  but  membrane  transporters.  Two  polymorphisms  have 
been  reported  to  date:  a  missense  L503F  substitution  in  SLC22A4  and  a  G/C 
transversion in the promoter region of SLC22A5^^^.  Both predispose to Crohn’s 
disease, particularly that with peri-anal involvement^^®.
64The  genes  encode  proteins  named  OCTNl  and  0CTN2  respectively^^^. 
These function as polytopic transmembrane organic cation transporters expressed 
in  enterocytes,  in  which  they  localize  to  the  apical  brush-border  membrane, 
macrophages  and T  lymphocytes.  The  polymorphism  in SLC22A4 maps to  the 
eleventh  transmembrane  domain,  known  to  be  required  for transport  function. 
The  promoter  polymorphism  leads  to  a  reduction  in  the  level  of  protein 
production.  The  mechanism  by  which  these  predispose  to  Crohn’s  disease 
remains highly speculative. Their substrates include camitine^^*, well known for 
its role in mitochondrial transport of fatty acids, but also a wide range of other 
organic cations including xenobiotics^^^.  It is possible that variant proteins lead 
to disruption of the enterocyte barrier, or altered transport of microbial products.
1.7.5  Functional clustering of  susceptibility genes
A  number  of  other  genes  have  been  highlighted  as  potentially  modifying 
susceptibility  to  Crohn’s  disease.  Several  of these  encode  cytokines  or  their 
related receptors and downstream  signal transducers^^^'^^*, and others  influence 
the  permeability  of  the  gastrointestinal  epithelial  barrier^^^’^'^^.  The  genes 
identified to date  seem to fall  into one of three  functional categories:  pathogen 
receptors; cytokines and related proteins; and molecules involved in maintaining 
epithelial  integrity.  The  connection  between  these  is  that  they  determine  the 
magnitude of the inflammatory response generated by intestinal bacteria.
651.8  Animal models of Crohn’s disease
1.8.1 Chemically-induced colitides
A number of animal  models  of inflammatory bowel  disease rely on the  use  of 
exogenous  chemicals  to  induce  colitis.  These  include  acetic  acid^'^^  phorbol 
esters^^^, F-met-leu-phe^'^^, and sulfated polysaccharides such as carrageenan^'*'*, 
amylopectin  sulfate^^^  and  dextran  sodium  sulfate  (DSS)^"*^.  These  disrupt  the 
epithelial barrier increasing mucosal exposure to the luminal flora; this leads to 
inflammatory  reactions  largely  neutrophil  mediated  with  relative  lymphocyte 
independence^'*^.  Whilst  these  provide  considerable  information  about 
mechanisms  of mucosal  immunity, they bear little pathological  resemblance to 
Crohn’s disease.
1.8.2 The lL-10 knockout mouse
IL-10  represents  a  prototypic  anti-inflammatory  cytokine,  involved  in 
inflammation  resolution  and  negative  regulation  of  the  immune  response^'**. 
Many have postulated that impairment in its production may underlie the chronic 
inflammation of Crohn’s disease, and cite the IL-10 knockout mouse as a good 
model of the condition^'*^. These animals develop a chronic enterocolitis, that can 
be  prevented  by  rearing  in  a  germfree  environment^^  or  with  prophylactic 
antibiotics^^®.
The inflammation, however, does not appear identical to Crohn’s disease. 
Whilst  leukocytes  infiltrate  the  bowel  in  a  transmural  fashion,  the  process 
remains  almost  entirely  confined  to  the  large  intestine^^’.  Bowel  involvement 
occurs in continuous segments rather than in skip lesions, without the formation 
of granulomata  or  any  of the  extraintestinal  stigmata  of human  inflammatory
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question.
This  mouse  model,  however,  illustrates  two  important  points  about  the 
generation of intestinal inflammation.  First,  it demonstrates the requirement for 
the  bowel  flora  in  driving  the  process.  It  also  implies  that  subclinical 
inflammation must normally occur in the bowel as a homeostatic process.  This 
inference  can  be  drawn  from  the  function  of IL-10  as  an  anti-inflammatory 
cytokine.  Were  inflammation  not  stimulated  in  the  first  instance  in  wild  type 
animals,  there  would  be  no  process  to  disinhibit  in  the  knockout.  It  is  highly 
likely, therefore, that low grade acute inflammation occurs physiologically in the 
gastrointestinal tract in order to remove any debris that accumulates within the 
bowel wall.
1.8.3  Other murine models
A  number  of  other  germ  line  models  of  intestinal  inflammation  have  been 
generated; few resemble Crohn’s disease. Two of the closest murine models are 
the TNF"^"^^ and SAMPl/Yit mice. The former possesses a targeted deletion of 
AU-rich  elements  located  in  3’-untranslated  region  of  the  TNF-a  gene  that 
dysregulates  processing of its mRNA causing overproduction of the protein^^^. 
This  mouse  develops  spontaneous  mucosal  inflammation, predominantly  in the 
terminal  ileum  and  occasionally  in  the  proximal  colon,  characterised  by 
transmural  infiltrative  lesions  and  granulomata;  it  also  develops  peripheral 
arthritis. The exact mechanism underlying this phenotype remains unclear but, as 
demonstrated by the variability in therapeutic efficacy of drugs targeting TNF-a
67(see  1.1.2)  and  murine  models  (see  1.5.2),  the  matter  is  not  as  simple  as  the 
overproduction of a pro-inflammatory cytokine.
The  SAMPl/Yit  mouse  also  develops  a  granulomatous  chronic 
inflammatory  bowel  disease^^^.  These  mice  were  produced  through  extensive 
inbreeding,  and  although the  underlying  defect  remains  unidentified,  abnormal 
epithelial cell biology has been demonstrated.
1.9  Outline of the thesis
1.9.1  Summary of background information
The cause of Crohn’s disease remains poorly understood but appears to relate to 
an  abnormal  interaction  between  the  bowel  luminal  contents  and  the  immune 
system.  Most  theories  emphasize  over-activation  of the  latter  as  the  primary 
event. Conversely, Crohn’s patients demonstrate reduced neutrophil recruitment 
after  epithelial  trauma  in  the  skin.  A  consequent  failure  to  clear  bacteria  and 
other  debris  from  the  bowel  wall  efficiently  has  been  postulated,  provoking  a 
granulomatous reaction. The relevance of this abnormality to the gastrointestinal 
tract  has  never been demonstrated,  and  its  molecular basis  remains  unresolved 
although factors extrinsic to the neutrophil itself appear important. Furthermore, 
the consequences in terms of the acute inflammatory response in vivo to bacteria 
have yet to be investigated.
The  discovery  of  polymorphisms  in  the  CARD15  gene  that  confer 
susceptibility  to  Crohn’s  disease  generated  considerable  excitement.  Precisely 
how they contribute to the pathogenesis has stimulated considerable debate. The 
protein is normally found predominantly in mononuclear phagocytes, where it is 
thought to function as a receptor for bacterial MDP. The polymorphisms impair
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Crohn’s disease remains highly speculative.
1.9.2  Studies conducted in this thesis
To  pursue  the  hypothesis  that  acute  inflammation  is  diminished  in  Crohn’s 
disease, four studies were conducted:
■   The acute response to epithelial trauma in the gastrointestinal tract was 
examined  in  Crohn’s  patients  and  controls  to  determine  whether  the 
same defect applied to the bowel.  A novel  serial  biopsy technique  was 
developed for this purpose (see Chapter i).
■   To delineate the profile of acute  inflammatory mediators produced and 
cellular  activation  states  in  control  and  Crohn’s  subjects,  the  skin 
window technique was modified to allow characterisation of most facets 
of the acute inflammatory response (see Chapter 4).
■   Macrophage responses to various  inflammatory  stimuli  were  studied  in 
vitro to try and identify the cellular and molecular bases for diminished 
responsiveness in Crohn’s disease (see Chapter 5).
■   The response to bacteria in the tissues was assessed directly in vivo by 
subcutaneous inoculation with killed Escherichia coli (see Chapter 6).
Throughout the  in  vivo  studies,  patients  were  carefully  selected to  avoid those 
taking  (or  who  had  recently  stopped)  immunosuppressive  medications.  Only 
subjects  in  remission  were  studied,  to  minimize  potential  confounding  factors. 
Participants  were  genotyped  for  the  CARD 15  polymorphisms  known  to
69predispose  to  Crohn’s  disease,  and  their  influence  on  the  various  parameters 
studied was determined.
1.9.3  Implications of these studies
The  findings  of these  studies  add  considerable  credence  to  the  theory that the 
underlying abnormality in Crohn’s disease relates to a weak initial inflammatory 
reaction. Although general mechanisms behind this impairment were elucidated, 
the  precise  molecular  defects  merit  further  investigation.  Concepts  regarding 
therapeutic maintenance of remission may also require some re-evaluation.
70Chapter 2: Methods
2.1 Subjects
2.1.1 General note on chemicals and equipment
All chemicals and reagents were of the highest purity and purchased from Sigma 
Aldrich  (MO,  USA),  and  all  reactions  were  conducted  at  room  temperature, 
unless  otherwise  stated.  All  equipment  use  in  cell  culture  experiments  was 
sterile.
2.1.2 Subject selection
Healthy subjects were defined as individuals with no inflammatory disease and 
taking no immunosuppressive medication. Patients with a definitive diagnosis of 
Crohn’s  disease,  confirmed  by  endoscopic,  radiographic  and/or  histological 
appearances,  were  recruited  from  the  gastroenterology  outpatient  clinic  at 
University College London Hospital (UCLH).  Standard diagnostic criteria were 
used to  distinguish  Crohn’s  disease  from  ulcerative  colitis^^"^:  these  included  a 
discontinuous  nature  of mucosal  involvement  (particularly  with  ileal  and  peri­
anal inflammation but relative sparing of the rectum); the formation of aphthous 
ulcers;  mucin  retention;  and  the  presence  of epithelioid  granulomata.  Subjects 
were  excluded  if the  diagnosis  had  been  made  less  than  1  year  previously;  if 
other causes of inflammation had not been excluded; if only non-specific features 
of  inflammatory  bowel  disease  were  present;  or  if  there  was  disagreement 
between  the  clinical  and  histological  diagnoses.  All  patients  had  quiescent 
disease  (see  2.1.4  for assessment).  Patients were taking no  immunosuppressive
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subjects were approximately matched for age, sex and smoking history. Patients 
with ulcerative colitis were recruited from the gastroenterology clinic and those 
with  rheumatoid  arthritis  from  the  rheumatology  outpatient  clinic,  under  the 
same criteria. All studies were approved by the Joint UCL/UCLH Committee on 
the  Ethics  of  Human  Research  (project  numbers:  00/0004,  02/0324  and 
04/Q0502/29). Written informed consent was obtained from all volunteers. Data 
were analyzed anonymously and blinded where possible.
2.1.3  Database of  patient characteristics
A  database  was  created  in  Microsoft®  Office  Access  2003  to  record  subject 
details,  and  registered  and  covered  by  the  Data  Protection  Act  1998.  For  the 
Crohn’s patients, information recorded included their age, sex, ethnicity and year 
of diagnosis;  any previous  intestinal  resections;  disease  location and behaviour 
according  the  Vienna  classification  (inflammatory,  fibrostenotic,  fistulating  or 
mixed fibrostenotic/fistulating)^^^; presence of granulomata on intestinal biopsy; 
CARD!5  genotype  (see  2.2);  smoking  history  (current  smoking  activity  and 
pack-year  history);  use  of the  oral  contraceptive  pill  or  hormone  replacement 
therapy; use of medication, previous failed medications and reasons  for failure; 
family  history  of  inflammatory  diseases;  presence  of  extra-intestinal,  upper 
gastrointestinal or peri-anal  features of disease; disease activity (see 2.7.4);  and 
current  co-morbidities  or  relevant  past  medical  history.  For  patients  with 
ulcerative  colitis  similar  data  was  recorded,  including  extent  of  colorectal 
involvement.
722.1.4  Assessment of disease activity
The  Harvey-Bradshaw  score  of disease  activity^was  calculated  (Table  2.1), 
based on a single assessment of symptoms and signs pertaining to the preceding 
24  hour period.  This  has  been  validated  and  shows  good  correlation  with  the 
more intensive Crohn’s Disease Activity Index based on a 7 day diary^^^.  Only 
patients with a Harvey-Bradshaw score <3 were studied. Peripheral venous blood 
was  collected  at  the  time  of each  experiment  for  measurement  of white  cell 
count,  erythrocyte  sedimentation  rate  (ESR)  and  C-reactive  protein  (GRP)  as 
systemic markers of inflammation. Serum albumin was measured as an indicator 
of the nutritional state^^*, along with serum vitamin B12 and red cell folate where 
these were clinically indicated. All were measured as part of the routine clinical 
assessment through UCLH clinical haematology and biochemistry services. No 
patients with current fistulating disease were studied, although past development 
of fistulae or stenoses was documented.
2.2  CARD15 genotyping
2.2.1  DNA extraction
Peripheral venous blood was collected by routine venesections into vacutainers 
containing  ethylenediamine  tetra-acetic  acid  (EDTA;  Becton  Dickinson,  NJ, 
USA).  Genomic  DNA  was  isolated  from  3  ml  of these  samples  by  magnetic 
separation  using  the  OCT™  Genomic  DNA  Purification  Kit  (DNA  Research 
Innovations  Ltd,  Kent,  UK),  following  the  instructions  from  the  manufacturer. 
Briefly, blood was lysed and DNA recovered using magnetic beads, then purified 
by protease digestion followed by isopropanol precipitation.
73General well-being 0  Very well
1  Slightly below par
2  Poor
3  Very poor
4  Terrible
Abdominal pain 0  None
1  MikJ
2  Moderate
3  Severe
Number of liquid stools per day 1  Per episode
-2  If previous bowel resection
Abdominal mass 0  None
1  Dubious
2  Definite
3  Definite and tender
Systemic Complications 1  per item
Arthralgia
Uveitis
Erythema nodosum
Aphthous ulcers
Pyoderma gangrenosum
Anal fissure
New fistula
Abscess
Table 2.1 Harvey-Bradshaw activity index.
742.2.2  Allelic discrimination
All  patients  were  genotyped  for  the  3  CARD15  SNPs  associated  with 
susceptibility to Crohn’s disease:  R702W,  G908R and L3020fsinsC, previously 
reported  as  SNP8,  SNP12  and  SNP13  with  reference  SNP  IDs  rs2066844, 
rs2066845 and rs2066847 respectively.
Genotyping was conducted using the Taqman® SNP Genotyping Assays 
(Applied Biosystems, CA, USA) and ABI  7900HT Sequence Detection System 
(Applied  Biosystems)  on  5  ng/pl  DNA,  using  allelic  discrimination  between 
probes  for  wild  type  and  mutant  alleles.  Primers  and  probes  for  SNP 12  were 
designed  through  the  Custom  Taqman®  SNP  Genotyping  Assay  (Applied 
Biosystems); those for SNP8 and SNP 13 were taken from previously published 
papers^^’^^^’^^ and were as follows:
SNP8 primer (forward): 
SNP8 primer (reverse): 
SNP8 probe (wild type): 
SNP8 probe (mutant):
5’-GCTGGCTGAGTGCCAGACATG-3’
5’-AGTGGAAGTGCTTGCGGAGG-3’
5 -CCTGCTCCGGCGCCAGGC-3’
5’-CCTGCTCTGGCGCCAGGC-3’
SNP 12 primer (forward): 
SNP 12 primer (reverse): 
SNP 12 probe (wild type): 
SNP 12 probe (mutant):
5 ’ -CTGTTG  ACTCTTTGGCCTTTTC AG-3 ’
5 -CCACCTCAAGCTCTGGTGATC-3’
5 ’ -CTGTTGCCCC AG  A  AT-3 ’
5 ’ -CTGTTGCGCC AG  A  AT-3 ’
SNP 13 primer (forward):  5’-GTCCAATAACTGCATCACCTACCT-3’
SNP 13 primer (reverse):  5’-ACTTCCAGGATGGTGTCATTCC-3’
75SNP13 probe (wild type):  5 -CTGCAGGCCCTTGA-3'
SNP13 probe (mutant):  5’-CTGCAGGCCCCTTGA-3’
A 1   pi aliquot of each sample was added to a clear optical reaction plate (Applied 
Biosystems)  and  left  to  dry  overnight;  wells  without  DNA  were  negative 
controls. A 5 pi mixture containing 2.5 pi Taqman® Universal Polymerase Chain 
Reaction (PGR) master mix (Applied Biosystems) and 0.25 pi of each primer in 
diethylpyrocarbonate  (DEPC)-treated water (Ambion,  TX,  USA)  was  added  to 
each  well.  The  plate  was  sealed  with  optical  adhesive  covers  (Applied 
Biosystems),  spun down, and run in a MBS  Satellite  384 Thermal Cycler PCR 
machine  (Thermo,  MA,  USA)  under  the  following  conditions:  94°C  for  30  s; 
94°C for 30 s, 55°C for 30 s and 72°C for 30 s for 30 cycles; 72°C for 30 s, then 
held at 4°C. All samples were genotyped in duplicate.  Any sample for which a 
conclusive genotype could not be established was directly sequenced.
2.2.3  Sequencing
The  region  of interest  was  amplified  by  PCR  using  20  ng  of genomic  DNA 
template, 5 pmol of each primer, 200 pM dNTPs (Promega, WI, USA) and  1.25 
U/reaction  Pfu  DNA  polymerase  (Promega).  Primers  used  for  sequencing 
(SNP 12  was  reliably  genotyped  by  Taqman®  in  all  cases)  were  ordered  from 
MWG-Biotech AG (Ebersberg, Germany):
SNP8 primer (forward):  5 ' -CTCGG  AGGG  A  A  AGGAC AGC AGCGTG-3 '
SNP8 primer (reverse):  5'-CCAGCCGCTCCTCCTGCATCTCGTA-3'
76SNP13 primer (forward):  5’-GGCTAACTCCTGCAGTCT-3’
SNP13 primer (reverse):  5’-TCCCGTCACCCCATTTTA-3’
Samples were run in a MBS  Satellite 384 Thermal  Cycler PCR machine under 
the following conditions: 95°C for 1   min; 95°C for 1   min, 61°C for 1  min (SNPS) 
or 50°C for  1   min (SNP 13), and 72°C for 2 min for 35 cycles; 72°C for  10 min, 
then held at 4°C.  PCR products were  run on an agarose  gel, purified using the 
Qiaex  II  gel  purification  kit  (Qiagen,  CA,  USA)  then  sequenced  using  the 
BigDye v3.1  kit (Applied Biosystems), according to the instructions supplied by 
the manufacturer.
2.2.4  Analysis of  genotype-phenotype correlations
The  database  was  probed  to  examine  phenotypic  correlates  of  carriage  of 
CARD 15 variants.  Associations were determined using the chi-squared (%^) test 
with  Fisher’s  exact test  for discrete  variables,  calculated  with  Graphpad  Instat 
version 3.00 for Windows ME (Graphpad Software, CA, USA). For continuous 
variables, the 2 -tailed students’ t-test was used for single comparisons and  1-way 
Kruskal-Wallis  Analysis  of  Variance  (ANOVA)  with  Dunn  post-tests  for 
comparisons  between  multiple  groups  to  avoid  errors  associated  with 
multiplicity. Both were calculated using Graphpad Prism version 4.01  (Graphpad 
Software). The threshold for significance was P < 0.05.
772.3  Serial intestinal biopsies
2.3.1 Biopsies
Biopsies were taken with 5 mm forceps from the posterior wall of the rectum in 7 
non-inflammatory bowel disease controls, 5 Crohn’s patients, and 3 patients with 
ulcerative  colitis.  A  second  biopsy  was  taken  6  h  later  under  direct 
sigmoidoscopic visualization. In a few subjects, paired biopsies were taken from 
two adjacent sites in the rectum, both of which were re-biopsied, to evaluate the 
internal  reproducibility of the  technique.  Paired  serial  biopsies  were  also taken 
from  the  rectum  and  neo-terminal  ileum  in  a  further  2  controls  with  familial 
adenomatous  polyposis  (FA?)  and  3  Crohn’s  patients,  all  of  whom  had 
colectomies with ileorectal anastomoses.
2.3.2 Immunohistochemistry
Samples  were  fixed  in  formalin,  embedded  in  paraffin  wax  and  serially 
sectioned. These were then dewaxed, rehydrated and incubated with 3% H2O2 in 
methanol  (VWR,  Poole,  UK)  for  20  min  to  block  endogenous  peroxidase 
activity. Antigen retrieval was performed by pressure-cooking in 0.01  M citrate 
buffer  pH  6.0  for  2  min  at  high  pressure.  The  sections  were  incubated  with 
serum-free  Protein  Block  (Dako,  Glostrup,  Denmark)  for  10  min  then  washed 
three times in TBST (Tris-buffered saline (TBS; 200 mM NaCl, 50 mM Tris-HCl 
pH 7.4), 0.5% (v/v) Tween-20).
Primary antibody was added for 1   h. Separate sections from each sample 
were treated with either monoclonal anti-human IL-8 (R&D Systems, MN, USA; 
1:100)  or  anti-myeloperoxidase  (Dako;  1:1,000)  antibodies  made  up  in  TBS. 
Sections  were  washed  3  times  with  TBST  then  incubated  with  appropriate
78biotinylated  secondary  antibodies  (Dako;  1:300)  for  30  min.  Sections  were 
washed  again  and  incubated  with  streptavidin-peroxidase  conjugate  (Dako; 
1:500)  for  30  min,  then  developed  with  3,3’-diaminobenzidine- 
tetrahydrochloride  (Dako)  and  0.1%  (v/v)  H2O2  solution  for  2  min, 
counterstained with haematoxylin, and mounted with distrene/plasticizer/xylene 
(DPX) mountant.  For negative  controls, duplicate  sections  were  used  in which 
primary antibodies were omitted.  Immunostaining was performed blinded to the 
patient identity and biopsy timing.
2.3.3  Analysis
The association between responses at paired sites in the rectum, or between the 
rectum and ileum, was determined using the Pearson correlation coefficient (the 
relationship  appeared  to  be  linear,  and  data  assumed  normally  distributed). 
Calculations  were  performed  on  Microsoft®  Office  Excel  2003.  Numbers  of 
MPO-positive  and  IL-8-positive  cells  between  different  groups  and  under 
different  conditions  were  compared  using  a  2-way  ANOVA  with  Bonferroni 
post-tests (Graphpad Software). The threshold for significance was P < 0.05. Cell 
counting was performed in a blinded fashion by two independent observers.
2.4  Skin Windows
2.4.1  Creation of  skin windows
Forearms  were  cleaned  with  70%  (v/v)  ethanol  (VWR).  Skin  windows  were 
created by abrasion of a 3  cm  x  1   cm  area on the volar surface using  grade  C 
sandpaper  (Homebase  Ltd,  Surrey,  UK),  until  capillaries  were  visualized  but 
before  bleeding  commenced.  Lesions  were  always  fashioned  by  the  same
79investigator,  and  for  each  subject  it  was  confirmed  by  a  second  independent 
investigator  that  window  sizes  and  duration  and  intensity  of  abrasion  were 
uniform.
Abrasions  were  overlaid  with  sterile  filter  papers  (Whatman  Ltd., 
Maidstone, UK) saturated with injection-grade normal saline (B. Braun Medical 
Inc.,  PA,  USA;0.9%  w/v)  either  alone  or  containing  MDP  (100  ng/ml)  or 
recombinant human  IL-8  (PeproTech, NJ,  USA;  10  pg/ml).  Filter papers  were 
then covered with a layer of Nescofilm sealing film (Karlan, AZ, USA) and an 
adhesive dressing. Dressings and filter papers were removed after either 30 min, 
6  h,  24  h  or 48  h  depending  on  the  experiment.  Subsequently,  windows  were 
washed briefly with water then left open without a dressing to heal.
2.4.2 Cell differential counts
Filter papers were layered for 3 s on a glass slide. Adherent cells were fixed with 
methanol (VWR), stained by Romanowsky dye and differential leukocyte counts 
determined  by  morphology.  Counts  were  taken  in  5  randomly  selected  high 
power  fields  and  mean  values  taken,  with  more  than  150  cells  counted  in  all 
control subjects.
2.4.3 Myeloperoxidase assay
Filter papers were then incubated in 400 pi normal saline on a rotating wheel (30 
min,  4°C) to elute proteins.  The  filter paper and  cells were  separated  from  the 
fluid  by  centrifugation  (15,000  g,  5  min,  4°C)  and  the  supernatant  containing 
secreted  proteins  recovered  (see  2.4.4).  Cellular  contents  were  extracted  by 
incubating  the  filter  papers  in  0.5  M  NaCl/1.5%  (v/v)  Triton  X-100  (VWR)
80containing  Complete  Mini  protease  inhibitor  cocktail  tablets  (Roche,  Basel, 
Switzerland)).  Samples  were  sonicated  (10  x  1   s  pulses;  MSE  Soniprep  150; 
Sanyo,  Leicestershire,  UK),  centrifuged  (15,000  g,  5  min,  4°C)  and  the 
supernatant  measured  for  myeloperoxidase  by  oxidation  of  2.5  mM  4- 
aminoantipyrine  (dissolved  in  phenol)  in  the  presence  of  1.7  mM  H2 0 2^^’. 
Absorbance  was  measured  at  510  nm  with  a  Shimadzu  UV-3000 
spectrophotometer  (Shimadzu,  Kyoto,  Japan).  Horseradish  peroxidase  (HRP) 
was used as a standard (0 -2 0 0 pg/ml).
2.4.4  Enzyme-Linked Immunosorbent Assays
Commercially  available  ELISA  kits  were  purchased  for  IL-lp,  IL-8,  TNF-a, 
prostaglandin  E2  (PGE2)  and  leukotriene  8 4  (LTB4)  (R&D  Systems),  albumin 
(Alpha Diagnostic International, TX, USA), histamine (IBL Hamburg, Hamburg, 
Germany),  and  C3a-desArg  (Progen,  Heidelberg,  Germany).  Assays  were 
conducted  following  the  instructions  from  the  manufacturer,  with recombinant 
human protein standards. Concentrations of these mediators were measured in 30 
min or 24 h skin window fluid from 2.4.3, with appropriate dilutions determined 
to obtain readouts within the linear range of the assay.  Sandwich ELISAs were 
used for cytokines, and competitive binding ELISAs for other mediators.
Protocols  for  the  IL-lp,  IL-8,  TNF-a  and  C3a-desArg  ELISAs  were 
similar for each kit. Briefly, samples or standards were incubated for 2 h (IL-lp, 
IL-8  and  TNF-a)  or  1   h  (C3a-desArg)  in  monoclonal  antibody-coated  96-well 
plates. Wells were washed and incubated with secondary antibody conjugated to 
HRP  for  1   h.  Washes  were  repeated,  and  substrate  solution  consisting  of 
tetramethylbenzidine (TMB) and H2O2 applied for 30 min (IL-ip, lL-8 and TNF-
81a) or 10 min (C3a-desArg) in the dark. The colour reaction was terminated with 
1   M H2SO4 (VWR), and the optical density of each well determined immediately 
using a microplate reader (Anthos Labtec Instruments, Salzburg, Austria) set to 
450 nm.
For PGE2 and LTB4, samples or standards were added to a 96-well plate 
coated with goat anti-mouse (PGE2) or anti-rabbit (LTB4) polyclonal  antibody, 
with  wells  reserved  to  assess  total  activity  (TA),  non-specific  binding  (NSB), 
maximum  binding  (Bo)  and  a  blank.  Purified  PGE2/LTB4  (as  appropriate) 
conjugated to alkaline phosphatase (ALP) was added to each well excluding the 
TA  and  blank  wells,  followed  by  mouse  monoclonal  anti-PGE2  or  rabbit 
polyclonal anti-LTB4 antibody to all wells except the NSB, TA and blank wells. 
These  were  incubated  for  24  h  at  4°C.  Wells  were  washed  then  5  pi  of the 
PGE2/LTB4-ALP conjugate added to the TA well.  Substrate solution containing 
p-nitrophenyl phosphate was added and incubated for  1   h at 37°C. The reaction 
was  stopped  with  trisodium  phosphate  solution  and  the  optical  density 
determined  at  405  nm.  To  normalize  the  results,  each  reading  had  the  NSB 
optical density subtracted then was divided by the optical density of Bo
For histamine, samples and standards were acylated in glass tubes using 
the reagents provided for 30 min. These were then diluted in 2 ml Assay Buffer 
and 50 pi of each added to a 96-well plate coated with goat anti-rabbit antiserum, 
together with 50 pi histamine conjugated to HRP and 50 pi rabbit anti-histamine 
antiserum.  This was incubated for 3  h, washed 4 times, and the colour reaction 
developed with 200 pi TMB substrate solution. The reaction was stopped after 15 
min with  1 0 0 pi H2SO4, and the optical density read at 450 nm.
82For albumin, samples or standards were added to a 96-well plate coated 
with  an  anti-albumin  emtibody,  in  the  presence  of  a  secondary  anti-albumin 
antibody conjugated to HRP. This was incubated for 30 min with gentle shaking, 
washed 4 times and HRP  substrate  solution added for  10 min in the  dark.  The 
reaction was stopped with 1  M H2SO4 and absorbance at 450 nm measured.
Efficiency of cytokine  recovery using this technique  was  determined  in 
vitro with filter papers blocked for  1  h in normal human serum then preincubated 
for 24 h with known concentrations of recombinant human IL-8 .  Extraction took 
place as above (see 2.4.3). Recovery efficiency was 76.02 ± 3.80% (mean ± s.d., 
n = 6), equivalent in the  10'^ and 1 0*^ g/ml ranges.
2.4.5 Cytokine protein array
Membranes  arrayed  with  42  different  cytokines  (RayBio™  Human  Cytokine 
Array  III;  RayBiotech,  GA,  USA;  Table  2.2)  were  probed  with  skin  window 
fluid, following the instructions from the manufacturer. Briefly, membranes were 
blocked  for 30 min and exposed  for 2  h to  skin window fluid (diluted  1:20  in 
block  buffer)  from  the  first  supernatant  derived  in  2.4.3.  Membranes  were 
washed,  incubated  with  biotin-conjugated  antibodies  against  the  different 
cytokines for 2 h, washed and incubated with HRP-conjugated streptavidin for 60 
min. Washes were repeated, detection carried out using the reagent provided, and 
imaged using a ChemiDoc machine (Bio-Rad, CA, USA).
2.4.6 TGF-P activity assay
TGF-P  activity  was  determined  using  mink  lung  epithelial  cells  (MLECs;  gift 
from D. Rifkin) that had been transfected with an 800 bp fragment of 5’  PAI-1
83IL-tp IL-lp IFN-y IFN-y TGF-pl TGF-pl Pos Pos
IL-1a IL-1a IL-15 IL-15 TARC TARC Neg Neg
1-309 1-309 IL-13 IL-13 SDF-1 SDF-1 Leptin Leptin
GRO-a GRO-a IL-12 IL-12 SCF SCF PDGF-p PDGF-p
GRO GRO IL-10 IL-10 RANTES RANTES VEGF VEGF
GM-CSF GM-CSF IL-8 IL-8 MIP-1Ô MIP-1S Tpo Tpo
G-CSF G-CSF IL-7 IL-7 MIG MIG OSM OSM
ENA-78 ENA-78 IL-6 IL-6 MDC MDC Ang Ang
Neg Neg IL-5 IL-5 M-CSF M-CSF IGF-1 IGF-1
Neg Neg IL-4 IL-4 MCP-3 MCP-3 EGF EGF
Pos Pos IL-3 IL-3 MCP-2 MCP-2 TNF-p TNf^p
Pos Pos IL-2 IL-2 MCP-1 MCP-1 TNF-a TNF-a
Table 2.2 Layout of multiple cytokine arrays.
84fused  to  a  luciferase  reporter  as  previously  described^^^.  The  cells  were 
maintained in D-MEM (Invitrogen, Paisley, UK) supplemented with  10% foetal 
calf  serum  (Invitrogen)  and  penicillin/streptomycin.  Cells  were  plated  to 
confluence. A standard curve was derived using recombinant human TGF-p (0-1 
ng/ml). Skin window fluid from 2.4.3 was diluted to 3-fold,  10-fold and 20-fold, 
and then heat-activated at 85°C for 10 min. These were added to MLECs with an 
equal volume of medium and incubated for 18 h. Medium was aspirated and cells 
washed  with  phosphate  buffered  saline  (PBS;  Oxoid,  ON,  Canada),  lysed  and 
incubated on a rocker for 30 min. Luciferase reagents (Promega, WI, USA) were 
added and the signal detected using a luminometer (PerSeptive Biosystems, MA, 
USA).
2.4.7  Protein gel electrophoresis
Sodium  dodecyl  sulfate-polyacrylamide  gel  electrophoresis  (SDS-PAGE)  was 
carried out using standard Laemmli methods^^^. Mini gels of 10 x  8 x 0.08 cm 
were  cast  using  30%  (w/v)  acrylamide/0.8%  (w/v)  bisacrylamide  solution 
(Protogel; National Diagnostics, GA, USA), for a final concentration of 8-12% 
acrylamide  depending  on  the  size  of the  protein  of  interest.  In  all  cases,  a 
stacking gel containing  5% acrylamide was used.  Samples of skin window cell 
extracts were prepared by  adding 20% volume  of sample buffer (0.06  M  Tris- 
HCl pH 6 .8,  1% sodium dodecyl sulfate (SDS), 0.03 M sucrose and  17.9 pM P- 
mercaptoethanol  (VWR),  0.04%  (w/v)  bromophenol  blue  (VWR)).  They  were 
heated to 95°C for 2 min and spun down (15,000 g, 2 min, 4°C). Hoefer Mighty 
Small  II  SE  250  systems  (Hoefer,  CA,  USA)  were  used  for  electrophoresis, 
operated at 2 0 mA per gel.
852.4.8 Western blotting
Samples  were  transferred  from  gels  to  nitrocellulose  membrane  (Hybond-P; 
Amersham Biosciences, Buckinghamshire, UK) using a semi-dry blotter (Trans- 
Blot SD Semi-Dry Transfer Cell, Bio-Rad), in transfer buffer (200 mM glycine, 
0.1  % SDS (w/v),  10% methanol (v/v)), 25 mM Tris-HCl pH 8 .8) for 1   h at 1.25 
mA/cm^.  Protein  sample  and  transfer  quality  were  confirmed  by  reversible 
staining with Ponceau Red.  Membranes were blocked  for  1   h with 5%  non-fat 
milk (w/v) in TBS/0.05% Tween-20 (v/v). Membranes were probed with primary 
antibodies (1:500, in 5% milk) against myeloperoxidase or lactoferrin (produced 
in  the  laboratory  by  E.  Reeves  by  immunization  of  rabbits  with  purified 
recombinant proteins) overnight at 4°C.
Membranes were washed (4x5 min) and incubated with HRP-conjugated 
anti-rabbit IgG antibody (Amersham  Biosciences;  1:2,000 in 5% milk) for  1   h, 
washed again, developed using the Enhanced Chemiluminescence method (ECL 
PLUS;  Amersham  Biosciences),  and  the  autoradiograph  processed  with  an  X- 
Omat film developer (Kodak, Hertfordshire, UK).
2.4.9 Multi-channel Western blots
In a separate  set of experiments, cells were removed from  filter papers using a 
cell scraper and lysed in  1   ml hypotonic buffer (10 mM HEPES pH 7.9,  10 mM 
KCl,  10  mM  EDTA,  10  mM  dithiothreitol  (DTT),  Protease  Inhibitor Cocktail. 
0.5%  IGEPAL  and  phosphatase  inhibitors 25  mM NaF,  1   mM Na3V0 4  and 25 
mM Na4P2Û7). The mixture was rotated at 4"C  for  10 min and then centrifuged
86(15,000 g,  3  min).  The supernatant was taken as the cytosolic  fraction, and the 
pellet retained for nuclear proteins (see 2.4.10).
Cytosolic protein was quantified by Bradford assay^^"^, by incubating with 
Coomassie  brilliant  blue  G-250  dye  (Pierce,  IL,  USA)  then  comparing  the 
absorbance at 595 nm to a standard curve of bovine serum albumin (ESA; 0-200 
pg/ml). Equal concentrations (250pg/ml) were run across the top of a  10% SDS- 
polyacrylamide  gel  containing  a  single  long  well.  Protein  was  transferred to  a 
Hybond-P membrane and blocked as before (see 2.4.8). The membrane was then 
placed on a Mini-Protean II multi-screen apparatus (Bio-Rad) that allows probing 
with 20 different antibodies on a single blot. Primary antibodies were incubated 
overnight (15:2,000  in  5% BSA  (w/v)/TBST;  see Table  2.3  for list of primary 
antibodies  used).  The  membrane  was  washed  (5x5  min),  incubated  with 
donkey  anti-rabbit  peroxidase-conjugated  secondary  antibody  for  1  h,  washed 
again and positive bands visualized with ECL Plus.
To determine phosphorylation status of different PKC isoforms, samples 
from different subjects were run on the same gel (as in 2.4.8), then transferred to 
Hybond-P membrane and probed using the same protocol with antibodies against 
pan-phosphorylated  PKC,  and  phosphorylated  PKCa/p,  PKCÔ,  PKCÇ/X,  PKC0 
and PKCp (Cell Signalling Technology, MA, USA).
2.4.10  DNA-bindingprotein arrays
Nuclear pellets were prepared as described in 2.4.9. These were resuspended in 
200  pi  Complete  Lysis  Buffer  (20  mM  HEPES  pH  7.9,  0.4  M  NaCl,  ImM 
EDTA,  ImM  DTT,  10%  glycerol  (VWR)  and  Protease  Inhibitor Cocktail)  and 
incubated on a shaking platform at 4°C for 30 min. The extract was centrifuged
87Protein
Phosphorylation
Site Company Catalogue Number
4E-BP1 8er65 Cell 8ignalling Technology #9451
Akt 8er473 Cell 8ignalling Technology #9271
Akt Thr308 Cell 8ignalling Technology #9275
Bad 8er112 Cell 8ignalling Technology #9296
Bad 8er155 Cell 8ignalling Technology #9297
cdc2 Tyr15 Cell 8ignalling Technology #9111
cdc25 8er216 Cell 8ignalling Technology #9528
Chk1 8er345 Cell 8ignalling Technology #2341
Cleaved caspase-3 np Cell 8ignalling Technology #9661
Cleaved caspase-7 np Cell 8ignalling Technology #9491
Cleaved caspase-9 np Cell 8ignalling Technology #9501
Cleaved PARP np Cell 8ignalling Technology #9541
c-Raf 8er338 Cell 8ignalling Technology #9427
CREB 8er133 Cell 8ignalling Technology #9191
EGFR Tyr1173 Cell 8ignalling Technology #2244
elF4E 8er209 Cell 8ignalling Technology #9741
FKHR 8er256 Cell 8ignalling Technology #9461
GSK-30 8er9 Cell 8ignallinq Technology #9336
IxB-a 8er32 Cell 8ignalling Technology #9241
Jak1 Tyr1022/1023 Cell 8ignalling Technology #3331
Jak2 Tyri 007/1008 Cell 8ignalling Technology #3771
MEK1/2 8er217/221 Cell 8ignalling Technology #9121
Mnk1 Thrl 97/202 Cell 8ignalling Technology #2111
mTOR 8er2448 Cell 8ignalling Technology #2971
NF-kB p105/p50 np Cell 8ignalling Technology #3035
NF-kB p65 8er276 Cell 8ignalling Technology #3037
p38 MAP kinase Thr180/Tyr182 Cell 8ignalling Technology #9211
p44/p42 MAP kinase Thr202/Tyr204 Cell 8ignalling Technology #9101
p53 8er15 Cell 8ignalling Technology #9284
p53 8er392 Cell 8ignalling Technology #9281
p53 8er6 Cell 8ignalling Technology #9285
p70 86 kinase Thr389 Cell 8ignalling Technology #9205
p90rsk 8er381 Cell 8ignalling Technology #9341
PDK1 8er241 Cell 8ignalling Technology #3061
PI3 kinase Tyr508 8anta Cruz SC-12929
PKA catalytic subunit 3 8er338 Biosource 44-992
PKA substrate Cell 8ignalling Technology #9621
PKCa/3 Thr638/641 Cell 8ignalling Technology #9375
PKCÔ 8er643 Cell 8ignalling Technology #9376
PKCÔ Thr505 Cell 8ignalling Technology #9374
PKC^i 8er744/748 Cell 8ignalling Technology #2054
PKCn 8er916 Cell 8ignalling Technology #2051
PKC0 Thr538 Cell 8ignalling Technology #9377
PKCCA Thr410/403 Cell 8ignalling Technology #9378
PLCy1 Tyr783 Cell 8ignalling Technology #2821
PLCy2 Tyri 217 Cell 8ignalling Technology #3871
PTEN 8er380 Cell 8ignalling Technology #9551
Raf 8er259 Cell 8ignalling Technology #9421
Rb 8er780 Cell 8ignalling Technology #9307
Rb 8er795 Cell 8ignalling Technology #9301
Rb 8er807/811 Cell 8ignalling Technology #9308
86 ribosomal protein 8er235/236 Cell 8ignalling Technology #2211
8APK/JNK Thr183/Tyr185 Cell 8ignalling Technology #9251
8rc Tyr416 Cell 8ignalling Technology #2101
8rc Tyr527 Cell 8ignalling Technology #2105
8yk Tyr323 Cell 8ignalling Technology #2715
8yk Tyr525/526 Cell 8ignalling Technology #2711
TrkA Tyr490 Cell 8ignalling Technology #9141
Zap-70 Tyr319 Cell 8ignalling Technology #2701
Table 2.3 Antibodies used for multi-channel Western blots.
88(15,000  g,  10  min,  4°C)  and  the  supernatant  used  to  probe  TranSignal 
Protein/DNA Arrays Version I (Panomics, CA, USA) following the instructions 
from  the  manufacturer.  These  arrays  are  spotted  with  54  different consensus- 
binding sequences, each corresponding to a specific transcription factor. In brief, 
15 pg of total nuclear proteins were incubated with biotin-labeled DNA-binding 
probes (Tran-Signal Probe Mix) to allow the formation of protein-DNA (or TF- 
DNA) complexes.  These were separated from free probes by electrophoresis in 
agarose gels. Probes present in the complexes were eluted and hybridized to the 
TranSignal  membrane  dotted  with  complementary  non-labeled  probes,  and 
signals detected by chemiluminescence.
2.4.11  Reverse transcriptase-Polymerase Chain Reaction
Cells  attached  to  approximately  one-eighth  of the  filter  paper  were  lysed  by 
vortexing in guanidium thiocynate solution (RLT buffer; Qiagen) supplemented 
with 0.1 M 2-mercaptoethanol. Total RNA was isolated with the RNeasy mini kit 
(Qiagen),  1   pg of which was reverse transcribed by use of dT primers. A cDNA 
equivalent corresponding to 20 ng of total RNA was amplified in each reaction. 
The primers used for PCR were:
CD14 primer (forward):  5’-CACGCCAGAACCTTGTGAG-3’
CD14 primer (reverse):  5’-CCCAGTCCAGGATTGTCAG-3’
GAPDH primer (forward):  5'-GTCACCAGGGCTGCTTTTAAC-3'
GADPH primer (reverse):  5’-TGCTTCACCACCTTCTTGATG-3’
89As a control of mRNA input, GAPDH mRNA levels were determined for each 
sample in separate reactions. The PCR reactions contained dNTPs and buffer as 
supplied  by  the  manufacturer,  500  pM  of each  specific  primer  and  3  U  Taq 
polymerase  (RedTaq).  Transcripts  were  amplified  for  29  cycles  with  CD 14 
primers  (30  s  at 94°C,  30  s  at  56°C,  30  s at  72°C)  and 20 cycles  for GAPDH 
primers (30 s at 94°C, 30 s at 58°C and 45s at 72°C), followed by 7 min at 72°C. 
PCR  products  were  analyzed  by  2%  agarose  gel  electrophoresis,  stained  with 
ethidium  bromide,  and  visualized  by  UV  illumination.  For  GAPDH 
amplification,  PCR was performed with different cycle  numbers to  ensure  that 
amplification was occurring within the linear range.
2.4.12  Analysis
Comparisons within one group of subjects for a treatment effect were performed 
using  a  2-tailed  students’  t-test  (Microsoft®  Excel  2003).  For  those  between 
different groups and under different conditions, data were compared using a  2 - 
way ANOVA with Bonferroni post-tests (Graphpad Software). The threshold for 
significance was P < 0.05.
2.5  Macrophage cytokine production
2.5.1  Macrophage isolation and culture
Peripheral venous blood was collected into 5 U/ml heparin (CP Pharmaceuticals, 
Wrexham, UK) and mixed with an equal volume of balanced salt solution (0.14 
M  NaCl,  0.01%  anhydrous  D-glucose,  5  pM  CaCb,  98  pM  MgCb,  0.54  mM 
KCl,  14.5 mM Tris HCl pH 7.6). Mononuclear cells were isolated by differential 
centrifugation  (15  min,  800  g,  20°C)  over  Ficoll-Paque  PLUS  (Amersham
90Biosciences) and washed repeatedly with phosphate-buffered saline (PBS) using 
low speed spins (15min, 200 g) to remove platelets.  Cells were resuspended in 
medium and plated at a density of approximately 5x10^ cells/ml in 8 cm^ tissue 
culture  dishes  (VWR).  The  medium  used  was  RPMI-1640  (Invitrogen) 
supplemented with  10% normal human serum and penicillin/streptomycin for the 
Escherichia coli LPS (see 5.2.1) and MDP (see 5.2.2-5.2.4) experiments, and X- 
Vivo-15 (Cambrex, MD, USA) containing gentamicin for the other experiments. 
Cells were cultured for 5 days at 37°C, 5% CO2.
Macrophage culture purity was assessed by immunostaining for the pan­
macrophage marker CD6 8^^^ (Santa Cruz Biotechnology, CA, USA). Cells were 
fixed on cover slips in 4% paraformaldehyde for  10 min, washed 3  times with 
PBS and blocked with normal goat serum (1:1,000 in TBST/10 mM NaBH#) for 
1   h. This was replaced with primary antibody at a dilution (1:200) overnight at 
4°C, and then washed four times with PBS. Secondary antibody was donkey anti­
mouse conjugated to FITC  (1:200 in TBST) and incubated for  1   h in the dark. 
Slides  were  washed  then  mounted  with  VectaShield  anti-fade  mountant 
containing  DAP!  nuclear  stain  (Vector  Laboratories,  CA,  USA).  For  controls, 
primary  antibody  was  omitted  or  lymphocytes  were  used;  neither  showed  any 
staining.  The  numbers  of positive  cells  in  five  randomly  selected  high  power 
fields per cover slip were averaged and calculated as a percentage of the positive 
staining nuclei. In all samples tested, purity was >95%.
2.5.2  LPS stimulation and IL-12 ELISA
Macrophages were incubated for  15 h at 37°C and 5% CO2 with or without  100 
ng/ml Escherichia coli 0157. B8 LPS. The supernatant was centrifuged (15,000 g.
912  min)  then  assayed  for  IL-12p70  by  ELISA;  the  protocol  for  the  latter  was 
similar to the sandwich ELISAs used previously (see 2.4.4).
2.5.3 MDP stimulation and RNA isolation
Macrophages  were  incubated  for  15  h  with  or  without  100  ng/ml  MDP.  This 
concentration  was  reported  to  cause  differential  effects  on  cells  carrying  wild 
type and variant CARD 15 alleles respectively at the time these experiments were 
performed^**.  Cells  were  lysed  in  TRlzol  reagent  (Invitrogen)  and  total  RNA 
isolated  by  extraction  with  chloroform  (VWR)  followed  by  precipitation  with 
isopropanol (VWR). The pellet was washed with 75% ethanol (VWR), air-dried, 
and  re-dissolved  in  DEPC-treated  water.  The  quality  and  quantity  of  these 
samples  was  determined  using  an  Agilent  Bioanalyzer  (Agilent  Technologies, 
CA,  USA)  following the  instructions  from  the  manufacturer.  In the  event  that 
insufficient  RNA  was  isolated,  equal  amounts  of sample  from  subjects  were 
combined  to  produce  adequate  starting  material.  These  were  then treated  as  a 
new  individual  sample.  Expression  patterns  from  samples  pooled  in  this  way 
were completely consistent with results obtained from individuals.
2.5.4 DNA microarrays
Approximately 5 pg total RNA from each independent sample was processed to 
produce biotinylated cRNA targets. Double-stranded cDNA was synthesized by 
reverse  transcription  of twice-purified  mRNA  using  T7-(T% 4)  primers  (Genset, 
CA,  USA)  and  the  Superscript  11  cDNA  Synthesis  System  (Invitrogen).  The 
cDNA  was  used  as  a  template  for  the  generation  of  biotin-labeled  in  vitro 
transcription  products  using  the  Ambion  T7  Megascript  System  (Ambion)  and
92biotin-11-CTP  and  biotin-16-UTP  (Enzo  Diagnostics  Inc.,  NY,  USA).  The 
biotinylated  cRNA  products  were prepared  and  hybridized to  Human  Genome 
U133A arrays following standard Affymetrix procedures (www.affvmetrix.com) 
using an Affymetrix Fluidics station (Affymetrix, CA, USA) and, after extensive 
washing, were scanned on a GeneArray scanner G2500A (Hewlett Packard, CA, 
USA).
Each array demonstrated control parameters within recommended limits 
(Raw Q  <30, background <100,  GAPDH  3’:5’  ratio  <4).  Global  normalization 
was  performed  on  each  chip  and  data  scaled  against  a  reference  chip.  After 
exclusion of the highest and lowest  2% of the  data points  from  each chip,  the 
mean and standard deviation of the log2(signal) from each chip were calculated 
and a mean-corrected log] value produced for each data point.  The scale  factor 
for the  chips  was  calculated  as  the  ratio  of mean-corrected  log]  values  of the 
reference [R] and each target chip [T] as:
S[log](signalR) -  mean log](signala)] / I[log](signalT) -  mean log](signalx)]
2.5.5  Gene expression analysis
Data from 2.5.4 were analyzed using the commercially available Spotfire® 
visualization and analysis program (www.spotfire.com; Spotfire, MA, USA). 
Probes were filtered for those showing at least 2-fold change in expression, 
sorted using a Euclidean distance matrix and clustered hierarchically then joined 
to form a dendrogram. The full length genes were annotated using the in-house 
system developed by Inpharmatica, which relies on the Biopendium™ 
(Inpharmatica, London, UK). All genes in which there was a change in the mean 
level of expression of 2-fold or greater were analyzed for the effects of treatment
93between the control and patient groups by 2-way ANOVA with Bonferroni post­
tests (Graphpad Software).
2.5.6 Post-genomic verification
Post-genomic verification was provided by measuring cytokine secretion in cell 
culture  supernatants  from  unstimulated  and  MDP-stimulated  cells  from  2.5.3. 
Samples were assayed using ELISAs for IL-ip,  IL-8,  IL-10,  IL-12  and TNF-a 
(R&D  Systems),  following  the  protocol  described  in  2.4.4.  Protein  from 
macrophages  was  also  prepared  by  lysis  in  sample  buffer  containing  protease 
inhibitors as described previously (see 2.4.7) and a Western blot performed (see 
2.4.8) using a rabbit anti-TIMP-3 antibody (1:1,000 in 5% milk/TBST).
2.5.7 Structural modelling
The full  length protein sequence of CARD 15  from  SwissProt (Q9HC29;  Swiss 
Institute  of  Bioinformatics,  Geneva,  Switzerland)  was  annotated  using  PSI- 
BLAST^^^ and GenomeThreader^^^ fold recognition algorithms as  implemented 
in the Biopendium™  To better define domain boundaries, 3D structures and 
aid alignments, the secondary structure of the LRR domain was predicted using 
the PSI-PRED algorithm^^* obtained from the Biopendium^'^; if necessary, some 
manual  adjustments  were  made.  Alignments  were  used  to  create  homology 
models  using  MODELLER^^^  v6.1  (University  of California,  CA,  USA).  The 
molecular surface and electrostatic potentials of the models were calculated using 
GRASP^^® (University of Leeds, Leeds, UK).
942.5.8 Collection of wound  fluid
Wound fluid was collected from otherwise healthy patients undergoing elective 
surgery for inguinal hernia repair.  Swabs, used to remove blood and fluid from 
the wound, were retrieved 2 min after the incision and the fluid eluted into  10 ml 
sterile normal saline. This was placed immediately on ice, centrifuged (20,000 g, 
10 min, 4°C), snap frozen and stored at -70°C until use. Serum was derived from 
peripheral  venous  blood  collected  into  a  serum  separator  tube  (Becton 
Dickinson), and then spun (2,000 g, 10 min).
2.5.9 2D gel electrophoresis and mass spectrometry
Two-dimensional  polyacrylamide  gel  electrophoresis  (2D-PAGE)  separates 
proteins  first  according  to  pi  (through  isoelectric  focusing)  followed  by 
molecular weight (by SDS-PAGE). Protein in each sample was quantified using 
the Bradford assay. Protein was precipitated with  110 pl/ml trichloroacetic acid 
in  acetone  (VWR),  spun  down  and  washed  in  80%  acetone  (v/v),  dried  and 
resuspended in CHAPS buffer (8 M urea, 2 M thiourea, 4% CHAPS, 0.8% (w/v) 
ampholyte,  1%  (v/v)  Triton  X-100,  65  mM  DTT,  Complete  Mini  Protease 
inhibitors).  The  sample  was  heated to  95°C  for  5  min,  sonicated  (10  x  10  sec 
pulses)  then  added  to  immobilized  pH  gradient  strips  (pH  3-10;  Amersham 
Biosciences). This was overlaid with 500 pi mineral oil, then run overnight on an 
IGPhor machine (Amersham Biosciences) for 60 kVh.  Strips were equilibrated 
twice for 15 min each in equilibration buffer (30% glycerol (v/v), 2% SDS (w/v), 
6 M  urea,  50 mM Tris-HCl pH  6 .8).  The  first equilibration step contained 2%
95(w/v)  DTT  and  the  second  4.5%  (w/v)  iodoacetamide.  The  second  dimension 
was run on a large 10% SDS-PAGE gel (see 2.4.7) at 40 V overnight.
Gels were fixed in 50% (v/v) methanol, 5% (v/v) acetic acid (VWR) for 
20 min. They were then washed in 50% methanol for  10 min and H2O for 2 h, 
sensitized  in  0 .0 2%  (w/v)  NaiSzO]  for  1  min,  washed  twice  with  H2O,  then 
incubated in cold 0.1%  (w/v) AgNO]  for 20 min.  Gels were washed with H2O 
and  developed  in  0.04%  (v/v)  formalin/2%  (w/v)  Na2C0 3 .  Staining  was 
terminated with 5% (v/v) acetic acid^^\ Spots of interest on the gel were cut and 
soaked in 200 pi 50 mM NH4HCO3 for 15 min. The buffer was removed and gel 
pieces dried in 200 pi acetonitrile for 10 min then in a Speedvac (Thermo) for 30 
min followed by rehydration in  10 mM DTT/100 mM NH4HCO3 for 30 min at 
56°C;  the  acetonitrile  step  was  then  repeated.  Samples  were  digested  with  75 
ng/pl  trypsin/25  mM NH4HCO3  and  incubated  overnight  at  30°C.  The  sample 
was  spotted  onto  a  target  plate  and  covered  with  10  mg/ml  a-cyano-4- 
hydroxycinnamic acid matrix in 35% (v/v) acetonitrile, 0.1% (v/v) trifluoroacetic 
acid  and  analyzed  by  MALDI-TOF  in  the  laboratory  of  J.  Godovac- 
Zimmermann.
2.5.10  IL-8 ELISA development kit
Macrophages from huffy coats were cultured as described previously (see 2.5.1) 
and  incubated  with  various  dilutions  of  wound  fluid.  IL-8  secretion  was 
measured  using  an  ELISA  Development  Kit  (R&D  Systems).  The  anti-IL-8 
capture  antibody was  used to  coat a 96-well  plate overnight.  This was washed 
three times with Wash Buffer (0.05% Tween-20 in TBS), then blocked with  1% 
BSA/0.05% NaN3  in TBS,  washed,  then  samples  and  standards  added  for 2  h.
96Wells were washed again then streptavidin-HRP added for 20 min in the dark. 
The colour reaction was developed using TMB substrate solution for 20 min in 
the dark, stopped with 1  M H 2S O 4 and read at 450 nm.
2.5.11  Wound  fluid inhibitor studies
The  effects  of different  inhibitors  on wound  fluid-induced  IL-8  secretion  were 
assessed.  These  included  pre-treatment  of the  wound  fluid  with  H-d-Phe-Pro- 
Arg-CH2C1  (PPACK,  10  nM  pre-heated  to  37°C),  Complete  Mini  Protease 
inhibitors (1  tablet/10ml) or heating to 56°C for 30 min, or pre-treatment of the 
macrophages for 30 min prior to addition of wound fluid with 100 ng/ml cholera 
toxin  (Calbiochem,  CA,  USA)  or  pertussis  toxin  (Calbiochem).  Individual 
inhibitors were incubated with the cells in the absence of wound fluid to confirm 
no adverse effects on viability.
2.5.12 CH50 assay
Antibody-sensitized  sheep  erythrocytes  were  suspended  in  ice-cold  gelatin 
veronal  buffer  (GVB^^).  A  200  pi  aliquot  was  lysed  in  2.8  ml  dH2 0   and  the 
optical  density  read  at  405  nm  (OD405).  Further  GVB^^  was  added  to  give  a 
concentration of 10* cells/ml (final volume = [OD405/O.7 3] x  10 ml). Serum was 
prepared from 3 healthy controls and 200 pi of this or wound fluid added to 50 pi 
erythrocytes. Controls were GVB^^ or dH2 0  for 0% and 100% lysis respectively. 
Samples were incubated at 37°C for 30 min (the reaction was then stopped with 
250 pi ice-cold PBS), spun (2,000 g, 5 min, 4°C) and the OD405 measured. CH50
97was calculated as the titre of serum or wound fluid producing the mean of the 
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2.5.13 Response to alternative inflammatory agonists
Macrophages were cultured for 5 days in X-Vivo-15 medium (serum-ffee), then 
re-plated at equal  densities in a 96-well plate and allowed to adhere overnight. 
These were stimulated for 6 h with wound fluid (300 pg/ml protein), C5a (500 
ng/ml),  TNF-a  (5  ng/ml;  Calbiochem)  or  Salmonella  typhimurium  LPS  (100 
ng/ml). The supernatants were removed and measured for the production of IL-8 
by  ELISA  as  described  in  2.5.10.  Numbers  of viable  cells  in  each  well  were 
determined using the Cell Counting Kit-8 (Alexis, CA, USA)^^\ Briefly,  100 pi 
medium and 8 pi  5 mM WST-8 were added to the cells, which were incubated 
for 90 min at 37°C, 5% CO2, and the A450 measured. This assay was validated by 
measuring the A450 for serial dilutions of buffy coat macrophages. Subjects from 
different groups were  stimulated and compared simultaneously.  Basal  cytokine 
secretion  was  minimal  and  similar  in  all  groups.  Cytokine  secretion  was 
expressed normalized to cell count with basal secretion subtracted.
2.5.14 Phosphorylation of  p44/p42 MAP kinase
Macrophages were prepared as above (see 2.5.13) and stimulated for 2 min with 
500  ng/ml  C5a,  then  washed  in  ice-cold  PBS  and  lysed  in  sample  buffer 
containing protease and phosphotase inhibitors (25 mM Tris-HCl pH 7.4, 25 mM 
NaCl,  25  mM NaF,  25  mM  Na4P20?,  1   mM Na3V0 4 ,  1   tablet  Complete  Mini 
Protease inhibitors per 10 ml, 0.05% Triton X-100, 0.5% (w/v) SDS, 0.5% (v/v) 
NP-40, 0.5% (w/v) sodium deoxycholate, 0.02% bromophenol blue). These were
98run on a 10% SDS-polyacrylamide gel (see 2.4.7) then blotted (see 2.4.8) against 
rabbit anti-phosphorylated p44/p42 MAP kinase (1:1,000 in 5% BSAATBST) for 
1   h. The secondary antibody was donkey anti-rabbit conjugated to HR? (1:2,000 
in 5% milk/TBST).
Membranes were then stripped (62 mM Tris-HCl pH  6 .8, 0.7% (v/v) 2- 
mercaptoetbanol, 2% (w/v) SDS) for  1   b at 50°C on a rotator, washed, blocked 
and  re-probed  with  rabbit  anti-p44/p42  MAP  kinase  (Cell  Signalling 
Technology;  1:1,500 in 5% BSA/TBST) for  1   b. The same secondary antibody 
was used (1:3,000).
2.5.15  Analysis
For single comparisons, the 2-tailed students’ t-test was used (Microsoft® Excel 
2003). Multiple comparisons were made by 1-way Kruskal-Wallis ANOVA with 
Dunn  post-tests  or  2-way  ANOVA  with  Bonferroni  post-tests  as  appropriate 
(Grapbpad Software). The threshold for significance was P < 0.05.
2.6  Bacterial injections
2.6.1  Bacterial culture and sterilisation
A fully antibiotic-sensitive clinical isolate of Escherichia coli NCTC  10418 was 
obtained  from  UCLH  Clinical  Microbiology  and  grown  overnight  in  minimal 
citrate  medium  (5  g/1  glucose,  10.5  g/1  K2HPO4,  4.5  g/1  KH2PO4,  1   g/1 
ammonium  acetate,  2.5  g/1  sodium  citrate,  0.2  g/1  MgS0 4 ,  10  mg/1  ferric 
ammonium  citrate,  10 mg/1  MnCh,  2 0 mg/1  CaCb)  supplemented with  1.25  g/1 
yeast extract (Oxoid) in sterile conditions. The bacteria were spun down, washed 
and resuspended  in PBS  and killed by beating to  80°C  for 30 min.  They were
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and stored at -70°C. Sterility was confirmed by culture. Bacterial concentrations 
were determined by measuring the optical density of the sample at 595 nm (OD 
for  1   X  10*  bacteria/ml  =  0.365  for Escherichia coli^^^).  Bradford  assays were 
performed to determine the amount of protein present (see 2.4.9).
2.6.2  Labelling with ^^^Technetium
Bacteria  were  incubated  with  for  5  min  with  30  MBq  [^^"^Tc]-sodium 
pertechnetate (Amersham Biosciences), reconstituted in the presence of either 40 
pM  stannous  chloride^^^  (reducing  the  chemically  stable  species  to  a  reactive 
ligand)  or  lipophilic  exametazime  (Amersham  Biosciences).  Both  led  to 
incorporation of the label into the cell membrane. Following this, 0.5 ml of 0.9% 
NaCl (injection grade) was added and the mixture centrifuged (15,000 g, 3 min). 
The  supernatant  was  removed  and  the  bacteria  washed  with  0.9%  NaCl, 
centrifuged  then  re-suspended  in  1   ml  NaCl.  Radioactivity  was  measured  to 
calculate labeling efficiency.
The  stability  of the  label  was  assessed  following  6  h  incubation  with 
normal human serum (see 2.5.8) or neutrophils. Neutrophils were obtained from 
peripheral  venous  blood  collected  under  heparin.  Red  cells  were  removed  by 
sedimentation with dextran (1% final concentration (w/v); mean MW = 260 kDa) 
and  granulocytes  isolated  by  centrifugation  through  Lymphoprep^^^.  Further 
erythrocytes in the neutrophil pellet were lysed by exposure to hypotonic dHzO, 
immediately followed by an equal volume of 1.8% (w/v) NaCl. Neutrophils were 
resuspended  in  Dulbecco’s  PBS  containing  5  mM  glucose.  Radioactivity  was 
measured with a handheld y-counter.
1002.6.3 Bacterial injections
Bacteria for injection were thawed and resuspended at a protein concentration of 
10 mg/ml in injection-grade normal saline. An aliquot of this suspension (100 pi 
containing 1  mg or 10^ organisms) was then injected into the volar aspect of each 
forearm.  In the one  subject into whom  radiolabeled bacteria were  injected,  the 
radioactivity  remaining  the  forearm,  original  sample  or  sample  of peripheral 
venous blood was measured using a y-counter and imaged using a y-camera in 
the Institute for Nuclear Medicine, UCLH.
Full clinical details were documented for each subject. In addition to the 
investigations described below, the use of any medication over the course of the 
experiment was  noted.  Pain  scores  for the  site  of injection were taken at each 
time point, using a visual analog scale between 0 (no pain) and  10 (worst pain 
imaginable).  Any other symptoms  occurring over the time  course  of the  study 
were  recorded,  as  was  the  time  of maximum  symptoms  and time  to  complete 
resolution. Any discomfort at the injection site that was great enough to interfere 
significantly with normal daily activities was treated with analgesics, usually  1   g 
paracetamol  orally.  Subcutaneous  masses  that  developed  at  the  injection  site 
were measured in all three dimensions by standard B-mode ultrasound, using the 
settings  for clinical  study of soft tissue masses,  in the Department of Imaging, 
UCLH.
2.6.4 Determination of blood  flow
The area of erythema at each injection site was measured at 8 h, 24 h and 48 h 
following  injection.  The  blood  flow in this region was determined at the  same
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Devonshire, UK)^^^. The laser was operated at a height of 30 cm from the skin 
surface with the arm in supination. Scans were always taken on the same default 
settings  from  the  manufacturer,  except  for  those  studies  in  which  subjects 
received an arterial cannula (see 2.6.9). In the latter, the arm needed to be raised 
onto  a  cushion,  such  that  the  distance  to  laser,  area  scanned  and  resolution 
settings had to be altered (although they were consistent throughout each study). 
These data were only used to compare the effects of different pharmacological 
agents on forearm blood flow and were not included in the comparisons to other 
subjects or other time points, for which separate scans using the regular settings 
were  acquired.  Data  were  analyzed  using  the  software  provided  by  the 
manufacturer,  and  blood  flow  calculated  as  a  volume  under  the  curve  by 
multiplying the area of increased flow by the mean pixel intensity for that region. 
In some subjects, the lower limb was also scanned as a control vascular bed, to 
test whether any  differences  in  blood  flow represented  generalized  or  specific 
vasodilatatory responses.
2.6.5  Systemic acute phase response
Blood was  collected prior to  and at 24  h and 48  h  following  inoculation.  Full 
blood  counts  were  performed  through  the  clinical  service  at  the  UCLH 
Haematology  Department  to  determine  circulating  total  white  cell  counts  and 
differential, haemoglobin and platelet numbers. Serum was isolated as described 
previously  (see  2.5.8)  and  measured  for  concentrations  of  GRP  and  serum 
amyloid A (SAA) by automated microparticle capture enzyme immunoassay^^*' 
Briefly,  the  assay  was  based  on two  monoclonal  mouse  anti-CRP  or  SAA
102antibodies, one immobilized onto microparticles, the other conjugated to alkaline 
phosphatase (ALP). The amount of acute phase protein captured from the sample 
was linearly related to the colour reaction, and compared to standards of purified 
CRP or SAA.
2.6.6 Multiple cytokine assay
Serum IL-lp, IL-6, IL-8, IL-10, IL-12, TNF-a and IFN-y were quantified using 
the  Bio-Flex  Cytokine  Assay  (Bio-Rad),  following  the  manufacturer’s 
instructions.  The  array  system  uses  a  combination  of  fluorescently-dyed 
microspheres  (each  containing  two  dyes  in  different  proportions  to  allow 
identification) to which antibodies recognizing specific cytokines are bound. The 
antibody-coupled beads were incubated with samples or standards for 30 min in a 
shgiker  to  allow  binding  of  cytokines,  then  washed  three  times  to  remove 
unbound  protein.  A  biotinylated  detection  antibody  specific  for  a  different 
epitope  on  the  cytokine  was  added,  incubated  for  30  min  then  washed. 
Streptavidin-phycoerythrin was  added  for  10  min and  a final  wash performed. 
The  constituents  of each  well  were  drawn  into  the  Bio-Flex  suspension  array 
system,  which  identifies  and  quantitates  each  specific  reaction  based  on  bead 
colour and fluorescence, and compared to cytokine standards.
2.6.7 Bacterial digestion by neutrophils and organ bath studies
Neutrophils  were  isolated  from  three  healthy  controls,  as  described  previously 
(see 2.6.2). Another sample of bacteria from the same batch of Escherichia coli 
that had been administered to  subjects (containing  10^ bacteria) was opsonized 
with either 1  mg purified human IgG or 1   ml human serum (see 2.5.8) for 30 min
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pi normal saline, added to 10* neutrophils and incubated for 60 min at 37°C with 
constant  stirring.  The  sample  was  spun  (13,000 g,  2  min)  and the  supernatant 
added  immediately  to  superior  mesenteric  arteries  in  organ  baths,  where  they 
were incubated for 1  h at 37°C.
Rings  of superior  mesenteric  artery  were  obtained  from  male  Sprague 
Dawley rats (200-300 g). The superior portion of the artery was dissected from 
its origin at the aorta to the distal portion. The vessel was placed in sterile Hanks 
Balanced  Salt  solution  (HESS),  cleaned  and  cut  into  rings  3-4  mm  in  length. 
Intact rings of artery were suspended between two tungsten wires in a jacketed 
organ bath (25 ml volume) containing physiological salt solution, maintained at 
37°C, 95% O2, 5% CO2. One of the wires was fixed to an external platform and 
the other connected to an isometric force displacement transducer (FT-03; Glass 
Instruments, Astro-Med UK, Slough, UK) for measurement of tension. Tension 
was  recorded  using  Powerlab  Chart  version  4  (ADInstruments,  Oxfordshire, 
UK). Parallel baths were used simultaneously in these experiments. Rings were 
maintained  at  a  resting  tension  of  1   g  for  1   h,  following  which  1   pM 
phenylephrine was used to contract the vessel then 5  pM acetylcholine to cause 
relaxation,  demonstrating  the  presence  of  functional  tissue  with  intact 
endothelium.  This  was  washed  out  and  tissues  allowed  to  return  to  resting 
conditions  before  adding  supernatants  from  the  neutrophils  that  had  digested 
bacteria.
The  medium  in  the  organ  baths  was  then  washed  out,  and  the  dose- 
response  relationship  between  vessel  mural  tension  and  concentrations  of 
phenylephrine  (1-10,000  nM)  determined.  EC50  was  calculated  as  the
104concentration causing 50% of the maximum contraction.  In all experiments, the 
effects of supernatants were compared to vessels that had not been pre-treated in 
this way, and expressed as a percentage of these controls from the same vessel at 
the same time.
2.6.8 LPS assay
To measure LPS liberated into the blood stream, serum from subjects taken 24 h 
after  bacterial  injection  was  tested  using  the  Pyrogent-5000  assay  (Cambrex). 
Gram-negative bacterial LPS catalyzes the activation of a pro-enzyme coagulase 
in lysates of amoebocytes from the Limulus polyphemus horseshoe crab^^\  The 
coagulase acts on a clotting protein, coagulogen, also present in the lysate, which 
then self-associates to form a gelatinous clot.  The readout relies on turbidity of 
the reaction mix, measured as the optical density, which precedes clot formation. 
The samples were prepared and the assay conducted according to the instructions 
supplied by the manufacturer.
2.6.9 Pharmacological manipulation of blood  flow
Three  healthy  subjects  were  studied  24  h  following  injection  of bacteria  to 
determine the effects on blood flow of intra-arterial norepinephrine (Clinalfa AG, 
Laeufelfmgen,  Switzerland;  240  pmol/min)  followed  by  NG-monomethyl-L- 
arginine  acetate  (1-NMMA;  Clinalfa  AG;  4  pmol/min),  with  a  normal  saline 
washout  between  the  two^*^.  These  studies  were  carried  out  with  the  subject 
supine  in a quiet,  temperature-controlled  laboratory.  The  brachial  artery  of the 
non-dominant  arm  was  cannulated  with  a  27-gauge  needle  (Cooper’s  Needle 
Works  Ltd.,  Birmingham,  UK)  inserted  under  local  anaesthesia  (2  ml  of  1%
105lidocaine).  Resting  blood  flow  was  allowed  to  normalise  following  needle 
insertion prior to the infusion of vasoactive agents. Drugs or saline were infused 
continuously at 0.5 ml/min for 15 min each, and Doppler measurements made at 
2 min, 5 min, 10 min and 15 min after beginning the infusion of each drug.
Some  subjects  were  treated  with  50  mg  sildenafil  citrate  (Pfizer,  NY, 
USA)  orally  at either 24  h or 48  h  (2  patients)  following  inoculation,  and the 
perfusion monitored at 30 min intervals over the next 90 min. Subjects had fasted 
for at least 8 h prior to these experiments.
2.6.10  Analysis
Comparisons within one group of subjects for a treatment effect were performed 
using  a  2-tailed  students’  t-test  (Microsoft®  Excel  2003).  For  those  between 
different groups and/or at different time points, data were compared using a  1- 
way or 2-way ANOVA with Dunn or Bonferroni post-tests (Graphpad Software) 
as appropriate. The threshold for significance was P < 0.05.
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3.1  Introduction
Numerous  theories  as  to  the  underlying  cause  of Crohn’s  disease  have  been 
proposed*^. The vast majority identify an over-activation of the immune response 
as the initiating event, either in reaction to abnormal infectious(see 1.3) or 
particulate  material  within  the  bowel^*"*,  or  as  an  autoimmune  phenomenon^*^. 
Conversely,  it  has  been  proposed  that  the  underlying  abnormality  relates  to  a 
failure  of  acute  inflammation.  Reduced  neutrophil  accumulation  has  been 
demonstrated  following  trauma  to  the  skin,  both  in  the  skin  window^^^  and 
cantharidin blister^*^ models. The mechanism behind this impairment was never 
fully elucidated.
The question remains whether the  same defect applies to the bowel, the 
site  of predilection  for  Crohn’s  lesions  and  therefore  the  most  relevant  if this 
truly represents the  underlying pathogenic  mechanism.  In order to  address this 
problem,  we  sought to  develop  a technique  to  allow  examination  of the  acute 
inflammatory response in a similar manner in the bowel. No method previously 
existed  for  such  an  experiment.  Those  applicable  to  the  skin  include  creating 
abrasive  lesions^*^  and  raising  blisters  either  through  use  of  suction^**  or 
chemical  agents^*^.  Transposed to the gastrointestinal tract, these could  include 
abrading  the  bowel  (for  example  with  a  cytology  brush)  or  provoking  blister 
formation  (using  a  suction  device  or,  in  theory,  chemical  infiltration  of  the 
mucosa). The viability of a blister-based method is somewhat dubious at this site.
107given the fragility of the mucosa in comparison to the skin. In contrast, it is more 
amenable to biopsy, which should provide the required inflammatory stimulus.
3.2  Results
3.2.1 Subject characteristics
Over the course of the whole  set of investigations presented in this thesis,  232 
Crohn’s patients were studied, along with  116 healthy controls and  105 patients 
with  ulcerative  colitis.  Appendix  1   contains  a  full  analysis  of their  clinical 
characteristics  and  carriage  of CARD!5  polymorphisms.  Of note,  14  patients 
with  CGD  were  also  genotyped;  in  this  small  sample  carriage  of  CARD15 
polymorphisms showed a putative association with the development of intestinal 
inflammation (see A 1.3).
Characteristics of the subjects participating in the serial biopsy study are 
detailed (Appendix 1: Tables A1.1-A1.3). All Crohn’s patients were in complete 
remission,  and  all  except  one  was  off treatment  for their  inflammatory  bowel 
disease. The latter had an ileorectal anastomosis and quiescent disease, and was 
willing to participate  in the  study.  Since these  individuals  were very rare,  this 
subject  was  included  in  the  study  despite  use  of mesalazine.  All  subjects  had 
systemic  markers  of  inflammation  within  the  normal  range,  and  none  was 
clinically or biochemically malnourished.
3.2.2 Biopsy lesions can be easily visualized and targeted
Initial biopsies were taken under direct sigmoidoscopic vision, in the presence of 
two investigators. The length of insertion of the sigmoidoscope was noted, and a 
photograph taken of the mucosa. Biopsy induced immediate bleeding at the site
108of  trauma,  with  subsequent  clot  formation.  At  the  second,  post-traumatic 
sigmoidoscopy,  the  site  of  the  earlier  trauma  was  readily  identified  by  the 
presence of the clot (Fig. 3.1 A). Correct location was confirmed by the length of 
insertion of the sigmoidoscope and comparison of the mucosal vascular anatomy 
to  the  previous  photograph.  Forceps  were  positioned  directly  above  the  lesion 
(Fig. 3.IB), a second biopsy taken (Fig. 3.1C) and accurate sampling confirmed 
visually  (Fig.  3.ID).  The  site  of previous  trauma  induced  by  biopsy  could  be 
readily  identified  in all  subjects.  In contrast,  alternative  methods  to  traumatize 
the  mucosa  (including  abrasion  using  a  cytology  brush,  suction,  or  crushing 
using biopsy forceps to injure but not sample tissue), did not generate a lesion 
recognizable after 6 h.
3.2.3  Biopsy triggers a reproducible inflammatory response 
In some control subjects, two biopsies were taken simultaneously from different 
sites (rectum and ileum, or two sites in the rectum). Both were re-biopsied 6 h 
after trauma. The correlation between the responses (number of positive-staining 
cells per high power field) in these duplicate biopsies was analyzed to determine 
variability of the technique.
There was no staining in negative control sections. No neutrophils were 
seen in any baseline samples (Fig.  3.2A,B), but substantial influx was observed 
at both sites on repeat biopsies (Fig. 3.2C-F). In familial adenomatous polyposis 
controls  and  Crohn’s  patients  in  whom  5  paired  biopsies  were  taken  from  the 
rectum and ileum following trauma, numbers of myeloperoxidase-positive or IL- 
8-positive cells were highly correlated (R^ = 0.927, P < 0.05 and  = 0.920, P < 
0.05 respectively). Similarly, in healthy controls in whom 4 paired biopsies were
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Figure 3.1 Post-traumatic biopsy in a control subject at repeat sigmoidoscopy. (A) The 
initial biopsy site was always readily identified (arrow). (B) Biopsy forceps were positioned 
directly over the lesion and (C) the underlying tissue sampled. (D) Correct siting of the 
second biopsy was always confirmed visually.
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Figure 3.2 Intra-indiN idual reproducibility of the inflammatory  response induced by 
mucosal biopsv. Two adjacent sites in the rectum were biopsied simultaneously, in two 
non-inflammatory bowel disease controls. Sections were stained with an antibody against 
myeloperoxidase. (A,B) No inflammation was seen at baseline. (C-E) Substantial 
neutrophil influx induced by biopsy was observ ed in both controls, to a similar degree 
at each parallel site (C&E and D&F respectively).
Illtaken  simultaneously  at  two  different  sites  in  the  rectum,  numbers  of 
myeloperoxidase-positive  or  IL-8-positive  cells  were  highly  correlated  (R^  = 
0.949, P < 0.05 and  = 0.984, f  < 0.01 respectively).
3.2.4  Impaired neutrophil influx and cytokine production in Crohn’ s disease 
In the  series of Crohn’s patients  and non-inflammatory bowel  disease  controls 
studied,  there  was  no  inflammation  in  untraumatised  bowel  (Fig.  3.3A-D).  In 
control subjects, trauma led to a large increase of neutrophils {P < 0.001) and IL- 
8-positive cells {P < 0.001) in the mucosa (Fig.  3.3E,G and 3.4A,B); the  latter 
were  predominantly  interstitial  macrophages  and  infiltrating  neutrophils. 
Numbers of both cell types were considerably reduced in Crohn’s disease (Fig. 
3.3F,H  and  3.4A,B).  Of  these  patients,  4  were  compound 
heterozygous/homozygous for polymorphisms in CARD15 and 5 were wild type. 
No  differences  were  observed  between  these  two  groups 
(homozygous/compound heterozygote:  38.54  ±  25.80  and  35.80 ±  13.19;  wild 
type:  62.00  ±  8.22  and  53.53  ±  6.81;  mean  ±  SEM  for  MPC  and  IL-8 
respectively).
In addition,  serial biopsies were conducted on 3  Crohn’s patients  and 2 
control  subjects  whose  colon  had  been  removed,  resulting  in  an  ileorectal 
anastomosis.  These  successfully demonstrated that  similar differences  between 
the two groups were observed following trauma to the ileum (Fig. 3.4A,B).
Serial  biopsies  were  also  taken  from  3  patients  with  ulcerative  colitis. 
These  revealed  modestly  elevated  numbers  of neutrophils  in  the  bowel  in  the 
resting  state,  despite  macroscopically  normal  mucosa  and  no  clinical  or
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Figure 3.3 Neutrophil accumulation and IL-8 production in traumatised bowel. 
Representativ e sections of rectal biopsies from a control subject and Crohn's patient 
are shown. These are stained for myeloperoxidase (MPO), as a marker of neutrophils, 
or IL-8. (A-D) Untraumatised bowel contained few cells of either t> pe. In the control 
subject, trauma induced a substantial neutrophil influx (E) and increase in 
IL-8-producing cells (G). This response was attenuated in Crohn's patients (F,H).
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Figure 3.4 Impaired acute inflammation in Crohn's disease. Number of cells staining 
positive for (A) myeloperoxidase (MPO) or (B) lL- 8  in specimens from different 
subject groups. In each case, the numbers of cells (mean + SEM) are show n. 
There was no significant difference in the degree of neutrophil influx between HC 
and UC patients. Numbers of subjects are show n, significance values compared
to post-trauma HC.
HC: healthy controls: CD: Crohn's patients: UC: ulcerative colitis patients: hpf: high power field.
*P < 0.05;  **P < 0.01:  ***P < 0.001
114biochemical evidence of disease activity. There was a normal augmentation (P < 
0.001) in response to trauma (Fig. 3.4A).
3.3  Discussion
3.3.1  Impaired acute inflammation in the bowel in Crohn’ s disease 
A new method was developed to  study the acute  inflammatory response  in the 
bowel.  Whereas analogous techniques in the skin rely on abrasive^*^, suction^** 
or chemical^*’ blister techniques to create new lesions, these were inappropriate 
for this site. Conversely, biopsy created lesions visible for study at 6 h, in which 
a vigorous inflammatory response was evident in control subjects.
The  degree  of  neutrophil  influx  was  highly  consistent  amongst  non­
inflammatory bowel disease controls. In individuals in whom paired sites in the 
rectum were biopsied, the inflammatory responses in sections from traumatized 
bowel were equally intense.  Similarly,  in individuals in whom both the rectum 
and ileum was biopsied, the magnitude of the inflammatory response was highly 
correlated  at  each  site.  These  observations  support  the  intra-individual 
reproducibility of this technique.
Using this technique,  we  found that Crohn’s  patients exhibited  a major 
impairment in recruiting neutrophils to the bowel. Although this had previously 
been demonstrated in the skin^^^’^^^, this is the first proof that the same applies to 
the site predominantly affected in Crohn’s disease. All patients except one were 
in complete remission and off medication (and had been so for at least 2 months 
prior to  study), rendering these highly improbable confounding influences.  The 
failure of migration was observed in all patients regardless of CARD!5 genotype, 
indicating either that this  molecule  is not relevant for this process or that wild
115type  individuals  possess  mutations  elsewhere  along  the  same  or  a  related 
pathway.
The impairment applies both to the large and small bowel, as well as the 
skin, suggesting a systemic abnormality in the inflammatory response that is not 
organ  specific.  Impaired  neutrophil  accumulation  could  result  in  reduced 
clearance  of any  debris  penetrating  the  bowel  wall,  underlying  the  granuloma 
formation  frequently  observed  in  this  disease.  The  predilection  for  lesions  to 
develop in the bowel may relate to the numbers of bacteria present at this  site, 
compared to other organs in the body.
The  pattern  observed  in  ulcerative  colitis  was  very  different.  Increased 
numbers  of  neutrophils  were  present  at  baseline,  despite  a  macroscopically 
normal  mucosal  appearance  and  absence  of  indicators  of  disease  activity. 
Following trauma, these individuals displayed a normal augmentation of mucosal 
neutrophils, suggesting that the impairment is specific to Crohn’s disease and not 
secondary to any chronic inflammation affecting the bowel.
Trauma  to  the  bowel  in  non-inflammatory  disease  controls  was  also 
accompanied  by  substantial  induction  of  IL-8,  predominantly  by  interstitial 
macrophages.  Such pro-inflammatory cytokines are central to the  initiation and 
co-ordination of acute inflammation. IL-8 itself functions as a potent neutrophil 
chemoattractant^^®, and failure of its production may play a primary role  in the 
reduction in their migration into traumatised Crohn’s bowel.
3.3.2 Further characterisation of the defect in acute inflammation
Although  the  serial  biopsy  technique  allows  investigation  of the  primary  site
affected in Crohn’s disease, the bowel remains relatively inaccessible for study.
116Elucidating  the  role  of the  CARD 15  protein  in  this  response  would  not  be 
feasible,  due  to  the  impracticality  of administering  the  proposed  ligand^**’^*^. 
Topical application of MDP by instillation in the rectum would not necessarily 
prove helpful: a thrombus rapidly forms over the biopsy site, the permeability of 
which  would  be  difficult  to  measure  without  using  a  radiolabeled  compound. 
Similarly, intra-mucosal injection would be difficult to control and might induce 
unwanted side effects that would limit its application. Given these considerations 
and the systemic nature of the defect, the skin window model was employed to 
further characterize the acute inflammatory response (Chapter 4).
117Chapter 4: Skin Windows
4.1  Introduction
The  results  presented  in  the  previous  chapter  replicated  the  earlier  finding  of 
diminished neutrophil  accumulation in Crohn’s disease  following trauma to an 
epithelial  surface^^^;  this time  in the  gastrointestinal  tract  (see  3.2.4)  in  which 
there was an association with reduced local IL-8 production. The defect therefore 
appears to have a systemic component. Consequently, in view of the difficulties 
of accessibility  for  study  inherent  with  the  intestinal  tract,  the  skin  window 
model  was  used  to  pursue  these  investigations  and  elucidate  the  influence  of 
CARD15.
Insult or injury to the body elicits an acute inflammatory response.  This 
serves to kill microbes, remove debris and promote healing, and depends on the 
extravasation of leukocytes  and  serum  proteins.  Numerous  chemical  mediators 
regulate these events^^*’^^^, produced first by resident immune cells in the tissues 
then by activated cells that accumulate at the site of insult. Abnormalities in this 
early response have been linked to the pathogenesis of several diseases^^^’^^^'^^^, 
and  its  modulation  by  pharmacological  agents  has  important  therapeutic 
implications.
The  “skin  window”  technique  permits  investigation  of  the  acute 
inflammatory response in vivo in humans. This typically involves the creation of 
a lesion  in the  stratum  comeum  of the  skin using a  surgical  scalpel^*^,  a high­
speed drill^^^  or tape  stripping^^^.  Whilst these  allow examination of leukocyte 
emigration, they remain unsuitable for measuring the concentrations of secreted 
mediators.  In addition,  exogenous chemicals cannot be applied reliably.  Others
118have  used negative  pressure  suction to  raise  blisters^**,  although these  contain 
only a small volume of fluid with few cells. Formation of large volume blisters 
can be provoked by topical application of cantharidin (derived from the Meloidae 
coleoptera beetle)^*^, aspiration of which enables the collection of high numbers 
of cells and quantification of inflammatory mediators. Cantharidin, however, acts 
by inhibiting protein phosphatase-1   and protein phosphatase-2a^^*, confounding 
its use in studying cell function and signalling.
To overcome these difficulties, the skin window technique was refined in 
this study. Abrasions were overlaid with filter papers onto which cells migrated 
and  soluble  mediators  were  absorbed.  Impregnation  of these  dressings  with 
inflammatory  modulators  enabled  assessment  of  their  effects  on  the  acute 
response.
4.2  Results
4.2.1  Acceptability
Skin windows were created in 6 healthy controls,  13 Crohn’s patients, 3 patients 
with  ulcerative  colitis  and  3  patients  with  rheumatoid  arthritis  (Appendix  1: 
Tables A 1.4-A 1.7 respectively). All subjects were in clinical remission. Crohn’s 
patients were taking no immunosuppressive medication and had not done so for 
at least the past two months, and none showed any evidence of malnutrition.
The technique  did not  interfere with the  daily  activities  of participants. 
Dermal abrasion (Fig. 4.1 A) was used to create windows of a standard area (Fig. 
4.IB).  This  process  was  described  as  uncomfortable  but  not  painful  until  the 
capillary  beds  were  visualized,  at which  point abrasion  was  discontinued.  The 
windows were not painful over the course of the experiment, although a minority
119Figure 4.1 Skin window technique. (A) Skin windows were created by 
dermal abrasion. (B) This was used to create lesions w ith a standard 
area of 3 cnf. which were then overlaid w ith filter papers. (C) Windows 
healed within 14 days.
120of  subjects  described  minor  discomfort  overnight  when  pressure  was 
inadvertently applied during sleep. No bleeding occurred into the windows, and 
re-epithelialization occurred within  14 days  (Fig.  4.1C).  A  minority of healthy 
subjects reported hypopigmentation at the abrasion sites, lasting no more that 2 
months. Interestingly, this appeared to persist slightly longer in Crohn’s patients, 
which  may  reflect  impaired  wound  healing.  There  were  no  additional  side 
effects.  In  terms  of acceptability,  therefore,  this  method  is  comparable  to  the 
alternative established techniques.
4.2.2  Neutrophil influx is diminished in Crohn’ s disease
In healthy controls, the majority of cells infiltrating skin windows by 6 h and 24 
h were  neutrophils  (Fig.  4.2A).  These  still  predominated  at 48  h,  although  an 
increased  proportion  of  monocyte/macrophages  and  lymphocytes  had 
accumulated. In concordance with previous studies^^^’^^"^, we observed a relative 
reduction  in  neutrophil  emigration  in  Crohn’s  patients  at  6  h  and  24  h  (Fig. 
4.2A).  This  appeared to represent a delay  in migration,  as  neutrophil  influx  in 
these  individuals  was  proportionally  greater  at  48  h.  Direct  measurement  of 
myeloperoxidase concentrations in skin window cell lysates from 24 h windows 
(Fig.  4.2B)  confirmed that the  relative  reduction  in  neutrophils  was  due  to  an 
absolute  deficiency {P = 0.2  x  10'^)  rather than  an increase  in the  numbers  of 
other leukocytes, which migrated normally.
The grossly diminished neutrophil efflux into skin windows (previously 
reported in Crohn’s patients after 5 h) was therefore also present after 24 h with 
an approximately 50% reduction in patients. This might be an underestimate: the
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Figure 4.2 Leukocy tes emigrating to the site of skin trauma. (A) Differential leukocyte 
composition in 3 healthy controls and 3 Crohn's patients over a 48 h time course. (B) Neutrophil 
emigration into skin windows was impaired in Crohn's disease, irrespective of CARD15 genoty pe.
Topical application of MDP corrected neutrophil recmitment only in CARD!5 wild type (wAv) 
patients, and not in homozygotes/compound heterozygotes {m/m). In each case, the numbers of cells 
(mean + SEM), the numbers of subjects in each group and the significance levels compared to
healthy controls are show n.
HC: healthy controls; CD: Crohn's patients; UC: ulcerative colitis patients:
RA: rheumatoid arthritis patients; MPO: myeloperoxidase 
***P< 0.001
122whole filter paper surface area was covered with cells in control subjects by this 
time, suggesting that the assay might be saturated.
A  similar  degree  of  impairment  was  observed  in  patients  who  were 
homozygous/compound heterozygous  for CARD 15 polymorphisms  {m/m)  as  in 
wild  type  patients  (w/w).  Neutrophil  emigration  was  normal  in  subjects  with 
ulcerative  colitis  and  in  those  with  another  chronic  inflammatory  disease  not 
affecting the bowel, rheumatoid arthritis.
4.2.3 Normal production of early inflammatory mediators
The concentrations of a panel of early inflammatory mediators were assayed in 
fluid  taken  from  skin  windows  30  min  following  trauma.  These  included 
histamine,  prostaglandin  E2  (PGE2),  leukotriene  B4  (L T B 4 ),  activated 
complement component C3a (measured as  C3a-desArg, the  stable product into 
which  C3a  is  rapidly  converted  that  allows  reliable  quantification  of  C3 
activation^^^),  and  IL-ip.  All  were  similar  in  healthy  controls  and  Crohn’s 
patients (Fig. 4.3A).
4.2.4 Diminished chemokine production in Crohn’ s disease
To  identify  cytokines  present  in  skin window exudates,  they were  assayed  on 
antibody arrays. Of the 42 cytokines examined (see Table 2.2), only IL-8 and IL- 
Ip were detected (Fig. 4.3B). Exudates from Crohn’s patients had levels of these 
cytokines  approximately  50%  {P  <  0.001)  of those  in  control  subjects  (Fig. 
4.3C,D). TNF-a and TGF-p were also assayed, as control cytokines. TNF-a was 
detectable in only 50% of skin windows (Fig. 4.3E), with no difference between
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Figure 4.3 Production of inflammatory mediators in skin windows. (A) A panel of early inflammatory signals 
was normal 30 min following trauma in CD. (B) A representative membrane arrayed with antibodies against 
42 different cytokines (each in duplicate), probed with fluid from a HC skin window 24 h after trauma, reveals 
predominant production of IL- 8  and IL-ip. Secretion of (C) IL- 8  and (D) IL-ip was diminished in CD at 24 h, 
irrespective of CARD! 5 genotype. Topical application of MDP augmented cytokine production in CARD 15 
wild type (w/w) subjects but not in homozygous/compound heterozygous {m/m) patients. (E) TNF-a secretion 
was similar and minimal in all subjects, and not affected by MDP. (F) Exudation of albumin was equivalent 
in each window created, indicating that differences observed do not reflect differential traumatisation.
Means + SEM and numbers of subjects in each group are shown.
HC: healthy controls; CD: Crohn's patients; UC: ulcerative colitis patients;
RA: rheumatoid arthritis patients; MPO: myeloperoxidase
124healthy controls and Crohn’s patients.  TGF-P activity could not be  detected in 
any sample. Samples from all subject groups were prepared and processed on the 
same day, such that differences are unlikely to reflect intra-assay variability.
4.2.5 Exogenous IL-8 corrects the defect in neutrophil accumulation
To determine whether depressed neutrophil emigration in Crohn’s patients might 
be due to  low levels of the potent neutrophil chemoattractant  two  skin
windows were performed on  3  patients  (2  w/w,  1   m/m) with recombinant IL-8 
applied to one abrasion.  In each patient, this resulted in doubling of neutrophil 
emigration (P < 0.05; Fig 4.4A) and augmented IL-lp production (P < 0.05; Fig. 
4.4C), to levels observed in healthy subjects exposed to trauma alone.
To  confirm  the  effects  of exogenous  IL-8  on  neutrophil  emigration  in 
healthy  individuals,  a  separate  experiment  was  performed  using  larger  filter 
papers  (35  x  15  mm)  to  circumvent  the  confounding  effects  of  saturation. 
Myeloperoxidase (P < 0.05; Fig.4.4B) and IL-lp (P < 0.05; Fig. 4.4D) were both 
increased.
4.2.6 MDP corrects the defect in CARD 15 wild type patients
Application  of MDP  to  skin  windows  amplified  IL-8  and  IL-lp  secretion  in 
healthy,  ulcerative  colitis  and  rheumatoid  arthritis  subjects,  and  also  in  w/w 
Crohn’s patients (Fig. 4.3C,D) in whom neutrophil migration was concomitantly 
normalised  (Fig.  4.2A).  In  contrast,  neither  cytokine  secretion  nor  neutrophil 
emigration was augmented in m/m patients (Fig. 4.2A; Fig. 4.3C,D).
For  comparability  with  previous  parts  of the  study,  regular  sized  filter 
papers  were  used  to  examine  neutrophil  emigration  in  control  subjects  (Fig.
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Figure 4.4 Augmentation of neutrophil emigration and IL-ip secretion into skin windows by 
topical lL-8 . Myeloperoxidase content was increased in CD patients (A) and HC subjects 
(B). IL-ip levels also rose in these groups (C,D). Mean + SEM shown.
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Figure 4.5 Confirmation of increased neutrophil emigration induced by topical MDP 
into skin windows of healthy controls. Representative immunoblots (equal protein 
loading) demonstrate increased content of the neutrophil markers MPO (A) and 
lactoferrin (B), but equal albumin exudation (C), in the presence of MDP compared 
to trauma with normal saline (NS) alone.
NS: normal saline: MDP: muramyl dipeptide: MPO: myeloperoxidase
1264.5A-C).  In  these  skin  windows,  MDP  led  to  an  increase  in  the  amounts  of 
myeloperoxidase  (P  <  0.05  by  biochemical  measurement  for  all  controls)  and 
lactoferrin'*^ but not albumin. This increase was more modest than that seen with 
lL-8, but could have been confounded by saturation.
4.2.7 Observed differences do not reflect differential traumatisation
Albumin was measured in each sample  as an indicator of the extent of trauma 
induced  to  create  skin  windows.  This  was  equivalent  in  the  different  subject 
groups  and  following  topical  application  of immunomodulatory  agents.  These 
albumin  concentrations,  combined  with  the  equivalent  levels  of  early 
inflammatory mediators (Fig. 4.3A), suggests that differences in cell recruitment 
and  cytokine  production  cannot  be  explained  by  differential  degrees  of  skin 
abrasion.
4.2.8 Abnormal phosphorylation of cytoplasmic signalling pathways
The  phosphorylation  status  of proteins  involved  in  major  signalling  pathways 
was examined in cytoplasmic extracts of leukocytes from the exudates.  In cells 
from 5 healthy individuals, with the panel of antibodies applied, phosphorylation 
of FKHR was observed at 6 h; 4E-BP1, p38  and p44/p42 MAP kinases, AKT, 
protein kinase C (PKC) and SAPK/JNK at 24 h; and AKT and PKC at 48 h (Fig. 
4.6A).  In 5 Crohn’s patients (Fig. 4.6B), phosphorylation levels of the majority 
of  these  proteins  were  equivalent.  A  few  differences  were  apparent,  most 
strikingly hyperphosphorylation of PKC,  specifically PKCa/p (Fig.  4.6C).  This 
was  observed  in  all  patients  at  each  time  point.  There  were  no  differences  in 
levels  of  phosphorylation  of  PKCÔ,  PKCÇA,  PKC0  or  PKCp.  Two  patients
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Figure 4.6 Altered phosphorylation of proteins in major cytoplasmic signalling 
pathways in Crohn's disease skin windows. Representative immunoblots 
(equal protein loading) illustrate some of the differences observed between 
healthy (A) and Crohn's (B) subjects. The most consistent alteration was 
hyperphosphorylation of PKC, observed in all Crohn's patients at each time 
point. This was specific to PKCa/p (C).
HC: healthy control; CD: Crohn's patients
128showed  reduced  phosphorylation  of 4E-BP1,  whilst that  of p70S6  kinase  was 
increased. A third patient had decreased phosphorylation of Akt and a fourth of 
p38 MAP kinase.
4.2.9 Transcription factor activation
DNA-bound nuclear protein extracts from exuded leukocytes were hybridized to 
arrays  (see  http://panomics.multipath.net/prdf/PD  Array  1   with  an.pdf  for 
layout) to allow simultaneous screening of a large number of transcription factors 
for DNA-binding activity.  Sufficient amounts of nuclear proteins were obtained 
to  allow  maximum  sensitivity  of the  assay.  Of  the  54  transcription  factors 
assayed, the activity of up to 44 could be detected in healthy subjects (Fig. 4.7A). 
A  total  of 4  healthy  controls  and  4  Crohn’s  patients  were  compared,  but  no 
consistent differences detected (Fig. 4.7B).
4.2.10 Gene expression
Sufficient  quantities  of  mRNA  could  also  be  extracted  to  permit  extensive 
analysis  of gene  expression by either reverse transcriptase-PCR or microarray. 
Approximately  1-2  pg  of total  RNA  could  be  isolated  from  one-eighth  of the 
total amount of exuded cells, which would be sufficient to analyze the expression 
of over 50 genes. To demonstrate the viability of such an assay, expression of the 
monocyte cell marker CD 14 and GAPDH were determined in 24 h extracts from 
2 healthy controls and 2 Crohn’s patients (Fig. 4.7C). Similar expression of both 
indicated equivalent levels of monocyte influx.
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Figure 4.7 Investigation of transcription factor activation and gene expression in skin windows.
Representative DNA-bound protein arrays from (A) healthy and (B) Crohn's subjects. No 
consistent differences were observed. (C) RT-PCR demonstrates the viability of gene expression 
analysis in leukocyte extracts from skin windows using the technique developed in this study. 
Equivalence of CD 14 levels in HC and CD subjects confirms equal extravasation of monocytes
between the two groups at 24 h.
HC: healthy controls: CD: Crohn's patients
1304.3 Discussion
4.3.1  Modifications to the skin window technique
The  skin  window technique  has  previously  been  used  to  investigate  the  acute 
inflammatory response, including in the context of human disease. All previously 
described  methods  possess  major drawbacks  in terms  of recovery of cells  and 
inflammatory  tissue  fluid^*^:  the  technique  has  been  modified  here  to  allow 
reliable  collection  of both.  The  protocol  permits  analysis  of all  facets  of the 
inflammatory  response,  including  cellular  influx  and  phenotype,  production  of 
secreted mediators, and cell function in terms of activation of cytosolic signalling 
pathways,  DNA-binding  activity  of transcription  factors  and  gene  expression. 
The system is also ideal for investigating effects of exogenous mediators, as they 
can  be  applied  directly  to  the  abrasion.  Equivalence  of  albumin  and  early 
mediator  release  indicates  that  windows  can  be  fashioned  in  a  reproducible 
manner. Further experiments in which two saline treated windows are performed 
on each subject would be helpful to characterize the intraassay variability^*®*.
The  side  effect  profile  of the  modified  technique  is  similar  to  those 
previously  described.  In  most  control  subjects,  the  lesion  resolved  completely 
within approximately 3 weeks, although a minority might experience continuing 
hyperpigmentation  for  up  to  1   year.  An  interesting  observation  was  that  in 
Crohn’s patients, healing tended to require slightly more time with an increased 
frequency of abnormal pigmentation. Although not objectively measured in this 
study, it would be consistent with the impaired wound healing described in this 
disease^^^.
1314.3.2 Characterisation of  skin window inflammatory contents
Cells migrating  into the  skin windows  in healthy  subjects  were  predominantly 
neutrophil  leukocytes,  classically  the  first  line  of  cellular  defence  against 
infection^®^. These were partially replaced by mononuclear phagocytes over the 
subsequent 48 h, which contribute to the removal of neutrophils and healing after 
initial clearance of debris^^*.  The differential  separation of these cells and their 
further characterisation using the technique  developed here has been described 
elsewhere"^®^.
Cellular  extravasation  was  accompanied  by  the  production  of  high 
concentrations of pro-inflammatory mediators, at similar levels amongst control 
subjects.  Early  inflammatory  mediators  were  elevated  30  min  after trauma,  at 
equivalent levels in all subjects.  At 24 h, the predominant cytokines were  IL-8 
and  IL-ip,  as  detected  using  cytokine  protein  arrays.  TNF-a  was  also 
demonstrable  at low levels  in some windows using  an ELISA,  by virtue  of its 
greater  sensitivity  than  the  membrane  array.  It  is  acknowledged  that  some 
cytokines, such as IFN-y, may be difficult to elute from filter papers'*^'.
4.3.3  Reduced chemokine production  in  Crohn's  disease  underlies  diminished 
neutrophil migration
Impaired  neutrophil  migration  into  skin  windows  in  Crohn’s  disease  was 
previously reported at 6 h following skin trauma^^^. This finding was replicated 
here,  in correspondence with the defect observed in the bowel  (see 3.2.4).  The 
study  was  designed to  minimize  potential  confounding  factors,  such  as  use  of 
immunosuppressive  medications.  In  active  inflammation,  reduced  neutrophil 
migration  could  theoretically  arise  from  their  sequestration  in  gastrointestinal
132lesions.  Patients  in  this  study,  however,  had  inactive  disease  (by  clinical  and 
biochemical  criteria),  and  the  impairment  was  not  observed  in  other  chronic 
inflammatory disorders, suggesting that these are unlikely explanations.
Although an in vivo impairment in neutrophil chemotaxis has previously 
been described, the mechanism remained speculative. Normal migration in vitro 
to casein, zymosan-activated serum or bacterial chemotactic factors  suggested 
an  extrinsic  defect.  An  inhibitory  chemotactic  factor  was  demonstrated  in  the 
serum of Crohn’s patients in ex vivo experiments^^^, although this inhibition was 
also present to a lesser degree when using normal  serum  and found equally  in 
Crohn’s disease and ulcerative colitis, varying with disease activity. Although a 
definitive  identification of the  factor was not made,  the biochemical properties 
implicate immunoglobulins. It was postulated that increased circulating levels of 
these proteins in active Crohn’s disease could underlie the failure in skin window 
chemotaxis.
An alternative mechanism is proposed here based on the observation of 
diminished concentrations of chemotactic cytokines that parallel the impairment 
in neutrophil  recruitment.  The  finding  of reduced  levels  of IL-8,  an extremely 
potent  neutrophil  attractant^^,  could  readily  explain  the  observed  defect.  The 
impairment  was  seen  in  patients  with  inactive  disease  and  not  in  the 
inflammatory disease controls, which also argues against the underlying problem 
relating to inhibition by circulating immunoglobulins.
In the few patients treated here, exogenous IL-8  corrected the defect in 
neutrophil  migration  indicating  that  the  chemokine  receptors  are  intact.  This 
suggests that the  impairment does  relate to  lack of the  appropriate  stimulus  in 
these subjects, although other patients could conceivably possess abnormal IL-8
133receptors or downstream signalling pathways. That neutrophil recruitment can be 
corrected  highlights  a  potential  therapeutic  approach,  should  this  prove  the 
underlying pathogenic mechanism.
4.3.4  CARD 15 polymorphisms exacerbate diminished neutrophil migration 
The  normal  function  of  CARD 15  remains  poorly  described.  It  is  expressed 
within  leukocytes,  including  monocytes,  macrophages^^^  and  granulocytes^^ \ 
Most  studies  have  focused  on  its  role  in  gene  expression  and  cytokine 
production^**’'^® ^,  whereas  none  have  examined  its  influence  on  chemotaxis  in 
vitro or in vivo.
Crohn’s  patients  in  this  study  were  subdivided  into  those 
homozygous/compound  heterozygous  for  CARD 15  polymorphisms  and  those 
without  any  of  the  three  common  variants.  The  two  groups  could  not  be 
distinguished  on  the  basis  of their  response  to  epithelial  trauma  alone  in  this 
model.  This  indicates  either  that  CARD 15  does  not  contribute  to  neutrophil 
migration  and  the  establishment  of acute  inflammation  to  a  stimulus  of this 
nature, or that other mutations elsewhere in this pathway  or in other pathways 
ultimately produce the same phenotype in wild type patients.
A  difference  between  subjects  was  observed  following  topical 
administration  MDP  (the  CARD 15  ligand),  never  previously  used  in  vivo  in 
humans in this manner. In wild type patients, this increased concentrations of IL- 
8  and  IL-lp  in  skin  windows,  leading  to  correction  of neutrophil  numbers  to 
normal levels.  In patients with the polymorphisms there was no response.  This 
result is very pertinent for resolving the conflicting theories concerning the role 
of CARD 15. Many attempts have been made to reconcile the originally reported
134apparent loss-of-fimction with the chronic inflammation characteristic of active 
Crohn’s disease. The leading suggestions remain that the polymorphisms either 
lead  to  impaired  induction  of  anti-inflammatory  cytokines^^^;  that  lack  of 
negative  regulation  by  CARD 15  engenders  unrestrained  activation  of  the 
adaptive immune system^^"^; or that there is a toxic gain-of-function^^^. This study 
demonstrates that the opposite appears to be the case: CARD 15 is normally pro- 
inflammatory in vivo, an action abrogated by the polymorphisms.
This  is  liable  to  pertain  to  the  situation  in  the  gastrointestinal  tract. 
Following a mucosal breach, the  luminal contents (including bacteria and their 
products) will ingress into the bowel wall. In the general population, there will be 
a normal distribution in the magnitude and quality of the inflammatory response 
that ensues. Some individuals will be towards the low end of this spectrum, and 
might be at risk of developing Crohn’s disease. Having responded poorly to the 
mucosal breach, however, there will then be additional stimulation by the influx 
of luminal  contents,  such  as  MDP  acting  through  CARD 15.  The  subsequent 
degree of augmentation of cytokine production will determine whether the initial 
defect is adequately compensated and clearance of debris sufficient. If this is not 
the  case,  then  suboptimal  phagocyte  recruitment could result  in persistence  of 
exogenous material, granuloma formation and chronic inflammation.
It is tempting to speculate that this mechanism explains the predisposition 
of CARD 15 polymorphisms to Crohn’s disease affecting the small bowel. MDP 
is a small 493 Da molecule, found at high concentrations in the terminal ileum'^®'*. 
A  highly  diffusible  molecule  such  as this  would  be  expected  to  exert  greatest 
influence in the region of the bowel containing fluid luminal contents with heavy 
bacterial  colonisation.  Another  prediction  of  this  model  would  be  that
135polymorphisms  in  other  pathogen  recognition  receptors  also  predispose  to 
Crohn’s disease, perhaps specific to other intestinal regions. This appears to be 
borne  out  by  preliminary  observations  hinting  at  susceptibility  variants  in  the 
CDI4^'^^ and TLR4^^* genes.
4.3.5  Signalling pathways in Crohn's disease
The  phosphorylation  status  of a number of major  signalling  proteins  was  also 
analyzed,  the  profiles  of  which  appeared  highly  consistent  amongst  control 
subjects. A central molecule indicated from this study was Akt, which has been 
documented  to  activate  many  of the  other  signalling  molecules  found  to  be 
phosphorylated here"^®^’"^^. Akt plays a critical role in cell survival by inhibiting 
apoptosis  through  phosphorylation  of  intermediaries  such  as  FKHR'^®^  and 
MEKÆRX"^®*.  It  can  also  activate  other  proteins  including  4E-BP1,  which 
promotes translation of mRNA"^®^.
A  preliminary  search  for  any  signalling  abnormalities  in  exuded 
leukocytes  in  Crohn’s  patients  revealed  that  phosphorylation  levels  of  most 
proteins were unchanged. Of the few differences apparent, the most striking and 
consistent was hyperphosphorylation of PKCa/p.  This was observed at all time 
points, including at 48 h when neutrophils were proportionally more prevalent in 
patients than in the controls.  Consequently, a genuine abnormality in activation 
of this  pathway  during  acute  inflammation  is  implied,  as  opposed  to  altered 
levels simply reflecting differential leukocyte migration.
Other  variations  in  some  patients  included  decreased  levels  of 
phosphorylation  of  4E-BP1,  Akt  and  p38  MAP  kinase,  and  increased 
phosphorylation of p70S6 kinase. The heterogeneity may relate to differences in
136the  underlying  molecular  aetiology  that  probably  exists  between  patients. 
Changes  in  phosphorylation  were  more  pronounced  than  the  deficits  in 
neutrophil exudation. This, and the similarity in levels of other proteins and their 
phosphorylation  ratios  between  controls  and  Crohn’s  patients,  argues  against 
differences relating solely to altered cellular distributions. To finalize this issue, 
exuded leukocytes could be fractionated in future using standard methodology"^®^.
The  functional  significance of the  changes observed in Crohn’s disease 
remains  unclear  and  merits  further  investigation.  Altered  phosphorylation  of 
molecules  involved  in  protein  translation,  including  p70S6  kinase"*'®and  4E- 
BPl"*®^, may contribute to defective production of inflammatory mediators. Other 
mechanisms  may be  more  complex:  PKC  interacts  with  a broad  range  of cell 
signalling  pathways  with  pleiotropic  effects"***.  This  could  be  studied  by 
examining the function of exuded leukocytes from controls and patients ex vivo, 
in  the  presence  of pharmacological  agonists  and  inhibitors"**^  of pathways  of 
interest.
4.3.6  The cellular basis for defective cytokine production
The data presented in this chapter confirm the  systemic nature of the defect in 
neutrophil  recruitment  and  implicate  a  failure  of  cytokine  production  as  an 
important causal mechanism. In the rectal biopsy model (see 3.2.4), considerable 
IL-8 was produced by healthy interstitial mononuclear phagocytes;  CARD15  is 
also  expressed  predominantly  in  these  cells  under  normal  conditions^*®. 
Consequently,  macrophage  responses  were  studied  in  vitro  to  determine  their 
ability to produce mediators involved in the initiation of the acute inflammatory 
response in Crohn’s disease (Chapter 5).
137Chapter 5: Macrophage Cytokine Production
5.1  Introduction
Macrophages are mononuclear phagocytes that contribute substantially to innate 
immune defences'*They possess a high capacity for uptake of micro-organisms 
and  particulates'**'*,  similar  to  neutrophils^**^.  In  contrast,  some  are  resident  in 
tissues  in  a  physiological  role'**^  and  their  circulating  precursors  are  recruited 
during a later phase of the inflammatory response^^^. They exert a more limited 
microbicidal action^**'*'**^, often requiring co-stimulation by lymphocytes'**^, and 
subserve  broader  functions  including  antigen  presentation'***.  Through  the 
expression  of  numerous  pathogen  recognition  receptors,  including  the 
TLRs^****’'**^, they play a critical role in detection of potential pathogens within the 
tissues.  They then co-ordinate the ensuing inflammatory response, mediated by 
secreted cytokines and direct interactions with other leukocytes'*^**.
CARD15 is principally expressed in mononuclear phagocytes^^^, where it 
is thought to act as a pathogen recognition receptor. It was originally believed to 
respond to bacterial LPS, on the basis of experiments in transfected cell lines. It 
was subsequently demonstrated that the cells were responding not to LPS but to 
contaminating peptidoglycan, another component of the bacterial cell wall from 
which the LPS had been prepared^**’^*^. Digestion of purified peptidoglycan into 
smaller  muropeptides  demonstrated  that  MDP  constituted  the  minimum  unit 
recognized by CARD 15.
The normal cellular function of CARD 15 remains poorly understood.  In 
humans in vivo it appears to exert a pro-inflammatory influence (see Chapter 4), 
augmenting  production  of  IL-8  and  IL-lp,  and  consequently  neutrophil
138recruitment  (see  4.2.6).  Some  further  aspects  of function  can  be  deduced  by 
examining  patterns  of gene  expression  in  MDP-stimulated  macrophages  from 
individuals with and without CARD 15 polymorphisms.  Inferences may also be 
drawn from computer models of its predicted protein structure.
Conversely,  the  abnormalities  in  neutrophil  recruitment  and  cytokine 
production observed  in previous  chapters  (see  3.2.4,  4.2.2 and 4.2.4)  appeared 
unrelated to CARD 15 genotype. Correction of leukocyte numbers in Crohn’s skin 
windows  by  exogenous  or  increased  endogenous  IL-8  (see  4.2.5  and  4.2.6 
respectively)  suggests that diminished production of this cytokine might play a 
central  role.  IL-8  predominantly  derives  from  macrophages'*^%   although 
infiltrating neutrophils can provide a further source'*^^; similarly in the intestinal 
serial  biopsy  model  the  majority  of  IL-8-positive  cells  were  mononuclear 
phagocytes.  Damage  to  an  epithelial  surface  will  provoke  release  of a  large 
number  of pro-inflammatory  mediators;  consequently,  the  most  physiological 
agonist to mimic conditions in the skin window would be fluid taken from a site 
of acute tissue injury.
5.2  Results
5.2.1  CARD 15 does not influence LPS-induced IL-12 production 
Peripheral blood mononuclear cells  were  cultured  for 5  days,  with purification 
and differentiation of macrophages  by adherence  (Fig.  5.1 A).  Cells were  more 
than 95% pure by this time, determined by CD68  staining, with no differences 
between Crohn’s patients and controls. In view of the original reports identifying 
CARD 15  as  a  LPS  receptor,  macrophage  responses  to  this  agonist  were 
determined  initially.  LPS  is  known  to  induce  substantial  IL-12  production  by
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Figure 5.1 LPS-induced IL-12p70 secretion by cultured macrophages. (A) Monocy tes were 
cultured for 5 days to allow purification and differentiation into macrophages. IL-12p70 
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140these cells"^^^, and was therefore assayed in 20 healthy controls and 21  Crohn’s 
patients.
Mean levels of IL-12p70 production were 8.80 pg/ml (standard deviation 
=  15.50 pg/ml) in control subjects and  12.65 pg/ml (standard deviation =  19.67 
pg/ml) in Crohn’s patients (Fig. 5.IB). No IL-12 was produced in the absence of 
stimulation.  There  was  no  apparent  relationship  with  CARD15  genotype  (Fig. 
5.IB),  disease  localisation  (Fig.  5.1C),  any  other  recorded  characteristic  (see 
2.1.3), or use of medication (Fig. 5. ID).
An interesting observation was that LPS-stimulated macrophages from 5 
Crohn’s patients failed to produce detectable levels of IL-12. This was not due to 
differences  in  numbers  of  cells  plated,  and  significant  secretion  was 
demonstrated in other samples processed at the same time. This impairment did 
not segregate with any documented patient characteristic. It is possible that these 
individuals possess genetic lesions along the LPS-sensing pathway"^^"^, shown to 
increase susceptibility to Crohn’s disease^^^’^^"^.
5.2.2  Effects of  MDP on macrophage gene expression
Global  gene  expression  profiles  induced  by  MDP  were  determined  in 
macrophages  from  6  CARD 15  w/w  healthy  controls.  MDP  was  pure,  as 
determined  by  mass  spectrometry  (Fig.  5.2A).  Total  cRNA  was  used  to 
interrogate  Affymetrix  Human  Genome  U133A  microarrays,  which  cover 
sequences  for  22,000  known  genes  and  expressed  sequence  tags  (ESTs).  The 
duration of stimulation and concentration of MDP used were based on conditions 
employed in the literature, demonstrated to elicit differential NF-kB activation in 
w/w versus m/m cells^**. The other advantage of these conditions was that they
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142corresponded closely to those employed in previous in vivo experiments in this 
study (see 4.2.6).
The  quantity and quality  of total  RNA  isolated  from  macrophages  was 
confirmed  using  an  Agilent  Bioanalyzer  (Fig.  5.2B).  Following  conversion  to 
cRNA, every sample was hybridized to an individual  microarray;  signals  from 
each  (Fig.  5.2C)  demonstrated  control  parameters  within  recommended  limits 
(see 2.5.4).
Expression  levels  of 229  probes  were  altered  by  2-fold  or  greater  in 
macrophages incubated with MDP compared to the unstimulated state. Of these, 
approximately  two-thirds  were  induced,  and  the  remainder  repressed  (Fig. 
5.3A,E; Table 5.1  and Appendix 2). Genes up-regulated predominantly encoded 
pro-inflammatory  molecules;  these  were  principally  cytokines,  amongst  which 
IL-8^^®,  IL-ip"^^^  and  RANTES"^^^  featured  prominently.  Other  induced  genes 
encoded cytokine-associated molecules (including indoleamine-2,3-dioxygenase, 
an  enzyme  known  to  potentiate  IL-8  production  and  function"^^^);  OTP 
cyclohydrolase-1  (involved  in  generation  of  the  NOS  co-factor 
tetrahydrobiopterin"^^*);  molecules  contributing to matrix repair (TNFa-induced 
protein-6 (TSG-6/^^, a 1-antitrypsin"^^®, various metallothioneins"^^*,  and growth 
factors HB-EGF"^^^ and VEGF"^^^); and molecules that participate in macrophage 
activation  and  the  respiratory  burst  (including  NADPH  oxidase  p47phox"^^"^, 
superoxide  dismutase-2"*^^,  C-type  lectin"^^®,  CD38"^^^,  interferon-regulatory 
factor-1"^^* and the Fey receptor I Bl"*^^).  Important transcripts that were down- 
regulated included various tissue inhibitors of metalloproteinases (TIMPs/"*®.
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Figure 5.3 Gene expression profiles in macrophages: effects of MDP. RNA from 
6 healthy subjects (A), 3 m/m Crohn's patients (B) and 6 w/w Crohn's patients with 
ileal disease (C) or colonic disease (D) was analyzed using Affymetrix Human Genome 
U133A arrays. Transcripts for IL-8 (filled arrows) and IL-lp (open arrows) are identified 
except in m/m macrophages, which failed to respond. (E) Hierarchical clustering clearly 
illustrates a normal pattern of expression changes in w/w macrophages in response to MDP, 
which is abrogated by the CARDI5 polymorphisms. Genes of interest that were strongly
induced are highlighted (*).
H: healthy control: mm: CARD!5 compound heterozygote homozygote Crohn's patients: w/w: wild type 
I: w/w ileal Crohn's patients: C: w/w colonic Crohn's patients: MDP: muramyl dipeptide
144HC CD m/m
Fold 1 Fold
Gene Increase SEM '  Pvalue Increase SEM Pvalue
MIP-3a 6.2 0.49 0.87 0.3 ns
IL-8 .  _5.8___ , 1.17 1 1.6 0.29 ns
GRO-3 5.1 0.82 1 1.1 0.14 ns
IDO 4.7  ! 2.23 : 1.6 0.21 ns
TSG-6 4.6  i 0.86 e* 1.2 0.09 ns
MIP-1Ô 4.5 0.27 1.7 1.02 ns
IL-1J3 4.2 0.2 1.6 0.4 ns
IL-1a 3.2  ^ 0.47 1.4 0.39 ns
PDE-4B 2.4 0.32 1 0.07 ns
CD38 2.4 0.62 * 1.4 0.39 ns
Table 5.1 Genes showing the most substantial induction in macrophages from healthy controls 
stimulated with MDP. Corresponding fold increases in cells from CD m/m patients are also shown.
HC: healthy controls; CD m/m: Crohn's patients compound heterozygous/homozygous for CARD  15 polymorphisms 
*P < 0.05;  **P < 0.01;  ***p < 0.001; ns; nonsignificant
1455.2.3 CARD  15 polymorphisms abrogate the MDP gene expression response
In  contrast  to  healthy  control  macrophages,  cells  from  m/m  Crohn’s  patients 
showed  a  general  failure  of the  transcriptional  response  to  MDP  (Fig.  5.3B, 
Table  5.1  and  Appendix  2).  Only  3  probes  appeared  differentially  expressed: 
these  encoded  ESTs  of no  known  function  or  clearly  recognizable  homology. 
Their  considerable  inter-individual  variability  rendered  these  changes  non­
significant.
Macrophages  from  w/w  Crohn’s  patients,  subdivided  into  those  with 
exclusively  ileal  (Fig.  5.3C)  or  colonic  (Fig.  5.3D)  disease,  showed  profiles 
comparable  to  healthy  controls.  Hierarchical  clustering  based  on  expression 
changes  across  the  4  groups  of  subjects  identified  a  normal  pattern  of 
transcriptional responses, equivalent in all w/w individuals regardless of disease 
status;  these  were  absent  in  m/m  macrophages  (Fig.  5.3E).  There  were  no 
significant differences in expression profiles of unstimulated cells.
5.2.4 Post-genomic verification
To  confirm  that  changes  in  gene  expression  were  translated  into  functional 
differences  in  protein  production,  cytokine  secretion  by  cultured  macrophages 
incubated  with  MDP  was  measured.  In  concordance  with  the  array  data, 
concentrations  of IL-lp  (Fig.  5.4A)  and  IL-8  (Fig.  5.4B)  were  substantially 
augmented in all w/w but not m/m cells; IL-8 was elevated in a dose-dependent 
manner (Fig. 5.4C). Only minimal, non-significant changes were observed in IL- 
10  production  (Fig.  5.4D)  and  no  IL-12p70  was  detected  in  any  sample.  At 
variance  with  the  array  data,  TNF-a  secreted  appeared  increased  in  w/w 
macrophages  (Fig.  5.4E).  This  is  consistent  with previous  work  suggesting  its
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Figure 5.4 Post-genomic verification of microarray data. MDP increased the secretion of (A) IL-1(3, 
(B) IL-8 and (E) TNF-a in macrophages from healthy controls and w/w Crohn's patients, but not m/m 
Crohn's patients. (C) In huffy coat macrophages, MDP induced lL-8 secretion in a dose-dependent 
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(F) Representative immunoblot confirming reduced expression of TlMP-3 in MDP-stimulated 
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compared to unstimulated cells are shown
HC: healthy controls; CD: Crohn's patients: NS: normal saline: MDP: muramyl dipeptide: 
m/m: CARD 15 compound heterozygote^homozygote; w/w: wild type 
*P< 0.05:  **P< O.OI:  *** P < 0.001
147regulation by MDP at the translational rather than transcriptional level'*'*^ Protein 
levels of TIMP-3  were  also  studied in w/w macrophages, to  assess  a molecule 
with  suggested  transcriptional  repression:  MDP  abolished  its  production  (Fig. 
5.4F).
5.2.5  Structural modelling of the CARD 15 leucine-rich repeat 
To  gain  further insight  into the  normal  function of CARD 15  and  mechanisms 
underlying  the  effects  of  disease-associated  polymorphisms,  the  predicted 
structure of its canonical LRR in which the polymorphisms occur was computed. 
Since its crystal  structure remains unsolved, the model was based substantially 
on  well-studied  LRRs  of other proteins  such  as  ribonuclease  inhibitor"*"*^.  The 
CARD 15 LRR was predicted to adopt a horseshoe conformation with a binding 
interface of at least 25 Â (Fig.  5.5A).  In other proteins with similar motifs, the 
inner  concave  surface  provides  an  interaction  surface  for  binding  partner 
proteins. The interface predicted here is considerably larger than that required to 
bind MDP, a small molecule of only 493 Da.
The effects on protein structure and surface charge introduced by SNP12 
and SNP13 were subsequently modelled. It was not possible to model SNP8, as 
this occurs in a region of poorly defined structure between the LRR and NBD. 
SNP12 is a missense substitution that replaces a glycine residue with an arginine, 
introducing a positive charge on the concave inner surface of the horseshoe (Fig. 
5.5B).  This  is  likely  to  impede  binding  of any  partner protein  by  interference 
with  van  der  Waal  forces.  The  charge  alteration  also  provokes  similar 
abnormalities at other points on the protein surface, which could similarly affect 
protein  conformation  and  interactions  with  other  molecules  binding  at  these
148M
Figure 5.5 Predicted structural model of the CARD15 leucine-rich repeat. (A) Wild t>pe 
protein. (B) Effects of the polymorphisms associated with Crohn's disease: SNP12 alters the 
surface charge and SNP13 truncates the horseshoe structure.
149sites. This could prove of major importance, as many CARD-containing proteins 
act only when assembled into large multi-molecular complexes^*'^’^°\
SNP13  introduces  an  additional  cytosine  nucleotide;  the  subsequent 
coding  base-pair  shift  generates  a  premature  STOP  codon.  The  resultant 
truncated  protein  lacks  its  final  a-helical  loop,  reducing  the  diameter  of the 
predicted  horseshoe  binding  surface  (Fig.  5.5B).  This  also  is  likely  to  affect 
receptor-ligand interactions.
5.2.6  Wound  fluid
CARD 15 polymorphisms did not appear to explain the basal defects in neutrophil 
recruitment  and  cytokine  production  in  the  serial  biopsy  and  skin  window 
models.  Consequently, an alternative explanation was sought. The skin window 
was modelled in vitro by exposing cultured macrophages to fluid taken from the 
site  of acute  tissue  injury.  Wound  fluid  was  derived  from  healthy  individuals 
having  routine  surgery  for  inguinal  hernia  repair.  Blood  and tissue  fluid  were 
recovered  from  the  operation  site  2  min  after the  initial  incision,  and  cellular 
components removed by high-speed centrifugation.
Protein concentration of wound fluid was determined by Bradford assay. 
Two  samples  were  analyzed  by  2D  gel  electrophoresis  (Fig.  5.6A),  and  the 
protein profiles found comparable to normal human serum (Fig.  5.6B). No IL-8 
(as measured by ELISA) was detectable in wound fluid itself, although the latter 
elicited substantial, dose-dependent IL-8 secretion from buffy coat macrophages 
(Fig. 5.6C).
Macrophages were cultured from 55 healthy controls, 50 Crohn’s patients 
and 20 control patients with ulcerative colitis,  and the  IL-8 response to wound
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Figure 5.6 Effects of wound fluid on cultured macrophages. Protein profiles of (A) wound fluid and 
(B) normal human serum were similar. Spots correspond to (i) albumin, (ii) haptoglobin, (iii) IgG heavy 
chain, (iv) apolipoproteins, (v) IgG kappa light chain and (vi) peroxiredoxin-2. (C) Wound fluid 
elicited lL-8 secretion from buffy coat macrophages in a dose-dependent marmer (n=3). (D) Validation 
of the WST-8 assay, illustrating that A450 varies linearly with cell numbers in the range used in these 
experiments (n = i). (E) Reduced secretion of IL-8 by CD macrophages in response to wound fluid, 
irrespective of CARD 15 genoty pe. Means, numbers of subjects and significance compared to HC show n.
HC: healthy controls; CD: Crohn's patients; UC: ulcerative colitis patients 
***P< 0.001
151fluid determined. Secretion was normalised to numbers of viable cells using the 
WST-8  assay based on the  activity of intracellular dehydrogenases^^^;  a  linear 
relationship with cell numbers was demonstrated (Fig. 5.6D). In control subjects, 
high  concentrations  of IL-8  (comparable  to  those  observed  in  skin  windows) 
were secreted, with a normal distribution possessing high and low responders at 
each tail  (Fig.  5.6E).  In  Crohn’s  patients,  the  distribution was  shifted towards 
lower  concentrations,  with  a  significant  reduction  in  mean  production  {P  < 
0.001). Secretion was not related to CARD 15 genotype in any group.
Wound  fluid  contains  numerous  pro-inflammatory  mediators.  In  an 
attempt to  identify those  eliciting  a weak response  in  Crohn’s  disease,  several 
basic characterisations were performed. Wound fluid-induced IL-8 production by 
healthy  macrophages  (n  =  5)  could  be  modestly  inhibited  by  the  G-protein 
inhibitors cholera toxin (for  P < 0.05) or pertussis toxin (for  P <
0.05),  and  by  the  thrombin  inhibitor  PPACK"^"*^  {P  <  0.05).  A  more  dramatic 
inhibition  (approximately  50%)  was  achieved  using  broad  spectrum  protease 
inhibitors {P = 0.004) or pre-heating the fluid to 56°C (Fig. 5.7A,B; P -  0.004). 
None of these stimuli were detrimental for cell viability.
Protease  inhibitors  and preheating were  assessed  for differential  effects 
on  Crohn’s  macrophages  (Fig.  5.7B).  Whereas  protease  inhibitors  resulted  in 
similar  absolute  reductions  in  IL-8  secretion  in  both  groups,  the  absolute 
reduction  induced  by  pre-heating  was  attenuated  in  Crohn’s  patients.  This 
indicates that there is a heat-labile component to which Crohn’s patients are less 
sensitive.  Although  a  number  of enzymes  are  denatured  on  heating,  another 
mediator  classically  inhibited  under  these  conditions  is  complement"^"^^.  This 
would be expected to be present in wound fluid and complement-induced lysis of
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Figure 5.7 Further characterisation of wound fluid. (A) Effects of various inhibitors on the abilit) 
of wound fluid to stimulate IL-8 secretion from buffy coat macrophages. Means + SEM and 
significance compared to wound fluid alone are show n (n = 5 for each condition). (B) Treatment of wound 
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IVF: wound  fluid: CTX: cholera toxin: PTX: pertussis toxin: GV'B: gelatin veronal buffer
*P<0.05
153sheep erythrocytes was demonstrable (n = 3), with a CH50 at an approximate titre 
ofl:100(Fig. 5.7C).
5.2.7 C5a,  TNF-a and LPS
To  directly  assess  the  response  to  complement,  macrophages  were  stimulated 
with recombinant human complement component C5a.  In healthy controls  and 
ulcerative  colitis  patients,  C5a  elicited  IL-8  secretion;  this  was  significantly 
diminished  in Crohn’s patients  (Fig.  5.8A;  P <  0.001).  Although there  was  an 
overlap between the groups,  50% of Crohn’s patients exhibited IL-8  secretions 
below the 10^^ centile of healthy controls.
Macrophages  were  then  exposed  to  other  inflammatory  agonists  to 
determine the stimulus specificity of the defect. A similar pattern of reduced IL-8 
secretion was observed following exposure to TNF-a (Fig. 5.8B; P < 0.001), but 
not  LPS  (Fig.  5.8C).  A  shared  defect  between  C5a  and  TNF-a  suggests  a 
molecular lesion downstream  of their receptors, but above the  IL-8  gene  given 
the  normal  response  to  LPS.  This  is  supported  by  the  correlation  in  Crohn’s 
macrophages  of responses  to  C5a  and  TNF-a  (R  =  0.55,  P  <  0.01),  but  not 
between either stimulus and LPS (R = 0.378, non-significant). Responses to each 
agonist were unrelated to CARD 15 genotype (Fig.  5.8A-C), site of disease (Fig. 
5.9A) and use of medication (Fig. 5.9B). All patients had quiescent disease.
5.2.8 Phosphorylation of  p44/p42 MAP kinase in response to C5a
The  stimulus-selective  failure  of  IL-8  production  implicates  a  probable 
abnormality in cytoplasmic signalling pathways or the transcriptional apparatus. 
The signal transducer p44/p42 MAP kinase is known act downstream of the C5a
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156recepto/"^^, and becomes phosphorylated in association with IL-8 production"^"^*. 
In buffy coat macrophages, it was minimally phosphorylated when unstimulated, 
with rapid phosphorylation (maximal at 2 min) following exposure to C5a (Fig. 
5.10A). Its phosphorylation state under these conditions was assessed in a small 
number of subjects (Fig. 5.1 OB), but no difference apparent between high (n = 5) 
and  low  (n  =  5)  responding  Crohn’s  patients  and  healthy  controls  (n  =  7). 
Interestingly,  in the  3  ulcerative  colitis  patients  studied  in this  experiment,  all 
appeared to show hyperphosphorylation.
5.3 Discussion
5.3.1  Response to MDP
Polymorphisms  in  CARD  15  have  been  proposed  to  play  a  central  role  in  the 
pathogenesis of Crohn’s disease^^"^’"^ "^ ^ . The mechanisms of the predisposition, as 
well  as  the  normal  functions  of the  protein,  remain poorly  understood.  Under 
basal  conditions,  predominant  CARD 15  expression  occurs  in  mononuclear 
phagocytes^^^’^*® . Originally thought to act as a LPS receptor, it was subsequently 
demonstrated  to  respond  instead  to  Detection  of  this  bacterial
product normally leads to NF-kB activation, which is abrogated in the presence 
of polymorphisms associated with Crohn’s disease.
In this study, CARD  15 polymorphisms did not influence lL-12 secretion 
by  macrophages  in  response  to  LPS,  further  refuting  the  initial  data^^^.  The 
response  to  MDP  was  subsequently  examined.  At  the  time  these  experiments 
were  conducted,  its effects on macrophages and appropriate outcome measures 
were  unknown.  Due  to  cost  considerations,  the  stimulus  duration  and 
concentration  applied were  based  on those  published  in the  literature^**  which
157-fffff <------- 44 kDa
0  15  30  45  60  90  0  2  5  15  45
sec  min
B
mm  M   I B   < ----------44 kDa,  phosphorylated
< ---------44 kDa,  non-phosphorylated
CD  CD  HC  UC
Figure 5.10 Phosphorylation of p44/p42 MAP kinase in macrophages stimulated with C5a.
(A) Immunoblots showing the time course of changes in buffy coat macrophages. (B) Representative 
immunoblot illustrating normal phosphorylation in 2 CD patients (1 high responder, 1  low responder 
in IL-8 assays), 1  HC subject and 1  UC patient. The latter demonstrates the hyperphosphorylation
observed in all UC patients studied.
HC: healthy controls; CD: Crohn's patients: UC: ulcerative colitis patients
158also  corresponded  well  to  the  conditions  employed  in  the  in  vivo  studies 
performed here (see 4.2.6).
DNA  microarrays  represent  a  powerful  methodology  for  determining 
global  changes  in  gene  expression,  particularly  useful  when  the  outcome  of 
exposure  to  a  stimulus  is  unknown  beforehand.  In  addition,  they  provide 
considerable contextual information about the background state of cells in which 
changes occur.  An important drawback for spotted arrays  is that for any probe 
there is an approximately  10% probability of chance hybridization, producing a 
signal  not  genuinely  reflecting  the  presence  of  the  corresponding  cRNA"*^®. 
Similarly,  there  is  an  approximately  5%  probability  that  single  spots  fail  to 
produce  signals,  even  with  the  complementary  cRNA  present.  Technology 
employed by Affymetrix attempts to overcome these  obstacles by representing 
every  gene  through  a  set  of  probes,  each  consisting  of  a  collectively 
representative series of short oligonucleotide sequences"^^*.
The cRNA data were processed by subtracting background fluorescence 
values  for each array from  those  of the  individual  spots.  Multiple  arrays  were 
compared  by  normalization  to  equivalent  levels  of total  fluorescent  intensity, 
usually achieved as here by dividing values for each signal by the signal mean 
over the whole array"^^^ followed by log transformation.  Processing data in this 
manner  also  helps  overcome  the  problem  that  distributions  of raw  expression 
values tend to be skewed, violating the normality assumption required for most 
statistical tests.
Differences  in  expression  levels  are  usually  analyzed  in  terms  of fold 
change  between  the  various  conditions  employed,  with  2-fold  alterations 
considered the threshold for significance"*^^. This has been criticized because of
159poor signal-to-noise ratios for genes with low expression and impaired sensitivity 
for true positives that are highly expressed originally. To increase confidence in 
the results of this study, significance of fold changes were confirmed by 2-way 
ANOVA on all  genes of interest"^^"^.  Differences  in transcripts of prime  interest 
were  also  validated  using  post-genomic  techniques,  to  verify  their  functional 
importance.
The  genes  principally  induced  in  macrophages  by  MDP  were  pro- 
inflammatory. They included a number of chemotactic cytokines of which IL-8 
and  IL-ip  were  prominent  members,  corresponding  closely  with  the  skin 
window  studies  (see  4.2.6).  Abrogation  of  the  transcriptional  response,  and 
identical basal gene expression profiles, in m/m macrophages argues in favour of 
loss  of the  pro-inflammatory  response  rather than  a  hyper-responsive  gain-of- 
function  caused  by  CARD15  polymorphisms.  The  normal  response  of 
macrophages  from  w/w  Crohn’s  patients  suggests  that  these  individuals  are 
unlikely  to  possess  molecular  lesions  elsewhere  along  the  same  signalling 
pathway. It would be interesting to repeat these studies in both a large population 
of simple  heterozygotes  (to  determine  whether  they  possess  an  intermediate 
phenotype)  and  in  m/m  healthy  controls  (in  whom  the  response  should  be 
abrogated). Although one such individual was identified in this study, it was not 
possible to obtain a further blood sample for this experiment.
Mechanistically important changes were confirmed to be translated into 
protein  effects.  As  predicted,  IL-8  and  IL-lp  secreted  were  considerably 
enhanced.  lL-10  was  examined  as  a  cytokine  for  which  only  small,  non­
significant  elevations  in  mRNA  levels  were  implicated  by  the  array;  this  was 
borne out by the concentrations secreted. No transcripts sufficient to produce the
160IL-12p70  heterodimer were  detected  in  any  sample,  and the  cytokine  was  not 
present  in  the  culture  supernatants.  The  only  cytokine  measured  that 
demonstrated a poor correlation was TNF-a, for which mRNA levels were rather 
variable across the samples with no clear pattern of change induced by MDP. In 
contrast, its secreted concentration was clearly augmented following stimulation. 
This  is  consistent  with  previous  reports  suggesting  that  this  cytokine  is 
principally  regulated  at  the  post-translational  stage'*'* %   largely  by  controlling 
cleavage  of  the  pro-cytokine  by  TNF-a-converting  enzyme  (TACE)  in  the 
plasma membrane'*^^.
The  transcriptional  profiles  observed  here  correspond  favourably  with 
those subsequently reported in the literature'*®^. Both contrast with other reports 
suggesting MDP action through CARD 15 elicits production of anti-inflammatory 
IL-10^^^, and that loss of negative regulation in m/m  individuals predisposes to 
chronic  inflammation.  These  apparently  polarized  findings  are  not  mutually 
exclusive, since the latter study stimulated mononuclear cells over a longer 48 h 
time  course.  It  is  clearly  documented  that  many  pro-inflammatory  agonists, 
including LPS, initiate counter-regulatory mechanisms  in addition to those that 
drive inflammation to limit its duration'*^®. The question then arises as to which 
phase of the response contributes to the pathogenesis of Crohn’s disease. Loss of 
anti-inflammatory  regulation  should  manifest  in  a  model  such  as  the  skin 
window  with  normal  initiation  of  inflammation  but  prolonged  resolution. 
Conversely,  the  reduced  accumulation  of neutrophils  and  cytokine  production 
observed  (see  Chapter  4)  supports  a  key  role  for  pro-inflammatory  mediator 
deficiency.
1615.3.2  CARD  15 may not bind MDP directly
A final consideration raised by this study pertains to whether CARD 15 directly 
binds MDP, as currently proposed. Although the LRR domain typically mediates 
protein-ligand  interactions, the predicted binding  surface  is considerably  larger 
than required.  One  possibility  would  be  presentation  of MDP  by  a  chaperone 
protein.  This could explain the interaction with CARD 15, which resides  in the 
cytoplasm^^^.  It  is  not  otherwise  apparent  how  MDP  crosses  the  plasma 
membrane,  although  it  has  been  proposed  that  CARD 15  does  moves  to  this 
cellular  compartment  on  activation"*^^.  A  final  possibility  would  be  a  specific 
membrane  receptor  for  MDP  that  initiates  an  intracellular  signalling  cascade 
activating CARD 15 downstream.
Should MDP bind CARD 15 directly, the interaction need not occur at the 
concave surface. CARD 15 bears significant structural homology to R proteins"^^* 
that  mediate  the  immune  or  “hypersensitive”  response  in  plants"*^^;  these  also 
possess LRRs.  Whilst originally believed to bind microbial avirulence products 
directly"*^®, this has never been satisfactorily demonstrated. A more recent theory, 
known as the guard hypothesis'^^  suggests that R protein LRRs bind instead to 
normal  cellular  proteins  (the  virulence  targets).  Detection  of any  alteration  in 
their  targets  induces  a  rapid  defence  response.  Whatever  binding  partner 
associates  with the concave  aspect of the  CARD 15  LRR,  computer modelling 
here  suggests that  SNPs associated with Crohn’s  disease act by disturbing this 
interaction.  MDP could fit into the  equation by associating with either another 
surface  of  the  CARD 15  molecule  or  an  alternative  protein  to  which  it  is 
complexed.
1625.3.3  Alternative inflammatory agonists
Polymorphisms in CARD 15 do not appear to explain the generic impairment in 
cytokine production or neutrophil recruitment in Crohn’s disease.  In an attempt 
to  understand  the  cellular  basis  of this  failure,  macrophages  were  studied  in 
culture to model cytokine production in the skin window. The novel stimulus of 
wound  fluid,  taken  from  an  acute  surgical  incision,  was  used  to  reproduce  a 
physiological mixture of inflammatory stimuli similar to that present at the site of 
epithelial trauma induced by skin abrasion.  A stimulus of this nature has never 
been used previously to stimulate macrophages.
In  control  subjects,  substantial  IL-8  production  was  elicited  in 
concentrations  reminiscent  of those  measured  in  skin  windows.  Secretion  in 
response  to  this  general  agonist  was  diminished  in  Crohn’s  macrophages, 
supporting this as a good in vitro model of the skin window. The intrinsic failure 
of IL-8 production by these cells further argues against the defect in neutrophil 
migration relating to a circulating inhibitor of inflammation^^^.
A number of pro-inflammatory mediators will be present in wound fluid; 
extensive  characterisation  was  beyond  the  scope  of this  study.  A  number  of 
general observations were made: the protein content appeared similar to normal 
human serum, and activated complement was demonstrable by lysis of opsonized 
sheep  erythrocytes'^"*^.  Although  protease  inhibitors  substantially  attenuated 
stimulation  of  IL-8  secretion,  this  was  equivalent  in  healthy  and  Crohn’s 
macrophages.  In  contrast,  the  latter  showed  a  restricted  diminution  after 
preheating wound fluid, suggesting reduced sensitivity to its heat-labile fraction.
Since complement is characteristically inactivated by heat treatment, pure 
recombinant C5a was assessed as an agonist and the response found defective in
163a significant proportion of Crohn’s  patients.  The  defect appeared to be  shared 
with TNF-a (and may extend to other untested stimuli) but not LPS, implicating 
an  abnormality  in  the  cell  signalling  or  transcriptional  apparatus.  The  lesion 
could  not  be  identified  in  the  preliminary  studies  described  here:  the 
phosphorylation of p44/p42 MAP kinase, known to act downstream of the C5a 
receptor and associated with IL-8 production, was normal. The exception was in 
ulcerative  colitis  patients,  in  whom  it  appeared  hyperphosphorylated  after 
stimulation. Although based on a small sample, this may be worth validating and 
could prove informative about the pathogenesis of this disease.
A  failure  in  the  response  to  complement  is  noteworthy  given  the 
predisposition of Crohn’s inflammation for the lower gastrointestinal tract.  The 
lumen  contains  considerable  numbers  of bacteria,  which  can  ingress  into  the 
bowel  wall  through  any  breach  in  the  mucosal  barrier.  Bacterial  cell  walls 
activate  the  alternative  pathway  of  complement"*^^,  and  gut  bacteria  such  as 
Escherichia  coli  strongly  trigger  C5a  production"^^^.  Complement  could  be 
critical for triggering homeostatic inflammation to remove bacterial debris from 
the gut,  since the principal repertoire of pathogen recognition receptors  (CD 14 
and  TLRs)  are  normally  down-regulated  on  intestinal  macrophages  and 
enterocytes"*^’*^.  This  is  usually  beneficial,  preventing  excessive  immune 
activation  in  non-pathogenic  conditions,  but  how  then  to  sense  potentially 
deleterious  infection?  The  C5a  receptor  by  comparison  is  expressed  at  high 
levels on intestinal macrophages"^^"^.  One possibility is that when bacterial loads 
in the bowel wall become sufflcient to cause serum extravasation, activation of 
the  complement  cascade  through  the  alternative  pathway  initiates  a  local 
inflammatory response.
164Interestingly,  some  congenital  complement  deficiencies  have  been 
associated with enteropathies  first diagnosed as  Crohn’s  disease'^^^'^^^,  and C5- 
deficient mice exhibit more prolonged and severe inflammation in DSS colitis"^^^. 
An impaired chemotactic response of Crohn’s neutrophils to C5a has also been 
reported"^^*,  which  could  indicate  a  generic  problem  in  signalling  pathways 
downstream of its receptor.
These  experiments  highlight  the  heterogeneity  inherent  in  Crohn’s 
disease, supporting the hypothesis that it actually represents a syndrome with a 
variety of molecular causes producing a  final  common phenotype"^^^.  As  such, 
alternative  components  of  wound  fluid  (which  could  be  investigated  using 
chromatographic  or filtration-based methods),  cellular aberrations  or molecular 
lesions  might underlie  failure  of cytokine production or acute  inflammation in 
different Crohn’s patients. This would be consistent with a failure as suggested 
here of the LPS response in a minority of patients {5.2.1 and possibly 4 patients 
in 5.2.7). Given the previously documented mutations in components of the LPS- 
sensing  pathway  in  Crohn’s  disease,  it  would  be  interesting  to  sequence  the 
relevant genes  CDI4™,  TLR/’ ’^,  MD-2^^'  and MyDSS*''')  in the non-
responders identified in this study.
The data presented in this chapter add further support to the concept of a 
general  systemic  defect  in  innate  immunity in  Crohn’s  disease.  Again,  it  is  of 
interest  that  the  abnormalities  appear  entirely  unrelated  to  CARD 15  genotype, 
questioning  the  centrality  previously  afforded  to  it  as  a  primary  pathogenic 
lesion.  The  hypothesis  that  the  CARD 15  pathway  provides  a  compensatory 
mechanism to augment acute inflammation was elaborated previously (see 4.3.4). 
Such secondary processes may determine the principal sites of inflammation, as
165CARD 15  does  for  ileal  disease,  based  on  the  nature  of the  microbial  sensing 
defect and the contents of the luminal flora.
5.3.4  Functional relevance of diminished acute inflammation 
Despite  the  probable  multiplicity  of  underlying  molecular  mechanisms,  the 
general  unifying  feature  in  Crohn’s  patients  appears  to  be  a  predisposition 
towards a weak acute inflammatory response. This could potentially culminate in 
suboptimal  clearance  of  bacteria  invading  the  tissues  and  a  granulomatous 
reaction to prevent collateral dissemination of infective material. The crux of this 
hypothesis is that Crohn’s patients will exhibit weak responses to the presence of 
bacterial  or other foreign material  in the tissues.  To  assess this  directly,  the  in 
vivo reaction to subcutaneous inoculation with heat-killed Escherichia coli was 
examined (Chapter 6).
166Chapter 6: Bacterial Injections
6.1 Introduction
Data  from  the  previous  chapters  demonstrated that  Crohn’s  patients  possess  a 
general  impairment  in  their  inflammatory  response,  manifested  by  reduced 
neutrophil recruitment to sites of epithelial damage (see Chapters 3 and 4). The 
frmctional  consequences  of  this  abnormality  in  vivo  remain  undetermined. 
Bacteria and their products will ingress through any discontinuity in the mucosal 
barrier^^. The hypothesis generated by this thesis predicts that any inflammatory 
response generated by their introduction into the tissues will be weak.  Delayed 
clearance could then drive chronic inflammation.
Escherichia coli are gram-negative aerobic bacilli prevalent in the normal 
bowel flora"*^^, which colonize the gastrointestinal tract within hours of birth. The 
relationship between host and microbe is usually symbiotic, with the exception of 
a few pathogenic strains. Commensal strains rarely cause disease, apart from in 
the  immunocompromised  host  or  following  disruption  of the  normal  mucosal 
barrier'^^^. In the event of the latter, they constitute a major population of bacteria 
infiltrating  the  bowel  wall.  A  failure  to  clear  such  organisms  is  postulated  in 
Crohn’s disease,  given the reduced neutrophil chemotaxis.  Consistent with this 
prediction  Escherichia  coli  DNA  has  been  detected  within  macrophages  of 
Crohn’s  granulomata"^^"^.  Whilst apparently  supporting the  hypothesis, there  are 
inherent  difficulties  in  drawing  inferences  from  chronic  established  lesions. 
Consequently,  the  in  vivo  acute  inflammatory  response  of  Crohn’s  patients 
following introduction of killed Escherichia coli into the tissues was examined.
1676.2 Results
6.2.1 Bacterial preparation
An  antibiotic-sensitive  clinical  isolate  of Escherichia  coli  NCTC  10418  was 
grown  up  in  synthetic  medium,  killed  by heating  and  divided  into  aliquots  of
1.05  mg  dry weight.  Five  randomly  selected  aliquots  were  cultured by  UCLH 
Clinical Microbiology under standard conditions and in enriched broth for 7 days 
at room  temperature,  30°C  and  37°C:  no  growth  was  observed.  Aliquots  were 
resuspended prior to use to  a concentration of 5  x  10^  bacteria/ml  (see  2.6.1), 
which contained 5 mg/ml protein as measured by Bradford assay.
To determine the kinetics of bacterial clearance from the forearm in vivo, 
a y-emitting ^^"Hechnetium label was attached^^^. Two labelling techniques were 
assessed, with radioisotope incubation in the presence of stannous pyrophosphate 
or lipophilic sodium exametazime"^^^.  The latter had three-fold greater labelling 
efficiency,  and  was  more  stable  following  6  h  in  vitro  incubation  of labelled 
bacteria with serum or neutrophils (Table 6.1).
A healthy individual was inoculated with 200 pi labelled Escherichia coli 
(activity = 115,200 counts per second). A signal could be detected at the forearm 
injection  sites  over the  subsequent  24  h  (Fig.  6.1 A).  Peripheral  venous  blood 
taken  at  6  h  contained  30  counts  per  second  (urinary  excretion  was  not 
determined).  Technetium possess a 6 h half-life"^^^ and a 70 kg male has a total 
blood volume  of approximately  5  litres.  This  equates  to  approximately  41,000 
counts per second of released radiolabel in the circulating blood volume, or 36% 
of that  attached  to  the  bacteria  when  injected.  Visualization  of  label  in  the 
forearm  at  48  h  using  a  y-camera  also  demonstrated  that  undigested  material
168Experiment Label Pellet Supernatant
Labelling Efficiency Stannous pyrophosphate 3 MBq 16 MBq
Lipophilic exametazime 7 MBq 12 MBq
Stability (6 h Incubation) Stannous + Neutrophils 180 cps 80 cps
Stannous + Serum 150 cps 200 cps
Lipophilic + Neutrophils 2,000 cps 20 cps
Lipophilic + Serum 1,000 cps 60 cps
Table 6.1 Efficiency and stability of Escherichia coli radiolabelling with two different techniques.
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Figure 6.1  Detection of radiolabelled bacteria injected into the forearm of a healthy control. (A) Signal could 
be readily measured over the subsequent 24 h using a gamma counter. Comparison to source and peripheral blood 
activities would allow quantification of bacterial clearance in future experiments. (B) Signal was still present 
at 48 h, visualized with a gamma camera. These images also illustrated that bacteria remain highly localised to the
inoculation sites (arrow) prior to clearance.
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Figure 6.2 Erythematous reactions after inoculation with killed Escherichia coli. Erythema developed in 
(A) healthy controls and (B) Crohn's patients. Left and right forearms from one subject of each group are 
shown, scale bar = 5 cm. (C) Areas of erythema were not significantly different in any subject group. Results
shown as mean ± SEM.
HC: healthy controls; CD: Crohn's patients: UC: ulcerative colitis patients
170remained localized to the  injection site  over the time course of the experiment 
(Fig. 6.1B).
6.2.2  Acceptability
Bacterial injections were conducted on  13 healthy controls,  12 Crohn’s patients 
and  2  patients  with  ulcerative  colitis  (Appendix  1:  Tables  A1.8-A1.10 
respectively). All patients were in clinical remission and the majority of subjects 
were  off  medication.  Given  the  difficulty  in  recruiting  subjects  for  these 
experiments, a few patients were enrolled receiving treatment. These included 6 
Crohn’s  patients  on  5-aminosalicylates  of whom  1   also  took  azathioprine  and 
another methotrexate, and 1  ulcerative colitis patient on olsalazine.
In  all  subjects,  injection  elicited  local  inflammation  within  2-4  h, 
characterized by erythema (Fig. 6.2A,B), oedema, and local pain with tenderness. 
Pain was maximal  12 h after inoculation, rated as 4.57 ± 2.09 (mean ± SEM) on 
a  10-point  visual  analog  scale.  Analgesia  was  required  and  successfully 
ameliorated pain in  10 participants; this  included  1   g paracetamol  (7 subjects), 
300 mg aspirin (1 subject) and 10/500 mg co-dydramol (2 subjects).
Systemic  symptoms  included  nausea  (9  subjects),  myalgia  of the  neck 
and  shoulder  girdle  (8  subjects),  headache  (5  subjects),  shivering/rigors  (3 
subjects),  pyrexia  (3  subjects),  vomiting  (2  subjects),  malaise  (2  subjects), 
lethargy  (2  subjects),  sweating/flushing  (2  subjects),  sore  throat  (1  subject), 
axillary pain without lymphadenopathy (1  subject) and gastrointestinal upset (1 
subject). These were typically mild, occurred within 12 h of injection and almost 
completely resolved by 24 h. The profile of adverse reactions was similar across
171all  subject  groups,  except  for  a  serious  adverse  event  in  one  ulcerative  colitis 
patient (see 6.2.10).
6.2.3 Local response in healthy controls
In healthy individuals, the area of erythema spread progressively over the course 
of  the  experiment  (Fig.  6.2A,C).  After  24  h,  it  became  more  diffuse  and 
disappeared  completely  by  72  h.  Laser  Doppler  measurement  of blood  flow 
around the injection site showed substantial increases by 8 h (Fig.  6.3A,D; P < 
0.001), maximal by 24 h (Fig. 6.3B,D; P < 0.001), and a return almost to baseline 
by 48  h (Fig.  6.3C,D).  Measurements  were  highly  correlated between  left and 
right arms  (Fig.  6.3E;  R = 0.918, P < 0.001),  and no changes  observed  in the 
lower limbs (monitored as a control vascular bed).
6.2.4 Impaired response in Crohn’ s patients
Although superficial appearances in Crohn’s patients were similar (Fig. 6.2B,C), 
elevations in blood flow were abnormally low at 8 h (Fig. 6.4A; Fig. 6.3D) and 
24 h (Fig. 6.4B; Fig. 6.3D), returning to baseline by 48 h (Fig. 6.4C; Fig. 6.3D). 
This  was  most  marked  in  patients  with  colonic  disease  {P  <  0.001),  although 
those with ileal disease also showed a partial defect {P < 0.01). Half of the latter 
patients  were  CARD15  m/m;  their  response  was  indistinguishable  from  w/w 
Crohn’s subjects. The degree of impairment was unrelated to use of medication 
or smoking status.
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Figure 6.3 Blood flow responses following subcutaneous injection of Escherichia coli, measured using 
laser Doppler. (A-C) Representative laser Doppler images from the left and right arms of a representative 
healthy control at (A) 8 h, (B) 24 h and (C) 48 h. Pixel intensity linearly correlates with blood flow.
(D) Time course of changes show s reduced blood flow in CD, particularly the colonic variety , and delayed 
resolution in UC. Results show n as mean ± SEM. Significance values compared to HC at same time 
point. (E) Blood flows in left and right arms were liighly correlated in each subject at every time point.
HC: healthy controls; CD: Crohn's patients; UC: ulcerative colitis patients 
*P<0.05;  ***P< 0.001
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Figure 6.4 Blood flow responses in a representative colonic Crohn's patient. (A) 8 h, 
(B) 24 h and (C) 48 h follow ing injection. Laser Doppler images for left and right 
arm are show n at each time point.
1746.2.5 Systemic response
Bacterial  injection also  elicited  a  systemic  inflammatory  response,  including  a 
raised peripheral blood leukocyte count at 24 h (f = 8.6x10'^), which returned 
close to  baseline by 48  h (Fig.  6.5A).  The  48  h  levels  were  higher in colonic 
Crohn’s patients than controls {P = 0.003),  although baseline counts were also 
raised {P = 0.03). The increases in all subjects were largely due to neutrophilia {P 
= 0.2x10"^), again greater in Crohn’s patients (Fig.  6.5B; P = 0.004). Monocyte 
numbers were also elevated (Fig. 6.5C; P = 0.01), and lymphocytes reduced (Fig. 
6.5D;  P  =  0.04),  without  significant  differences  between  subject  groups. 
Eosinophil (Fig. 6.5E) and basophil counts (Fig. 6.5F) were unchanged, as were 
other  parameters  of the  full  blood  count  including  haemoglobin  and  platelet 
numbers.
Concentrations of multiple serum cytokines were assayed using an array- 
based system, at baseline, 24 h and 48 h. These included IL-lp (Fig. 6.6A), IL-6 
(Fig.  6.6B),  IL-8  (Fig.  6.6C),  IL-10 (Fig.  6.6D),  IL-12  (Fig.  6.6E), TNF-a and 
IFN-y. Only IL-6 was elevated in all samples, attaining highest concentrations in 
colonic Crohn’s patients {P < 0.05).  TNF-a and IFN-y were only detected in a 
minority  of  samples,  with  no  difference  between  patients  and  controls.  All 
induced cytokines showed peak elevation at 24 h, with return to baseline by 48 h, 
but  only  IL-6  concentrations  rose  to  a  physiologically  relevant  range^^*’'*^^’'^^*. 
Systemic acute phase reactants CRP (Figure 6.1  A) and SAA (Figure 6.7B) were 
also increased by 24 h, reaching even greater levels by 48 h. Their induction was 
significantly higher in colonic Crohn’s patients {P < 0.01  for each). These serum 
factors were undetectable or within normal limits in all subjects at baseline.
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Figure 6.5 Changes in peripheral blood leukocyte counts. (A) Total systemic leukocyte 
counts following injection. (B) Neutrophils. (C) Monoc\ tes. (D) Lymphocytes. (E) Eosinophils. 
(F) Basophils. Results shown as mean ± SEM. Significance values compared to HC at same
time point.
HC: healthy controls; CD: Crohn's patients; JJC: ulcerative colitis patients 
*P<0.05;  **P<0.01
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Figure 6.6 Changes in serum cytokine concentrations. (A) IL-ip. (B) IL-6. (C) IL-8. 
(D) IL-10. (E) IL-12. Results shown as mean ± SEM. Significance values compared to
HC at same time point.
HC: healthy controls: CD: Crohn's patients: UC: ulcerative colitis patients 
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1776.2.6 Bacterial digestion products reduce vascular tone
The presence of bacteria in the tissues normally induces neutrophil recruitment. 
Following  their  phagocytosis  and  digestion,  the  vacuole  bursts  releasing 
solubilized  material  extracellularly^®^.  Many  bacterial  cell  wall  constituents, 
including LPS,  can interact with the vascular endothelium  directly and  lead to 
smooth  muscle  relaxation'^^^'^*®.  A  potential  explanation  for  impaired 
vasodilatation in Crohn’s disease could be reduced generation of such vasoactive 
products  secondary  to  diminished  neutrophil  extravasation  and  consequently 
bacterial uptake.
To test the viability of this hypothesis, neutrophils from healthy controls 
(n =  3) were  incubated  with opsonized Escherichia coli  for  1   h.  Supernatants 
were assayed for effects on vascular tone in explants from rat superior mesenteric 
arteries'^*’’'^*^.  Prior  to  all  experiments,  vessels  showed  normal  contractile 
responses  to  the  adrenergic  agonist  phenylephrine  (EC 50  =  0.15  pM);  mural 
tensions  returned  to  baseline  after  washing.  The  phenylephrine  dose-response 
was  then  investigated  in  vessels  pre-incubated  for  1   h  with  the  neutrophil 
supernatants. A reduction in maximum tension but not EC50 was observed (Fig. 
6.8), indicating non-competitive inhibition of contraction. There was no evidence 
of vessel damage. Controls were rings from the same vessels not pre-exposed in 
this manner.
Serum from subjects taken 24 h after injection was also measured for free 
circulating LPS. None was detected in the majority of samples; this might relate 
to insufficient assay sensitivity or choosing too late a time point.
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Figure 6.7 Serum acute phase reactants. (A) CRP. (B) SAA. Results shown as 
mean ± SEM. Significance values compared to HC at same time point.
HC: healthy controls; CD: Crohn's patients; UC: ulcerative colitis patients 
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Figure 6.8 Dose-response to phenylephrine in rat superior mesenteric artery. Vessels 
were pre-incubated w ith medium alone (black line) or supernatants from healthy 
neutrophils mixed w ith opsonized Escherichia coli (blue line). Results shown as 
mean ± SEM. Significance values compared to control at same concentration.
*P<0.05
1796.2.7 Pharmacological manipulation of blood  flow
In animal  models,  LPS  induces vasodilatation  in through a nitric  oxide  (NO)- 
dependent  mechanism"**^.  To  investigate  the  relevance  of this  mediator  in  the 
normal elevation of blood flow induced by Escherichia coli, 3 healthy controls 
underwent  brachial  artery  cannulation  24  h  following  inoculation.  Baseline 
measurements  were  taken  (Fig.  6.9A,E)  then  noradrenaline  infused,  with 
minimal effect (Fig. 6.9B,E).  Saline washout normalized blood flow again (Fig. 
6.9C,E). The NOS inhibitor NG-monomethyl-L-arginine acetate (1-NMMA) was 
subsequently  infused^*^’ '^*'*,  which  rapidly  attenuated  the  blood  flow  response 
(Fig. 6.9D,E; P = 0.008).
The  effects  of  sildenafil  citrate  (Viagra™),  a  cyclic  GMP  (cGMP) 
phosphodiesterase-5  (PDE-5)  inhibitor  and  vasodilator"^*^,  were  consequently 
examined.  A  50  mg  oral  dose  was  administered  to  5  healthy  subjects  and  10 
Crohn’s  patients  at  24  h (8  patients)  or 48  h  (2  patients)  after  injection.  This 
caused  marked  elevation  in  blood  flow  in  most  subjects  {P  =  0.02)  over  the 
subsequent  60  min  (Fig.  6.10A-C,E),  particular  in  those  with  colonic  disease. 
The  effects  were transient, returning towards  baseline  by 90 min (Fig.  6.10D), 
but supported an NO-related defect.  They also demonstrated that this  could be 
overcome using pharmacological treatment (Fig. 6.10E).
6.2.8 Ultrasound analyses
In  most  participants,  discrete  masses  could  be  felt  at  the  injection  sites  on 
completion of the experiment; their volumes were quantified by ultrasound in a 
proportion of subjects at 7 days. Masses, where measured, were most substantial 
in healthy controls (Fig. 6.11 A; mean = 2.37 cm\ standard deviation = 1.25 cm^.
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Figure 6.9 Pharmacological manipulation of blood flow in healthy controls. A cannula 
was inserted into the brachial arter\  24 h following bacterial injection, and measurements 
taken at (A) baseline. (B) after infusion of noradrenaline (NorA), (C) after normal saline 
washout and (D) after infusion of the NOS inhibitor 1-NMMA. (E) Time course of changes 
in 3 different healthy controls are shown. Significance values compared to baseline.
*P<0.05
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Figure 6.10 Augmentation of blood flow responses by sildenafil citrate. Administration 24 h following 
bacterial injection. Measurements were taken at (A) baseline, (B) 30 min, (C) 60 min and (D) 90 min in 
a colonic Crohn's patient. (E) Time course of changes in healthy controls (blue), ileal Crohn’s patients 
(orange) and colonic Crolm's patients (red). Mean changes ± SEM also shown.
182Figure 6.11 Ultrasound visualization of subcutaneous masses 7 days after injection. 
Representative images from (A) a healthy control (HC), (B) an ileal Crohn's (CD) 
patient and (C) a colonic CD patient.
183n = 5), smaller in ileal Crohn’s patients (Fig. 6.1 IB; mean = 0.65 cm^, standard 
deviation = 0.45 cm^, n = 5), and minimal or absent in colonic Crohn’s patients 
(Fig. 6.12C; n = 5). All masses resolved within 6 weeks.
6.2.9 Delayed resolution of vascular responses in ulcerative colitis
The  2  ulcerative  colitis patients  enrolled  in this  study (see  Appendix  1:  Table 
A 1.10  for  details)  both  demonstrated  initial  local  and  systemic  inflammatory 
responses comparable to healthy controls (Fig. 6.2C; Fig. 6.3D; Fig 6.5-Fig. 6.7; 
Fig. 6.12A-D). In marked contrast, both failed to resolve by 48 h (Fig. 6.12E,F; 
Fig. 6.3D; f  = 0.6 x 10*^). In the first patient, there was a 24 h delay with return 
to baseline by 72 h (Fig. 6.12G); all other signs of inflammation also remitted. In 
the  second patient,  the  vascular response  was  only  gradually  declining  at this 
time (Fig. 6.12H).
6.2.10 Development of  pyoderma gangrenosum in an ulcerative colitis patient
In  contrast  to  all  other  subjects,  in  whom  inflammation  resolved  completely 
within 4 days of injection, it persisted in the second ulcerative colitis patient (Fig. 
6.13A).  By day 6, it had become increasingly severe, with local vésiculation at 
each  injection  site  (Fig.  6.13B).  This  caused  clinical  concern,  and was  treated 
with  a  single  intravenous  dose  of hydrocortisone  and  the  NSAID  diclofenac. 
Over  the  subsequent  8  h,  vesicles  coalesced  forming  3  cm  diameter  painful 
blisters.  These were treated by incision and drainage  (Fig.  6.13C),  resulting  in 
considerable  pain relief after discharge  of the  non-cloudy  serous  contents.  The 
latter was assayed for cytokine levels (Table 6.2), of which IL-8 was markedly 
raised. Systemically, the patient was apyrexial, haemodynamically stable and had
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Figure 6.12 Delayed resolution of blood flow response in patients with ulcerative colitis. 
Measurements were taken at (A 3) 8 h, (C,D) 24 h, (E,F) 48 h and (G,H) 72 h following
injection of Escherichia coli.
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Figure 6.13 Development of vésiculation and ulceration at the site of bacterial injection 
in a patient with ulcerative colitis. Following a prolonged er> thematous reaction (A), vesicles 
developed (B) that coalesced to form a single bhster. This w as incised (C), after which 
the skin became ulcerated with a tender violaceous margin (D).
Cytokine Concentration Units
IL-ip 3.728 ng/ml
IL-6 1.905 ng/ml
IL-8 1.597 ng/ml
IL-10 37.49 pg/ml
IL-12 Not detectable
IFN-y 584.7 pg/ml
TNF-a 404.34 pg/ml
TGF-p 150 pg/ml
Table 6.2 Cytokine concentrations in fluid aspirated from blisters that developed 
in one ulcerative colitis patient.
186no  other  symptoms  (including  gastrointestinal).  The  white  cell  count  was 
elevated to  10.56 x  loVml  (9.38  x  10^/ml neutrophils)  and CRP to  37.3  mg/1. 
This adverse event was immediately reported to the ethics committee, and studies 
in ulcerative colitis patients electively terminated.
The  following  day,  two  2.5  x  3.0  cm  superficial  tender  ulcers  had 
developed  at  both  injection  sites.  These  possessed  purple  margins  with 
surrounding erythema and induration (Fig. 6.13D); a diagnosis of vesicobullous 
pyoderma gangrenosum was made.  A  single infusion of 5  mg/kg  Infliximab'^*^ 
resulted  in  50%  reduction  of the  area  of each  ulcer  overnight.  Slow  healing 
continued  on  topical  0.05%  clobetasol  propionate,  although  the  lesions  still 
appeared markedly inflammatory. Four weeks later, treatment with topical 0.03% 
tacrolimus"*^^  induced  re-epithelialization  and  remission  of erythema  within  2 
weeks.
The  original  batch  of injected  bacteria  was  sterile  on  culture,  as  were 
swabs from the ulcers on day 7. At the same time, biopsies were taken from the 
wound  margins,  sectioned  and  stained  with  haematoxylin  and  eosin.  These 
showed granulation tissue with active chronic inflammation; marked neutrophil 
and  mononuclear  infiltration  extending  into  the  subcutis;  oedema  and  fibrin 
exudation in the superficial dermis; and focal pseudoepitheliomatous hyperplasia 
(Fig. 6.14A-D). These were consistent with the clinical diagnosis'***.
6.2.11  Potential pro-inflammatory genes in ulcerative colitis 
After  the  prolonged  inflammatory  reaction  developed,  the  patient  recalled  a 
similar episode  6  years  previously  after operation  for an  ingrown toenail.  The 
incision site became infected and vesicles arose identical to those on the forearm
187Figure 6.14 Haematoxy lin and eosin stained sections from biopsies of the ulcer margin. Samples 
taken from the skin lesion that developed in one ulcerative colitis patient. (A) Low power image 
show ing granulation tissue, inflammation in the subcutis, fibrin exudation into the superficial 
dermis, and pseudoepitheliomatous hyperplasia. (B,C) Medium power view s. (D) High power 
image show ing extensive neutrophil and mononuclear cell infiltration.
188at  this  presentation.  These  resolved  slowly  over  two  months  on  steroids  and 
antibiotics,  but  poor  wound  healing  necessitated  debridement.  Hospital  notes 
from  this  prior  incident  were  not  available,  and  the  information  was  not 
volunteered  when  originally  inquiring  about  the  past  medical  history.  This 
stereotyped  reaction  raises  the  possibility  of  an  underlying  molecular 
abnormality,  as  opposed  to  a  stochastic  reaction.  The  patient  also  had  a 
documented Grade 3 reaction on previous Heaf testing, which may be relevant.
Pyoderma gangrenosum can be genetically determined as part of an auto- 
inflammatory syndrome: pyogenic sterile arthritis, pyoderma gangrenosum, and 
acne  (PAPA)  syndrome"**^.  The  brother of the  patient  in  this  study  developed 
cervical  inflammatory  arthritis  in  his  third  decade,  suggesting  a  potential 
hereditable  syndrome.  Consequently,  genes  known  to  predispose  to  auto- 
inflammatory  syndromes  (Familial  Mediterranean  Fever"^^®;  TNF-Receptor- 
Associated  Periodic  Syndrome'^^*;  Hyperimmunoglobulinemia  D  and  Periodic 
Fever"^^^;  Cutaneous  Articular  Syndrome/Neonatal-Onset  Multi-system 
Inflammatory Disease'^^^'*^'^; PAPA syndrome;  and Muckle-Wells  Syndrome"*^^) 
were sequenced in this patient. No mutations were detected.
6.3 Discussion
63.1  Bacterial injection technique
The  technique  developed  here  allows  investigation  of the  acute  inflammatory 
response  induced  by  bacteria  in  humans  in  vivo.  Injection  of  heat-killed 
Escherichia coli was safe in healthy controls and Crohn’s patients. Attachment of 
a radiolabel to the bacteria demonstrated that organisms remain highly localised 
to  the  inoculation  site  prior  to  clearance.  Liberation  of this  label  following
189digestion by phagocytes could also be used in future to quantify this clearance, 
possibly in combination with detection of leukocyte recruitment using  indium- 
tagged neutrophils (as employed clinically'^^^). Infiltration of high energy indium 
and  disappearance  of  low  energy  technetium  signals  would  allow  detailed 
measurements  of this  acute  process.  The  reproducibility  and  minimal  intra­
individual  variability  of  this  method  are  highlighted  by  the  substantial 
correlations between blood flows in left and right arms at each time point in this 
study in all subjects.
The side effect profile of the technique, whilst not pleasant, was tolerable. 
Most resolved by 24 h without medication or on simple analgesia. Subjects were 
encouraged  to  take  paracetamol  for  pain  relief,  and  avoid  potentially 
immunosuppressive  NSAIDs  if  possible.  The  reaction  in  ulcerative  colitis 
patients was very different from other subjects (see 6.2.10), resulting in elective 
termination of the study in this group. Replication of these experiments in such 
individuals may not be safe under the conditions employed here.
6.3.2  Reduced resistance vessel dilatation in Crohn’ s disease 
In  healthy  controls,  killed  bacteria  elicited  a vigorous  inflammatory  response. 
One  component of this was  a  large  increase  in  forearm  blood  flow,  involving 
dilatation  of  both  resistance  vessels"*^^  (leading  to  flow  augmentation  as 
visualized by laser Doppler) and capillaries'*^* (causing erythema). Measurement 
of flow relied on the Doppler principle, detecting scattering (due to erythrocyte 
movement)  of  light  from  a  monochromatic  laser  directed  at  the  tissue. 
Photodetection  of  the  frequency  broadened  light  produced  a  photocurrent, 
computer processed to provide blood flow measurements proportional to average
190erythrocyte velocity. This method samples approximately 1   mm tissue thickness, 
with  measured  surface  changes  representative  of  the  larger  tissue  volume 
undemeath^^^.
A  major  impairment  in  blood  flow  was  observed  in  Crohn’s  patients, 
most marked in those with colonic disease and unrelated to CARD  15 genotype. 
Whereas  measured blood flows were  grossly different,  superficial  appearances 
and areas of erythema were similar in all groups. This indicates an abnormality in 
relaxation of medium-calibre resistance arteries'^^*, rather than the capillary bed. 
The  mechanism  of this failure  could potentially relate to  reduced  liberation of 
bacterial  products  from  the  cell  wall  or  vasoactive  mediator  release  from 
leukocytes;  recognition  of  these  agents  by  leukocytes  or  the  vascular 
endothelium;  the  response  of either  of these  cells;  or  an  abnormality  in  the 
vascular smooth muscle contractile machinery.
Many  bacterial  cell  wall  products,  including  LPS,  exert  vasodilatatory 
effects  by direct interaction with the  endothelium"*^ ^   .  Some  of these  will  be
solubilized from bacteria, in part by neutrophils infiltrating the tissues following 
infection that  digest cell  walls  into  smaller  muropeptides.  Reduced  neutrophil 
recruitment  as  found  in  Crohn’s  disease  (see  3.2.4  and  4.2.2)  could  diminish 
release of these mediators. The viability of this hypothesis was demonstrated in 
the organ bath model, which illustrated that neutrophils normally produce soluble 
vasoactive products after phagocytosis of bacteria.
6.3.3  Resistance vessel dilatation has an NO-mediated component
In  animals,  the  vascular  response  to  LPS  and  whole  bacteria  has  been
demonstrated to occur through NO release"*^^’^ ® ® . The response to bacteria can be
191attenuated by prior neutrophil depletion,  through a mechanism reducing cGMP 
production^^.  NO  causes  vascular relaxation by  diffusing  into  smooth muscle 
cells, in which it activates guanylate cyclase increasing cGMP production^®^ The 
latter  reduces  intracellular  calcium  release  and  leads  to  dephosphorylation  of 
myosin (through actions on myosin light chain kinase) impeding interaction with 
actin^®^.  These  perturbations  to  the  contractile  machinery  translate  into  lower 
vessel wall tensions.
In  the  human  model  developed  in  this  study,  the  response  in  healthy 
controls to bacteria could be attenuated by infusing a non-isoform selective NOS 
inhibitor.  Failure  of high  dose  noradrenaline  to  cause  vasoconstriction  in  the 
same experiments attests to the specificity of the blockade.
PDE-5  catabolizes  cGMP,  terminating  its  action^®^.  Consequently,  the 
effects of the PDE-5  inhibitor sildenafil citrate on blood flow were assessed in 
healthy individuals and Crohn’s patients. Most subjects augmented their response 
following  its  administration,  with  a  time  course  consistent  with  established 
pharmacokinetics.  In a number of Crohn’s patients, blood flow was restored to 
near-normal  levels.  One  possibility  is  that  cGMP  production  is  diminished  in 
these patients, normalized by sildenafil. Another is that a right shift has occurred 
in  its  dose-response  curve  that  can  be  overcome  by  elevation  of  cGMP 
concentrations  to  supra-normal  levels.  Direct  measurement  of cGMP  in  these 
studies  was  not  possible,  although  the  experiment  could  theoretically  be 
performed on vasculature isolated from intestinal resection specimens.
The  impaired  vascular  response  was  observed  in  all  Crohn’s  patients, 
including those off treatment with quiescent disease. The very different response 
in ulcerative colitis patients argues against a state of tolerance induced by long
192term  Escherichia  coli  exposure  secondary  to  a  chronically  inflamed  and 
permeable  intestinal  wall.  The  failure  of vascular  dilatation  could  therefore 
represent either a primary pathogenic abnormality or a marker of the underlying 
process.  Previous  vascular  theories  of  Crohn’s  disease  have  been  proposed, 
suggesting  either  a  vasculitic  process^®"^  or  an  arteriosclerotic  mesenteric 
ischaemia^®^.  Diminished NO  production has  been reported  in Crohn’s  bowel, 
but only  in regions  of active  inflammation^®^.  These  observations  are  all  very 
different from the abnormality in vasodilatation following exposure to bacteria 
described here.
Reduced  tissue  perfusion  could  contribute  to  attenuated  leukocyte 
delivery, although normal migration of monocytes and lymphocytes (see  4.2.2) 
argues against this exerting a major role. It is more likely to represent a marker of 
an impaired acute inflammatory response, albeit one that could further compound 
the underlying abnormality. If this were the case, reversal of this phenomenon by 
PDE-5 inhibitors might prove therapeutically useful. A trial of the longer-acting 
agents in this class, such as vardenafil and tadalafil^®^, merits investigation.
6.3.4  The systemic inflammatory response in Crohn's disease 
Despite  the  weakened  response  in  the  forearm,  Crohn’s  patients  mounted  a 
strong  systemic  acute  phase  reaction^®*.  This  confirms  that  bacteria  are 
recognized and induce  some inflammatory sequelae.  Interestingly, the  systemic 
response  was  greatest  in  colonic  Crohn’s  patients,  who  exhibited  the  greatest 
attenuation of local changes. This illustrates the general principal that failure of 
local  acute  inflammation  can  drive  a  systemic  pro-inflammatory  state,  with 
characteristics identical to those observed in active Crohn’s disease^®®.
193Of the  serum  cytokines  measured,  only  IL-6  was  substantial  elevated, 
again to greatest levels in colonic Crohn’s patients. IL-6 is principally produced 
by macrophages, and potently stimulates lymphocyte activation, proliferation and 
differentiation^*®. It also provides the molecular link between local inflammation 
and  the  systemic  response,  driving  production  of acute  phase  proteins  by  the 
liver^**. The rise in IL-6 observed in all subjects 24 h following injection is likely 
to  account  for the  sustained  increases  in  CRP  and  SAA,  proportional  to  IL-6 
concentrations.  These  observations  are  also  consistent  with  findings  of high 
mucosal^and serum^*^ IL-6 concentrations in active (but not inactive) Crohn’s 
disease, but its normal production by monocytes in vitro^^^. This argues that high 
levels arise secondary to over-stimulation of normal mechanisms, possibly due to 
persistence  of bacteria within the  mucosa and  consequent increased uptake  by 
mononuclear phagocytes.
6.3.5  Impaired resolution of inflammation in ulcerative colitis 
The response to bacteria in ulcerative colitis was very different to that observed 
in Crohn’s patients.  The  local  and  systemic  reactions  over the  first 24 h were 
essentially  normal,  indicating  no  abnormality  in  initiation  of inflammation.  In 
contrast, resolution was delayed in both patients studied, by 24 h in the first and 
considerably longer in the  second; the  latter developed a serious complication.
Pyoderma  gangrenosum  is  an  ulcerating,  non-infectious  neutrophilic 
dermatosis  of unknown aetiology^*"*.  It develops  in  up to  5%  of inflammatory 
bowel  disease  patients,  often  coinciding  with  an  exacerbation  of  intestinal 
disease. It was once considered pathognomonic of ulcerative colitis^Although 
the underlying insult usually remains unidentified, a minority of cases may occur
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ulceration developing at the site of an insect bite^*^, but none following exposure 
to bacteria as found here.
Lesions most commonly develop in 30-50 year olds^^*, typically affecting 
the lower limbs and trunk. It has a characteristic appearance: rapid development 
and  progression  of  a  painful,  necrolytic  cutaneous  ulcer  with  an  irregular 
violaceous undermined border"***. A number of clinical variants are recognized, 
including  vesicobullous  disease  as  here,  characterized  by  rapidly  evolving 
painful vesicles and bullae that coalesce with central necrosis and a surrounding 
halo  of erythema.  Histopathological  findings  are  non-specific,  and  include  a 
mixed  cellular  inflammation  with  neutrophil  predominance;  disruption  or 
necrosis of dermal or pannicular blood vessels; peri-vascular deposition of IgM, 
complement component C3 and fibrin^and high levels of IL-8^^*, thought to 
drive the neutrophil recruitment.  The  low incidence of pyoderma gangrenosum 
renders  randomised  controlled trials  of treatment  impractical.  Steroids  provide 
the mainstay of therapy although, as in this case^*^,  immunosuppressive agents 
such  as  Infliximab"**^  and  tacrolimus"**^  (a  calcineurin  inhibitor)  may  be 
preferable. Many other immunosuppressants have  some reported efficacy^^^'^^*, 
and  a  beneficial  effect  of heparin  has  been  suggested  secondary  to  reduced 
neutrophil adhesion and transmigration^*^.
In this  case,  the  underlying  abnormality  is  likely  to  relate  to  defective 
termination  of  the  immune  reaction  to  bacteria,  or  mediators  activated 
specifically  in  the  presence  of  microbes  (such  as  the  alternative  or  lectin 
pathways of complement"*^^, as hinted at in 5.2.8). The patient in this study had 
previously  undergone  multiple  venesections,  tattooing,  acupuncture  and  ear
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stereotyped reaction did, however, previously occur in relation to infection of a 
surgical wound site, underscoring the importance of a bacterial trigger. Whether 
this  is  a  general  abnormality  or  specific to  coliform  organisms  remains
undetermined.
An  impairment  in  inflammation  resolution  in  ulcerative  colitis  is 
therefore  implicated,  either  secondary  to  defective  termination  of  pro-
inflammatory  mediator  production  or  activation  of  counter-regulatory 
mechanisms  such  as  anti-inflammatory  cytokines  or  resolvins^"*^  (see  1.5.6). 
Either  mechanism  could  account  for  the  sustained  elevation  in  IL-8
concentrations  measured  in  the  lesions,  which  probably  drove  continued 
neutrophil  accumulation  and  pathology  in this  subject.  It  would  also  be
interesting to determine the presence of T cell subsets in the skin biopsy sections, 
with particular reference to those with suppressor Tpeg characteristics.
6.3.6  Defective acute inflammation has functional relevance in Crohn’ s disease 
The  results  presented  in this  chapter  demonstrate  the  in  vivo  relevance  of the 
impaired  acute  inflammatory  response  in  Crohn’s  patients  described  in  this 
thesis.  They  illustrate  that  a  weak  local  response  to  intestinal  bacteria  in  the 
tissues engenders a systemic pro-inflammatory state identical to that observed in 
active Crohn’s disease. A potential novel therapeutic approach using vasodilators 
such as the PDE-5 inhibitors has been highlighted for evaluation. Furthermore, a 
hypothesis of ulcerative colitis as a disease of impaired inflammation resolution 
has been generated, based on preliminary but dramatic pilot data.
196Chapter 7: Discussion
7.1 Novel findings in this thesis
7.1.1 Novel findings generated by this research
These studies were undertaken to evaluate the hypothesis that a deficient acute 
inflammatory response underlies the pathogenesis of Crohn’s disease. The work 
builds on previous data^^^ that demonstrated diminished neutrophil accumulation 
to the  sites of skin abrasions in this condition.  To this end, a number of novel 
techniques  were  developed  or  evolved,  the  key  findings  of  which  were  as 
follows:
■   Serial intestinal biopsies illustrated that attenuated neutrophil recruitment 
also applies to the bowel, the primary site of disease.
■   A  modified  skin window technique  allowed replication of the  original 
data^^^ and identified a reduction in cytokine production (particularly IL- 
8)  in  Crohn’s  disease.  This  was  postulated  to  explain  the  defect  in 
neutrophil recruitment.
■   The  novel  experiment  in  which  cultured  Crohn’s  macrophages  were 
exposed to  wound  fluid  from  healthy  individuals  revealed  an  intrinsic 
defect  in  their  ability  to  produce  IL-8.  Characterisation  of this  fluid 
suggested  that  failure  of the  response  to  complement  (amongst  other 
mediators) might be a central problem in many patients.
■   Subcutaneous  injection  of killed  Escherichia  coli  into  the  forearms  of 
Crohn’s patients demonstrated that diminished acute inflammation leads
197to functional consequences in vivo. These experiments also showed that a 
weak local response in these individuals could engender a systemic pro- 
inflammatory state.
7.1.2  Revised schema for the pathogenesis of Crohn's disease 
Neutrophils  are primarily responsible  for the  killing  and digestion of bacteria, 
accomplished  by  the  potent  digestive  enzymes  released  into  the  phagocytic 
vacuole from cytoplasmic granules^®^. They eradicate infecting micro-organisms 
and are discharged as pus or apoptose^^^, resulting in resolution. Macrophages by 
comparison are also phagocytic but with lower killing and digestive capacity^^*. 
They play more  of a containing role,  forming  granulomata to  wall  off foreign 
material from the remainder of the body,  and secrete  cytokines that prime  and 
amplify  the  immune  response.  This  results  in  florid  local  and  systemic 
reactions"^^®.
The hypothesis outlined in Chapter  1   (see  1.5.4) can now be confirmed 
and elaborated based on the data presented in this thesis. Although the intestinal 
mucosa provides a very effective barrier in health, insults such as infection and 
trauma allow the luminal contents access to the tissues of the bowel wall. In the 
absence of adequate numbers of neutrophils for effective clearance of bacteria^^^, 
the  latter will  be  taken  up  by  macrophages"^^"^.  This  leads  to  the  formation  of 
granulomata^^ ^  and  consequently  the  foci  of chronic  inflammation  containing 
activated leukocytes (producing TNF-a and other Thl  cytokines) characteristic 
of Crohn’s disease.
The  studies  performed  here  indicate  that  Crohn’s  disease  is  associated 
with failure to translate acute tissue damage into an effective neutrophil response.
198substantiating  the  original  hypothesis.  The  immune  system  detects  bacteria 
through  their  interaction  with  either  cell-associated  pathogen  recognition 
receptors^^'^ or soluble serum factors"^^^. Precisely how they are sensed within the 
bowel wall therefore presents a dilemma, since the former are down-regulated in 
healthy non-inflamed mucosa'^^. One possibility is that bacterial infiltration of the 
mucosa elicits serum extravasation and subsequent activation of mediators such 
as  members  of  the  complement  cascade.  The  latter  induce  synthesis  of 
chemokines including IL-8 by resident macrophages (which express high levels 
of  complement  receptor"*^),  driving  recruitment  of  neutrophils  out  of  the 
vasculature  into the tissues.  The  diminished response  to  complement observed 
here  in  Crohn’s  patients  impedes  this  whole  chain  of events,  predisposing  to 
suboptimal acute inflammation and a chronic granulomatous reaction.
7.1.3  The role ofCARDlS
The  discovery  that  polymorphisms  in  CARD 15  predispose  to  Crohn’s 
disease^^"*'^^^  generated  considerable  excitement.  These  have  frequently  been 
afforded  a  primary  role  in  many  pathogenic  schemata.  To  date,  only  weak 
mechanistic  relationships  have  been postulated  (see  1.6.3),  some  contradictory 
and none proven. Apart from the specific response to MDP, which was normally 
pro-inflammatory,  patients  compound  heterozygous/homozygous  for  CARD 15 
polymorphisms could not be differentiated from those who were wild type in any 
experimental  model  in these  studies.  This  questions  the  centrality  of CARD 15 
(see 4.3.4 and 5.3.1 for discussion, including attempted reconciliation of current 
theories)  and  suggests  that  at  most  it  represents  one  of a  number  of genetic 
variations that give rise to a common phenotype.
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first  is  a  generic  reaction  following,  for  example,  non-specific  damage  to  the 
epithelium,  achieved  through  mediators  such  as  the  complement  cascade. 
Impairment of this response represented the common defect in Crohn’s patients, 
irrespective of CARD15 genotype. In the general population, the magnitude and 
quality  of an acute  inflammatory  reaction will  follow a Gaussian  distribution. 
Those  at  the  low  tail  will  be  prone  to  inadequate  clearance  of  luminal 
constituents  infiltrating  the  bowel  mucosa.  Fortunately,  many  of  these 
individuals can augment their response by detection of micro-organisms or their 
products  that  ingress  through  a  mucosal  defect,  using  molecules  such  as 
CARD 15. Under this model, those at risk of developing Crohn’s lesions possess 
attenuation  of both  the  general  response  and  compensatory  mechanisms  (Fig. 
7.1).  Polymorphisms in CARD 15 probably predispose to  ileal disease^^^  as the 
luminal contents in this region are fluid.  In these conditions, a small diffusible 
product such as MDP (present in high concentrations'^^) would be more likely to 
penetrate  a damaged mucosa than  in the  large  bowel  where  contents  are  more 
solid.  It  is  probable  that  CARD  15  wild  type  patients  have  lesions  in  other 
pathogen receptor pathways, a view supported by recent genetic data^^^’^^'^’^^^.
7.1.4  Combination with existing theories of  pathogenesis
The assertion that there is an attenuated acute inflammatory response in Crohn’s 
disease  would  not  be  mutually  exclusive  with  the  majority  of data  present  in 
favour of alternative hypotheses. The latter broadly divide into those advocating 
an infectious agent, a primary autoimmunity, or a breakdown in mucosal barrier
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Figure 7.1 Schematic representation of the proposed mechanisms involved in the pathogenesis of Crohn's 
disease. Damage to the mucosa allows penetration of gut contents including bacteria (brown ovals) 
into the bowel wall. The outcome depends upon the subsequent inflammatory response. A vigorous 
response leads to the secretion of high levels of IL-8 attracting large numbers of neutrophils, which 
phagocytose and digest the bacteria and foreign material. A weak inflammatory response predisposes 
to Crohn's lesions because the foreign material is taken up by macrophages to form granulomata and 
foci of chronic inflammation. A naturally weak response can be boosted in the small bowel by MDP 
signalling through the CARD 15 pathway of macrophages to induce them to produce IL-8. In the large 
bow el a similar role might be performed by TLR4 or CD 14. The predisposition to Crohn's disease is 
greatly increased by a combination of a low innate inflammatory  response coupled to failure of one of
the compensatory  mechanisms.
201function (see 7.5, 1.4.2 and 1.5.1 respectively). Much of the evidence for any of 
these theories remains indirect and therefore open to interpretation.
Support  for  infectious  aetiologies  largely  relies  on  more  frequent 
detection  of  pathogens  in  patients  that  controls.  Whereas  this  could  imply 
increased infection rates, a failure of clearance as postulated here could produce 
identical results. The apparent lack of pathogen specificity described in Crohn’s 
disease (see  1.3.2) argues more  strongly for the  second scenario.  The evidence 
for autoimmunity has been very circumstantial. Findings of autoreactive T cells 
or  broken  immunological  tolerancecould  be  secondary  to  longstanding 
inflammation rather than the primary cause. A disrupted epithelial barrier could 
also  represent  a  secondary  phenomenon,  but  might  additionally  compound  a 
weak acute inflammatory response. The adequacy of immune clearance from the 
bowel  will  depend  not  only  on  leukocyte  influx  but  also  on  the  quantity  of 
foreign  material  infiltrating  the  mucosa.  Increasing  this  load  could  place  an 
already stretched system under excessive strain, beyond its capacity to function 
efficiently.  The  familial  tendency  towards  increased  bowel  permeability 
described in relatives of Crohn’s patientsmay only manifest clinically once a 
certain threshold is passed (although evidence for subclinical inflammation has 
been  reported^^^).  Overt  disease  will  depend  on  other parameters  determining 
movement  of luminal  constituents  into  the  mucosa  and  potency  of the  acute 
inflammatory response.
The  hypothesis  present  here  is  also  consistent  with  established  risk 
factors. It concords well with the “hygiene hypothesis” (see 1.4.4), under which 
the  increased  incidence  of  Crohn’s  disease  has  been  attributed  to  improved 
standards of sanitationThe inflammatory response to bacterial ingress would
202be  much  more  effective  if primed  from  a  state  of  subclinical  inflammation 
induced by repeated mild infections or parasitic  infestation^^^ that if started de 
novo. This could also partially explain the preliminary evidence for efficacy of 
helminthic  treatment**®.  Other  susceptibility  factors  include  smoking^^^  and 
possibly  stress^^*.  The  former  (whilst  exerting  pleiotropic  effects)  acts  in  a 
generally  immunosuppressive  manner^^^.  It  also  specifically  reduces  IL-8 
concentrations  in  the  mucosa^"*®,  IL-8  secretion  by  LPS-stimulated 
macrophages^"**, and compromises mucosal blood flow^"*^.  All these  factors are 
closely related to rates of neutrophil emigration into the tissues^^®’^"* ^.
7.1.5 Comparison with CGD
The  granulomatous  colitis  that  develops  in  prototypic  neutrophil 
immunodeficiency  conditions  such  as  CGD  sets  a  clear  precedent  for  the 
existence  of such  an  underlying  mechanism.  In  CGD,  the  problem  relates  to 
impaired  bacterial  digestion  secondary  to  a  defective  respiratory  burst^*^,  in 
contrast  to  Crohn’s  disease  where  inadequate  numbers  of  neutrophils  are 
recruited. The final common effect is nonetheless identical: that the ability of the 
mucosa to clear foreign material from the tissues becomes overwhelmed, leading 
to granuloma formation as a protective measure.
The  hypothesis  that  Crohn’s  disease  is  secondary  to  an  impaired 
inflammatory response  might  suggest that these  patients  should be  abnormally 
susceptible  to  infection.  Although  the  condition  is  not  described  as  such,  this 
does not necessarily weaken the hypothesis.  Firstly, the impairment in Crohn’s 
disease  is  of a partial  nature,  and  neutrophils  once  recruited  can  kill  bacteria 
effectively.  The  abnormality  could  therefore  be  limited  to  digestion  and  not
203stretch to reduced bactericidal capacity. Alternatively, it is possible that Crohn’s 
patients may have heightened susceptibility to infection, but of a subtle  nature 
not yet visible.  It may prove necessary to  study a large population to  detect a 
positive  phenotype,  as  illustrated  in  a  study  of high  infectious  risk  children 
carrying polymorphisms in mannose-binding lectin^"^"^.
The  process  of acute  inflammation  is  stochastic  in  its  occurrence  with 
inbuilt redundancy. Even patients with CGD, the most severe of the neutrophil 
disorders, can live for years or even decades without infection^**. The difficulty 
is further compounded because Crohn’s patients have varying levels of nutrition, 
immunosuppressive  treatment  and  surgical  intervention.  Isolating  features 
integral  to  the  disease  from  confounding  external  influences  in  such  a 
heterogeneous population poses a considerable methodological obstacle.
7.2 Limitations of the study and future directions
7.2.1  Assumptions and general limitations in these studies 
A key challenge when investigating chronic conditions such as Crohn’s disease 
remains the distinction of abnormalities representing primary pathogenetic events 
from those arising as secondary phenomena due to longstanding inflammation or 
treatment.  Although  difficult  to  prove,  the  fact  that  the  defects  reported  here 
occurred in patients with apparently quiescent disease off treatment, in the skin 
as well as the bowel, and not in inflammatory disease controls argues strongly for 
the former. Similarly, the fact that macrophages were cultured for 5 days prior to 
stimulation makes suppression by some humoral or therapeutic factor less likely.
The principal limitation in this study relates to the relatively low numbers 
of subjects  studied  in  the  in  vivo  experiments.  Two  factors  underlie  this:  the
204restrictive selection criteria employed to maximize validity and the nature of the 
techniques  themselves.  Most  involved  a  degree  of  discomfort  and  all  had 
potential risks and side effects. Given the magnitude of observed differences and 
high statistical significance levels, expanding numbers was not felt justifiable in 
most cases. In some instances, explicit number limits were also imposed by the 
local ethics committee.
An understanding of the molecular mechanisms that give rise to Crohn’s 
disease remains the ultimate goal. Unfortunately, no novel specific genes could 
be  proposed  here.  The  main  obstacles  lie  in  the  complexity  of cellular  and 
signalling  pathways  involved,  and the  heterogeneity  of Crohn’s  patients.  Data 
from  these  studies  and  others^^^’^"^^,  based  on  both  clinical  and  laboratory 
observations, indicate that it is not a single disease but a syndrome with a variety 
of predisposing lesions. This would be consistent with a condition characterized 
by an attenuated acute inflammatory response, orchestrated by multiple factors. 
A  combination  of  defects  in  any  group  of  these  could  elicit  the  described 
pathology. An opportunity is nonetheless presented by the studies in this thesis, 
since  a  clinical  abnormality  (failure  of  neutrophil  migration  and  cytokine 
production)  has  been  linked  to  a  physiological  in  vitro  model  (macrophages 
stimulated with wound fluid). Recapitulation of the latter by exposure to C5a and 
TNF-a provides specific stimuli in a defined system. This can be used to probe 
cell  signalling  pathways  thoroughly,  in  poorly  responsive  patients  identified 
using an ELISA-based screen.
Finally, it is worth remembering that Crohn’s disease is a condition that 
only affects humans.  There  is no animal model that reliably reproduces all the 
features  of  the  condition.  Consequently,  studies  to  elucidate  the  causal
205mechanisms  have  to  be  conducted  almost  exclusively  on  patients  and  control 
subjects.  Human  experimentation  is  completely  different to  all  other  forms  of 
investigation.  Subjects  must be  carefully  selected and experiments  designed to 
give  answers  within  the  limits  of procedures  feasible  for  conduct  on  human 
volunteers.  In many  situations  it remains  difficult or impossible  at  a practical 
level  to  follow  serial  changes  and  obtain  a  complete  description  of  a 
phenomenon.  For example, to observe the  local  inflammatory reaction directly 
following  subcutaneous  Escherichia  coli  injection  would  have  required  serial 
skin biopsies. Such a procedure would have been neither practicable nor ethically 
justified in these volunteers. Unavoidably therefore some interpretations have to 
be inferred following acquisition of as inclusive a data set as possible.
Specific limitations inherent to any particular methodology are discussed 
in the Results chapters reporting use of that technique.
7.2.2  Therapeutic implications
If accepted, the findings of this thesis may carry important implications for the 
clinical  management  of  Crohn’s  disease.  At  present,  immunosuppression 
provides  the  mainstay  of  treatment.  Whilst  still  appropriate  for  patients 
presenting  acutely  in  the  proposed  secondary  chronic  phase  of inflammation, 
maintenance  of  remission  may  prove  best  accomplished  using  immune 
stimulants.
This  has  already  been  attempted  with  GM-CSF^^*,  which  works  on  a 
systemic level primarily by promoting granulocyte efflux from bone marrow^"^^. 
Although provisional benefits have been reported, efficacy appeared marginaP^*. 
Two  potential  explanations  for  this  were  that  treatment  was  administered  to
206patients with active disease although theoretically lesion prevention would be a 
more appropriate target, and that GM-CSF does not act locally at the level of the 
bowel mucosa.
Conversely,  IL-8  applied  topically  corrected  the  defect  in  Crohn’s 
patients  in  the  skin  window  model  (see  4.2.5),  as  neutrophils  can  migrate 
normally when presented with an appropriate  stimulus^^^. A similar effect may 
be achievable in the bowel. IL-8 could be introduced using an oral enteric-coated 
preparation or by enema. Local synthesis may also prove feasible by genetically 
modified gut organisms, as has been demonstrated in principle with Lactococci 
producing IL-IO^'^^. The same could also be achieved by any immune adjuvant 
that  enhances  local  IL-8  production  (see  4.2.6)  or  the  acute  inflammatory 
response in general. Such mediators are likely to permeate the bowel at regions 
of mucosal disruption, precisely those areas at greatest risk. Local action should 
minimize systemic adverse effects. Finally, use of a peptide or protein molecule 
is probably not contraindicated, as the majority of Crohn’s lesions affect regions 
of the bowel distal to sites of digestion.
The other potential novel therapeutic avenue identified here relates to use 
of vasodilators,  including but not limited to those of the PDE-5  inhibitor class 
(see 6.2.7).  Although failure of blood vessel relaxation in Crohn’s disease may 
not represent a primary problem  (see  6.2.2),  it could compound the underlying 
abnormality.  Given  the  safety  profile  of these  agents,  a  pilot  clinical  trial  is 
warranted, perhaps using the long-acting drugs vardenafil and tadalafil.
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This thesis  opens  a number of avenues  for future  research.  The  key  areas  are 
elucidation of the molecular mechanisms underlying the abnormalities described 
herein and trialling the therapeutic predictions highlighted above (see 7.2.2). The 
following would be appropriate for further study:
■   Serial  biopsies.  The  numbers  of inflammatory  disease  controls  should 
firstly be increased. Signalling in this model could then be investigated by 
transcription  factor  and  gene  expression  profiling  of  mucosal 
macrophages  and  epithelial  cells.  Ileostomies  could  be  used  as  an 
accessible  means  to  perform  multiple  simultaneous  biopsies  and 
determine the effects of immune modulators injected into the mucosa.
■   Skin windows.  These  could be  used  as  a model  to test the  efficacy  of 
other immune  stimulants,  as well  as to  further investigate  activation of 
cell signalling pathways and transcription factors  in fractionated exuded 
leukocytes.  The  latter  studies  could  be  supported  by  pharmacological 
agonist and inhibitor experiments.
■   Macrophage  cultures.  Patients  could be  screened  to  determine  C5a and 
TNF-a receptor levels. Cell signalling pathways activated by stimulation 
could  be  determined  by  studying  protein  phosphorylation,  either 
specifically  using  immunoblots  or  in  general  with  proteomic 
methodologies^"^*.  Transcription factor activation could also be profiled. 
An  attempt  should  be  made  to  replicate  findings  in  resident  intestinal 
macrophages, as some aspects of their biology and function are known to 
differ from circulating monocyte-derived macrophages^"^^. Any candidate
208genes  to  emerge  from  these  studies  could  be  sequenced.  Additionally, 
given the potential identification of patients whose macrophages may not 
respond  to  LPS  (see  5.2.1  and  5.27),  the  endotoxin  pathway 
genes^^^'"*^^'^^"^ could be sequenced in these individuals.
CARPI5.  Other  aspects  of  macrophage  function,  for  example 
phagocytosis and respiratory burst, could be assessed for the influence of 
CARD 15  polymorphisms.  Partner  proteins  might  be  detectable  by 
attaching  recombinant  CARD 15  to  a  column  subsequently  exposed  to 
macrophage  cytosol  extracts,  from  cells  with  and  without  prior  MDP 
stimulation.  Any  molecules  that  bind  could  by  identified  by  mass 
spectrometry.
Bacterial  injection.  The  normal  mechanisms  of the  vascular  response 
could be further characterised by exposing rat superior mesenteric artery 
sections in an organ bath to Escherichia coli with or without neutrophil 
digestion.  The  vascular  function  of  mesenteric  vessels  isolated  from 
Crohn’s patient or cancer patient control  intestinal  resection  specimens 
could also be determined in the same model system. The kinetics of the 
inflammatory response in vivo could be determined using a combination 
of radiolabelled neutrophils and bacteria (as described in 6.3.1).
Other defects in innate immunitv. Under this hypothesis, any abnormality 
that  leads  to  a  weak  acute  inflammatory  response  could  predispose  to 
Crohn’s  disease.  CGD  patients  appear particularly prone  to  developing 
peri-anal disease with fistulation^*^.  Crohn’s patients with these clinical 
characteristics  may  possess  a  CGD-like  abnormality  of  neutrophil 
function.  Subjects could be screened by looking at a composite measure
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incorporated into the cell wall. Any individual showing impairment could 
then  have  the  process  dissected  out  by  assaying  phagocytosis  (of 
fluorescently  labelled  bacteria^^®),  respiratory  burst  (measuring  oxygen 
consumption^^*  and  cytochrome  c  reduction^^^),  ion  fluxes^^^ 
(radioisotope  uptake)  and  digestive  enzyme  content  and  function 
(proteomic  methodologies  and  bactericidal  capacity  of  extracted 
granules).
Clinical  trials.  The  therapeutic  potential  of  both  IL-8  and  PDE-5 
inhibitors  could  be  investigated  as  outlined  above  (see  7.2.2).  The 
greatest benefits would be expected in maintenance of remission. Patients 
who have recently undergone intestinal resections would provide an ideal 
pilot group, as these individuals normally develop endoscopic recurrence 
within 1  year.
Ulcerative colitis. Finally, exciting although preliminary data suggest that 
the  abnormality  in  ulcerative  colitis  could  relate  to  a  failure  of 
inflammation  resolution  (see  6.2.9).  These  findings  should  ideally  be 
replicated, although some risk might be involved (see 6.2.10). It remains 
unclear  whether  the  adverse  event  that  occurred  in  one  patient  was 
idiosyncratic.  Reducing  the  quantity  of  bacteria  injected  might 
diminished  either  the  probability  or  magnitude  of  such  a  reaction 
developing  again.  Should  the  defect  be  reproduced,  the  termination  of 
pro-inflammatory  signals  in macrophages,  neutrophils  and  lymphocytes 
(each  cell  in isolation or co-culture)  could  be  investigated.  Analysis  of 
signalling pathways should follow identification of any abnormality. The
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might prove relevant. Counter-regulatory mediators such as the resolvins 
(see  1.5.6) may play critical roles, although the molecular techniques to 
study such systems in detail have yet to be developed.
7.2.4 Conclusion
A hypothesis of Crohn’s disease as a form of immunodeficiency has the potential 
to  re-orientate  approaches  to  understand  its  pathogenesis  and  the  clinical 
management. Clinically relevant impairments in the acute inflammatory response 
have  been mechanistically  linked to  defects  in cellular function.  This  research 
has highlighted a number of areas relevant for future study. These include novel 
potential  therapeutic  avenues  that  might  improve  maintenance  of  disease 
remission.  Such an approach could prevent the chronic inflammatory pathology 
that underlies the considerable morbidity associated with Crohn’s disease.
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253Appendix 1: Subject Characteristics
A 1.1 Demographics
Of the Crohn’s patients, 47.8% were male, compared with 54.3% and 58.1% of 
the  healthy  and  ulcerative  colitis  controls  respectively.  The  mean  age  of the 
Crohn’s patients was 44.5 years of age (standard deviation = 15.88, range:  16-87 
years old); 43.1  years old in healthy subjects (standard deviation =  18.52, range: 
22-84 years old) and 46.4 years in ulcerative colitis patients (standard deviation = 
16.59, range: 20-90 years old). The age distributions in each condition are shown 
(Fig. Al.lA).
The majority of subjects studied in each group were Caucasian, although 
in Crohn’s patients there was a slight over-representation of Jewish subjects with 
under-representation  of  people  from  the  Indian  subcontinent  (Fig.  Al.lB). 
Smoking was more prevalent in Crohn’s patients (36.7% current smokers,  11.1 
mean pack-year history) compared to healthy controls (18.4% current smokers, 
7.3  mean  pack-year history)  or patients  with  ulcerative  colitis  (15.8%  current 
smokers, 6.4 mean pack-year history).
A 1.2 Disease characteristics in Crohn’ s patients
Approximately equal proportions of patients presented with disease involving the 
ileum, colon or both sites (Fig. A1.2A). The majority had simple inflammatory 
changes  on endoscopy;  approximately  20%  of the  remainder had  fibrostenotic 
disease and a further 20%  showed evidence of fistula formation at some  stage 
over the course of their disease, with a small number of individuals displaying
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Figure Al.l Profile of subjects studied. (A) Age and (B) etlinicity.
HC: healthy controls; CD: Crohn's patients. UC: ulcerative colitis patients.
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Figure A1.2 Disease characteristics of Crohn's patients studied. (A) Site of disease and 
disease behaviour. (B) Duration of disease since first diagnosis. (C) Extra-intestinal
manifestations.
AS: ankylosing spondylitis; EN: erythema nodosum: PG: pyoderma gangrenosum;
PSC: primary sclerosing cholangitis.
256both characteristics (Fig. A 1.2A). Of the  157 patients for whom histological data 
was available, 38.2% were reported as showing granulomata on biopsy.
The mean duration of disease  in this patient population was  14.5  years 
(standard  deviation  =  11.84;  range:  1-52  years),  with  the  majority  diagnosed 
within  the  preceding  20  years  (Fig.  A1.2B).  In  terms  of  family  history  of 
inflammatory disease,  17.6%  of patients  had an affected relative  with  Crohn’s 
disease, 5.7% with ulcerative colitis, 1.3% with ankylosing spondylitis, and three 
individual patients had a first degree relative with rheumatoid arthritis,  coeliac 
disease  or  systemic  sclerosis  respectively.  A  significant proportion  (43.6%)  of 
patients had required at least one  intestinal resection during the course of their 
lives. A minority (9.0%) developed lesions in the upper gastrointestinal tract, and 
23.6%  showed  evidence  of peri-anal  lesions.  The  majority  of patients  had  no 
extra-intestinal  manifestations  of disease  and,  in  those  who  did  develop  such 
features, arthropathy was the most frequent complaint (Fig A1.2C).
A1.3 CARD 15 genotypes
Good allelic discrimination using fluorescent probes was achieved for each SNP 
(Fig. A1.3A-C). In the few cases in which results were ambiguous, samples were 
sequenced  directly.  Consistent  with  previous  reports^^"*,  the  three  CARD! 5 
polymorphisms  were  overrepresented  in  the  Crohn’s  population  (Fig.  A 1.4A) 
with  9.3%  of  subjects  carrying  two  variant  alleles  (5.5%  compound 
heterozygous,  3.8%  homozygous).  This  supports  the  predisposition to  Crohn’s 
disease  conferred  by  these  genetic  variants  (% ^  =  18.77,  P  <  0.001),  both  by 
simple heterozygosity (odds ratio = 3.2, f  = 0.03) and compound heterozygosity 
or  homozygosity  (odds  ratio  =  7.7,  P  =  0.03).  A  single  healthy  control  was
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Figure A1.4 CARD 15 polymorphisms. Distribution amongst different subject groups of 
(A) CARD!5 genotv pe and (B) SNPs associated with susceptibility to Crohn's disease.
HC: healthy controls: CD: Crohn's patients, UC: ulcerative colitis patients.
259compound  heterozygous  for  SNP8  and  SNP 13.  All  three  SNPs  were  more 
prevalent in Crohn’s patients, with most substantial enrichment in SNP 13  (Fig. 
A1.4B).  Polymorphisms  were  almost  entirely  restricted  to  Caucasian  subjects 
and people of Jewish extraction:  they were not found in any Afrocaribbean or 
Oriental Asian individuals, and only one Indian patient was simple heterozygous 
for a single SNP.
Amongst  Crohn’s  patients,  there  was  no  difference  in  the  duration  of 
disease based on  genotype  (Fig.  A1.5A).  As previously described^^^,  CARD15 
predisposed specifically to lesions  in the  ileum  (odds  ratio =  14.4, P =  0.008) 
(Fig. A1.5B). There was no association with any disease behaviour (Fig. A1.5C); 
granuloma formation; family history of Crohn’s disease; or extraintestinal, peri­
anal or upper gastrointestinal manifestations of disease; although patients in this 
series carrying two polymorphisms had an increased rate of intestinal resection 
(odds ratio = 3.8, P = 0.04).
In addition to the control subjects above,  14 patients with CGD were also 
genotyped for the CARD 15 polymorphisms. Of these,  10 were wild type, 3 were 
simple  heterozygous,  and one  patient was  compound heterozygous  for  SNP 12 
and  SNP 13.  Of these  individuals,  5  had  intestinal  inflammation  complicating 
their CGD of which 4 carried the CARD!5 polymorphisms.
A1.4 Patients studied are representative of the general Crohn’ s population 
A  large  population  of  Crohn’s  patients  and  controls  were  genotyped  for 
polymorphisms in CARD 15 known to predispose to Crohn’s disease. The groups 
were  largely matched for age and sex.  In Crohn’s patients, Jewish background
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Figure A1.5 Genot\pe-phenot\ pe correlations. Distribution of CARD15 genoty pes 
in Crohn's patients according to (A) time since diagnosis. (B) site of intestinal 
involvement and (C) disease behaviour.
261was  more  prevalent,  and  they  were  more  likely  to  be  current  smokers  with  a 
greater pack-year history, consistent with established disease risk factors^^^’^^"^.
Amongst Crohn’s patients, the distribution of lesion sites throughout the 
gastrointestinal  tract  was  similar to  other  reported  populations^^^,  as  were  the 
clinical disease behaviours*; frequency of granulomata in clinical biopsies^^; and 
development of overt upper  gastrointestinal^^^,  peri-anal^^^  and  extra-intestinal 
manifestations^^^.
In  concordance  with  previous  studies,  the  prevalence  of  CARD 15 
polymorphisms was greater in Crohn’s patients than in non-inflammatory bowel 
disease  controls  or  patients  with  ulcerative  colitis^^’^^^’^^^,  supporting  the 
hypothesis  that  these  predispose  to  Crohn’s  disease.  We  found  lower  SNP 
frequencies than those quoted in earlier reports^^"^, although subsequent studies 
have  documented  substantial  variation  in  their  occurrence  between  different 
Caucasian  populations^^*'^^^,  and  their  absence  in  people  of OrientaP^^’^ ^ "^   or 
Afrocaribbean  background^^*’^^^.  The  presence  of  a  significant  number  of 
individuals of these ethnicities in this study could have further diluted the allele 
frequencies:  polymorphisms  were  almost  exclusively  carried  by  Caucasian  or 
Jewish  subjects.  In  addition,  we  detected  one  healthy  individual  carrying  two 
polymorphisms  in  CARDI5.  This  was  a male  in his  early 20s, just before  the 
peak age of onset for Crohn’s disease. It is therefore impossible to state whether 
this  individual  is  a  true  healthy  control  or  someone  who  may  develop 
inflammatory bowel disease in later life. A number of individuals in their ninth 
decade  have  been  reported  carrying  two  polymorphisms  with  no  history  of 
gastrointestinal problems over their lifetime^^^, illustrating that CARD!5 variants 
are not sufficient to induce bowel inflammation.
262In  patients  in  this  study,  carriage  of CARD 15  variants  predisposed  to 
disease  involving  the  ileum.  Unlike  but  not  all^^*’^^^  previous
reports,  there  was  no  association  with  any  other  disease  characteristic,  in 
particular fibrostenotic behaviour, although patients carrying two polymorphisms 
may be more prone to requiring intestinal resection.
Finally, an interesting observation was made on genotyping subjects with 
CGD.  In  this  genetic  disorder  of neutrophil  function,  approximately  30%  of 
patients  develop  inflammatory  bowel  disease  almost  indistinguishable  from 
Crohn’s disease^In this very limited sample, the number of heterozygotes was 
unexpectedly high (28.57%) compared to 9.78% and 8.89% in healthy controls 
and ulcerative colitis patients.  It is not known why only a proportion of CGD 
patients develop colitis. The apparent association with CARD  15 polymorphisms 
is therefore of interest and may illustrate a requirement for at least two molecular 
lesions.  Of the wild type CGD patients, only one developed colitis.  Whilst this 
might be a true negative, there are a number of rare mutations in CARD15 not 
genotyped in this study but which predispose to Crohn’s disease^^"*, and it would 
be worth sequencing the gene in this subject.
A 1.5 Clinical characteristics of  subjects for in vivo studies 
The clinical characteristics of subjects for the serial biopsy (Tables A 1.1-A 1.3), 
skin window (Tables  A1.4-A1.7)  and  bacterial  injection  studies  (Tables  A1.8- 
Al.lO) are provided.
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Non  inflammatory Bowe Disease Controls
ID Diagnosis Age Sex
Current
Smoker
Pack-
Year
History Medication
WCC
(x1Ô®/L)
CRP
(mg/L)
ESR
(mm/h)
Albumin
(g/L)
B12
(ng/L)
Red Cell 
Folate
(pg/L)_
CARD15
Genotype
1 Post-operative 
rectal pain
57 F N 0 Hormone
replacement
therapy
w/w
2 Gastric
carcinoma
63 M N 80 Metoclopramide w/w
3 Irritable bowel 
syndrome
51 F N G Mebeverine w/w
4 Angiodysplasia 61 M N 40 Omeprazole w/w
5 Asymptomatic, 
family  history  of 
colorectal cancer
63 F N 20 Salbutamol
Methyldopa
Senna
w/w
6 Irritable bowel 
syndrome
48 F N 0 Nil w/w
7 Asymptomatic, 
family history  of 
colorectal cancer
48 F N 0 Nil m/w
8 Haemorrhoids 52 F N 0 Nil w/w
9 Familial
adenomatous
polyposis
59 M Y 2 Penicillin V w/w
10 Familial
adenomatous
polyposis
56 M N 5 Simvastatin w/w
Table A l.l Characteristics of non-inflamniatoiy bowel disease controls in serial biopsy study.
WCC: white cell count; CRP: C-reactive protein; ESR; erythrocyte sedimentation rate; w/w: wild type; m/w: simple heterozygote; m/m: compound heterozygote/homozygote.Crohn's Patients
ID
Site & 
Behaviour Age Sex
Current
Smoker
Pack-
Year
History Medication
WCC
{x^(ÿlL)
CRP
(mg/L)
ESR
(mm/h)
Albumin
(fl/L)
B12
(ng/L)
Red Cell 
Folate
(pg/L)_
CARD1S
Genotype
1 Ileal 66 M N 20 Nil 4.9 <0.5 7 44 573 m/m
2 Ileal,  stenotic 37 F N 10 Nil m/m
3 Ileocolonic,
stenotic
49 M Y 20 Metronidazole 11.8 3.1 3 43 477 273 m/m
4 Ileal 28 F N 0 Nil 2.8 47 253 m/m
5 lleocaecal 54 F N 0 Nil 5.2 <0.5 8 46 w/w
6 lleocaecal 51 F N 20 Nil 4.8 <0.5 8 43 w/w
7 Ileocolonic,
previous
fistulation
36 F Y 21 Oral
contraceptive
pill
13.3 <4.0 2 46 206 w/w
8 Ileocolonic, 
previous 
fistulation and 
pan­
proctocolectomy
44 F Y 3 Nil 7.3 <4.0 10 43 165 w/w
9 Ileocolonic,
previous
fistulation
52 F N 0.5 Mesalazine 8.4 <4.0 30 42 533 w/w
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Table A1.2 Characteristics of Crohn's patients in serial biopsy stutfy.
WCC: white cell count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; w/w: wild type; m/w: simple heterozygote; m/m: compound heterozygote/homozygote.w O N
ON
Ulcerative Colitis Paltientts
ID Extent Ago Sex
Current
Smoker
Pack-
Year
History Medication
WCC
(x10®/L)
CRP
(mg/L)
ESR
(mm/h)
Albumin
(fl/L)
B12
(ng/L)
Red Cell 
Folate 
(rifl/L)
CARD15
Genotype
1 Left-sided 27 M N 0 Sulfasalazine w/w
2 Proctitis 72 M N 0 Mesalazine
Enalopril
Allopurinol
Aspirin
Simvastatin
11.2 23.0 5 48 w/w
3 Left-sided 62 F N 0 Mesalazine 3.52 <5.0 46 w/w
Table A1.3 Characteristics of ulcerative colitis patients in serial biopsy study.
WCC: white cell count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; w/w: wild type; m/w: simple heterozygote; m/m: compound heterozygote/homozygote.Non inflammatory Disease Controls
ID Diaqnosis Aqe Sex
Current
Smoker
Pack-
Year
History Medication
WCC
(x10%)
CRP
Imq/L)
ESR
(mm/h)
Albumin
(q/L)
B12
(nq/L)
Red Cell 
Folate
(WJ/U
CARD1S
Genotype
1 Healthy 23 M N 0 Nil m/w
2 Healthy 61 M N 0 Nil w/w
3 Healthy 55 M N 0 Nil w/w
4 Healthy 39 M Y 20 Nil w/w
5 Healthy 49 M N 0 Nil w/w
6 Healthy 23 F N 0 Nil w/w
Table A1.4 Characteristics of healthy controls in skin window study.
WCC: white cell count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; w/w: wild type; m/w: simple heterozygote; m/m: compound heterozygote/homozygote.
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Crohn's Patients
ID Site & Behaviour Aqe Sex
Current
Smoker
Pack-
Year
History Medication
WCC
(xiOP/L)
CRP
(mg/L)
ESR
(mm/h)
Albumin
(g/L)
812
(ng/L)
Red Cell 
Folate 
(Fg/L)
CARD1S
Genotype
1 lleocaecal,
stenotic
39 F N 10 Nil m/m
2 lleocaecal 28 F N 0 Nil 5.20 <0.5 8 46 m/m
3 lleocaecal 47 F N 4 Nil 5.00 <0.5 13 47 239 333 m/m
4 lleocaecal 48 M N 40 Nil 5.50 <5.0 8 50 422 w/w
5 Colonic 26 M N 0 Nil 7.10 2.4 9 49 w/w
6 lleocaecal 53 M N 0 Nil 6.50 4.6 5 52 187 252 w/w
7 Colonic 69 M N 0 Nil 8.60 2.8 45 289 486 w/w
8 lleocaecal 37 M N 0 Nil w/w
9 Ileocolonic,
previous
fistulation
53 M N 0 Nil 5.60 1.5 8 49 519 542 m/m
10 lleocaecal 18 M N 0 Nil 4.90 <5.0 7 45 w/w
11 Colonic 47 M N 5 Nil 4.36 6.0 46 w/w
12 Ileocolonic,
previous
fistulation
70 F Y 30 Aspirin
Loperamide
Buscopan
5.75 <5.0 13 44 626 w/w
13 lleocaecal,
stenotic
43 M Y 20 Nil w/w
Table A1.5 Characteristics of Crohn's patients in skin window study.
WCC: white cell count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; w/w: wild type; m/w: simple heterozygote; m/m: compound heterozygote/homozygote.Ulcerative Colitis Patients
ID Extent Aqe Sex
Current
Smoker
Pack-
Year
History Medication
WCC
(x10®/U
CRP
(mq/L)
ESR
(mm/h)
Albumin
(q/L)
B12
(nq/L)
Red Cell 
Folate 
(ttg/L)
CARD15
Genotype
1 Pan-colitis 38 M Y 15 Nil w/w
2 Pan-colitis 54 M N 5 Mesalazine w/w
3 Proctitis 42 F N 0 Nil w/w
Table A1.6 Characteristics of ulcerative colitis patients in skin window study.
WCC: white cell count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; w/w: wild type; m/w: simple heterozygote; m/m: compound heterozygote/homozygote.
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Rheumatoid Arthritis Patients
ID Diaqnosis Aqe Sex
Current
Smoker
Pack-
Year
History Medication
WCC
(xiO^L)
CRP
(mg/L)
ESR
(mm/h)
Albumin
(g/L)
B12
(ng/L)
Red Cell 
Folate
(^g/L)
CARD15
Genotype
1 Rheumatoid 
arthritis, sicca 
syndrome
38 M N 7 Nil m/w
2 Rheumatoid
arthritis
48 F N 5 Nil w/w
3 Rheumatoid
arthritis
42 F N 3 Nil w/w
Table A1.7 Characteristics of rheumatoid arthritis patients in skin window study.
WCC: white cell count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; w/w: wild type; m/w: simple heterozygote; m/m: compound heterozygote/homozygote.Non inflammatory Disease Controls
ID Diagnosis Age Sex
Current
Smoker
Pack-
Year
History Medication
WCC
(xIO^L)
CRP
(mg/L)
ESR
(mm/h)
Albumin
(g/L)
B12
(ng/L)
Red Cell 
Folate 
(ug/L)
CARD15
Genotype
1 Healthy 24 F N 0 Nil 8.98 0.4 w/w
2 Healthy 26 M Y 2 Nil 6.25 w/w
3 Healthy 41 M N 0 Nil 5.37 3.4 w/w
4 Healthy 24 M N 0 Nil 6.29 1.3 w/w
5 Healthy 61 M N 0 Nil 5.16 1.0 w/w
6 Healthy 27 F Y 2 Nil 6.91 0.3 w/w
7 Healthy 28 F Y 3 Nil 7.07 1.0 w/w
8 Healthy 43 M Y 10 Nil 4.26 0.5 w/w
9 Healthy 45 M N 0 Nil 4.40 0.7 w/w
10 Healthy 22 F N 0 Nil 5.87 1.1 w/w
11 Healthy 21 F N 0 Nil 6.26 1.3 w/w
12 Healthy 25 M Y 0.5 Nil 6.50 1.8 w/w
13 Healthy 21 M N 0 Nil 4.41 0.4 w/w
to
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Table A1.8 Characteristics of non-inflairmiatoiy bowel disease controls in bacterial injection study.
WCC: white cell count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; w/w: wild type; m/w: simple heterozygote; m/m: compound heterozygote/homozygote.to 'O
Crohn's Patients
ID
Site & 
Behaviour Age Sex
Current
Smoker
Pack-
Year
History Medication
WCC
(xlO*/L)
CRP
(mg/L)
ESR
(mm/h)
Albumin
(g/L)
812
(ng/L)
Red Cell 
Folate 
(f9/L)
CARD15
Genotype
1 lleocaecal,
stenotic
39 F N 10 Nil 9.30 <5.0 49 398 m/m
2 Colonic 41 F N 5 Nil 6.46 <5.0 5 47 349 w/w
3 Colonic 26 M N 0 Nil 6.39 <5.0 38 400 w/w
4 lleocaecal 67 M N 0 Mesalazine
Ibuprofen
Codeine
Paracetamol
6.18 <5.0 5 47 728 542 m/m
5 lleocaecal 43 F N 0 Azathioprine
Pentasa
5.87 <5.0 8 46 229 m/m
6 lleocaecal,
stenotic
26 F N 0 Mesalazine 5.69 <5.0 7 46 374 w/w
7 Ileocolonic,
prevous
fistulation
71 F Y 30 Aspirin
Loperamide
Buscopan
7.25 1.8 15 45 375 w/w
8 Ileocolonic 54 F Y 70 Nil 6.91 4.5 43 482 m/w
9 Colonic 44 M Y 10 Nil 7.79 2.4 5 42 508 w/w
10 Colonic 43 M N 0 Methotrexate
Mesalazine
Metronidazole
8.77 1.4 w/w
11 Colonic 69 M N 0 Mesalazine 8.98 1.5 45 289 w/w
12 Colonic 65 M Y 38 Mesalazine
Lansoprazole
9.31 3.7 5 42 532 w/w
Table A1.9 Characteristics of Crohn's patients in bacterial injection study.
WCC: white cell count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; w/w: wild type; m/w: simple heterozygote; m/m: compound heterozygote/homozygote.to -o
to
Ulcerative Colitis Patients
ID Extent Age Sex
Current
Smoker
Pack-
Year
History Medication
WCC
(x10®/L)
CRP
(mg/L)
ESR
(mm/h)
Albumin
(g/L)
B12
(ng/L)
Red Cell 
Folate 
(^g/L)
CARD15
Genotype
1 Pan-colitis 50 F N 15 Polyethylene 
glycol '3350'
6.58 0.6 10 49 w/w
2 Left-sided 23 F N 0 Olsalazine 4.84 0.7 7 48 w/w
Table Al.lO Characteristics of ulcerative colitis patients in bacterial injection stucfy.
WCC: white cell count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; w/w: wild type; m/w: simple heterozygote; m/m: compound heterozygote/homozygote.Appendix 2: Microarray Data
A2: Raw and normalized data
The following tables present data from the microarray experiments in Chapter 5, 
first before normalization then scaled values. Genes and ESTs for which at least 
2-fold  differences  in  expression  were  detected  are  provided,  regardless  of 
statistical significance. The data set covers each group of subjects in the relevant 
pools, with and without MDP;  labels refer to Affymetrix annotations.  Methods 
for data collection  and  normalization  are  detailed  in  Chapter 2  (see  2.5.4  and 
2.5.5).
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202357_s_at 35.9 89.4 6.6 104.9
204748_at 16.2 12.8 12.7 327.2
214974_x_at 2.5 15.2 3.2 46.4
209774_x_at 9.6 27.8 30.1 67.6
202688_at 67.2 173.6 21.8 252.6
210511_s_at 132.1 145.9 1 1037.3
205890_s_%t 38.4 267 36 521.2
208747_s_at 55.4 128 4 195.3
204470_at 6.9 26.4 8.8 20
214038_at 9.2 338.2 11.9 282.1
204614_at 1.5 27.2 11.5 78.5
217165_x_at 29.4 205.1 100.6 136.8
205000_at 118.5 140.5 1.9 203.9
204409_s_at 112.7 117.2 0.3 196.9
201909_at 587.1 719.1 12.4 628.1
216598_s_at 32 1350.5 278 201.3
MDP
2078
849.5
1017.4
2448.7
3314.5
2092.7 
387.3 
281.1
267.5
1735.8
1957.9
184.9
999.2
364.2
141.3
365.7
563.2
171.9 
117
140.1 
41.8
535.9
239.4
158.3
166.4
160.9
124.2
591.7
485.2
85.9
650.3
155.5
125.8
868.3 
2186.7
Table A2.1: Pre-Normalisation Data
NIL  MDP
180.3
1640.5
1664.3
2706.7
3723.4
2962.2
415.7
113.5 
488
2032.6
2750.6
258.3
1165.8
169.5
1232.2
460.7
927.2
564.2
507.5
240.5 
515
1390.1
704.4 
295
1808.6
600.1
302.2
1072.7 
1894.6
729.5
625.7 
199.1
175.3
670.6
2282.9
2
66.2
128.8
93.9
175
136.7
51.8 
3.4
25.2
14.8
69.7
36.3
111.7
32.1
2.3
25.2
21.7
12.3
21.9
14.3 
20.6 
111.8
19.7
29.6
132.1
12.3 
5.2
14.9
31.1
6.6
94.4 
1
0.4
22.9
292.4
16.7
25.8
67.2 
200.3
90.9
97.4
70.6
2.3
30.9
30.2
52.2
32.9
132.8
32.1
17.6
11.4
64.4
8.3
22.7
33.2
12.5
8.3
14.3
15.6
66.9
39.9
165.8 
7
6.1
13.5
83.4
201.9
138.2
557.9
360.9
4.1
73.3
163.1 
126.9
90.5
46.8 
27
1.1
30.3
38.9
15.1
16.9
86.2
24.2
2.3
14.8 
19 
1.6 
21.1
23.6 
7
6.3 
10.4
30.2
101.2
2.8 
3.8 
4.5 
14.3
6
105.5
0.5
0.2
15.9
59.9
29.5 
110.1
212
388.6
324.7
156.9 
68.2
24.9
70.8
65.8
490.4 
38
250.1
23.9
30.4
4.5
106.3
8.9 
152.6
58.7
8.5
7.9 
8.1
78.9
123.5
118.7
139.6
9.9 
34.5 
13.4
62.1 
5.6 
0.5 
15.8
119.3
18.4
48.9
72.4
345.3
484.3
267.2
41.9
15.5 
54 
73
86.8
42.5
74.8
19.6 
8.1
35.6
56.9
15.7
42.9
15.9
21.2
19.4
20.4
22.8
95.7
66.7
30.6 
10.2
26.9
30.1
56.7
125.1
57.6
652.6 
353.3
0.9
72
143.6
152.9
76.1
80.5
29.8
1.8
34.3
35.1
15.3
17.5
91.4
30.1 
4.8
8.3
25.5
4.2
10.7
17.7
19.9
9.2
14.3
39.5
96.2
3.5
1.9
6.4
5.8
1.4 
71.6
5.7
2.9 
17.8
53.5
NIL
1.5
61.3
111.9
156.3
120.3
86.9
57.9
3.7
39.8
34.3
109.9
31.5
222.9
23.5
4.5
13.8
92.8
5.7
67.4 
36.6
14.5 
20.4
19.6
62.3
82.3
60.9 
107.5
7.9 
65.1
8.5 
116.2 
99.8
80.5 
625.2 
406.7
MDP
168.4 
2037.9
1759.3 
2299.2
2954
2267
636.5 
62.1 
409.7
1651.8
2101.5
324.3
807.8
73.1 
1629.9
566.8
512.8
697.3
245.4
140.1
983.4 
1040.7
709.4
114.3
1487.4
315.8
241.8
711.3
1217.4 
67.5
314.2
147.2
108.9 
558.6
292
NIL
11
47.5
96.9 
278
142.9 
136.3
39
27.5
30.2
66.3
37.3 
21.1
88.7
42.6
4.7
18.6
23.8
10.3
22.4
32.2 
12.6 
47.6
14.5
86.3 
52 
12.1
19.3
13.1
55.8
12.6 
468.5
84.3
102.3
545.1 
155
MDP
107.4 “
1608.8
1523
2539.6
2727.9
2122.6 
285.5
54.6
190.6
1457.9
333.9 
122.8
580.8
55.9
898.4
127.2
190.2
300.7
60.4
74.8
570.2 
1094.6
293.8
24.6 
861.1
31.6
26.5
159.1
133.3
207.7
312.8
166.5 
107
678.4
124.1
Mi P-1 delta 
TSG-6 
TSG-6 
IL-8 
IL-1beta 
IL-1beta 
PDE-5 
EBI-3 
Hypothetical Protein 
IL-8 
IDO 
PDE-5 
G  TP Cyciohydrolase 
TSC403 protein 
MiP-3aipha 
IL-1 alpha 
CD38 
GRO-3 
HM74 
Properdin 
COX-2 
Not Processed 
MIP-2alpha 
TRAIL 
lnhibin-t>etaA 
Ubiquitin-like protein FAT10 
01 Esterase 
Neutrophil-activating Protein-3 
MCP-2 
PAI-2 
Metallothionein-1F 
DEAD-box Protein-3 
Eukaryotic Translation Initiation Factor 1A 
40S ribosomal protein 
MCP-1
to
s;NIL MDP NIL MDP mJSLmt MDP NIL MDP
203915_at 241.2 1351.5 86.1 923.2 453.8 2109.4 79.3 89.3 26.5 204 114.6 39.1 279.6 1034.4 40.3 74.9 MIG
204533_at 63.3 2054.2 48.7 1200.1 530.8 1746.8 108.7 46.6 33.3 137.9 67.3 27.8 402.3 528 95.7 69.5 IP-10
203290_at 34.2 105.4 35 27.5 3914.5 110.6 5.4 1569.2 9.5 5.4 715.1 5.8 424.1 1516.2 14.5 3 HLA-OQalphal
219519_s_at 24 277.3 10.8 54.2 195.9 260.5 2.2 4.4 6 35.6 23.5 4.3 42.5 42.1 110.8 32.5 Sialoadhesin
208075_s_at 36.4 224.4 166.9 81.2 123.4 763.2 120.9 63.6 25.9 45.3 79.9 8.9 51.6 77.6 78.8 54 MCP-3
220655_at 1.5 1.5 1.1 14.6 48.5 31.2 3.7 1.9 5 2.9 2.3 1.1 1.5 35.4 1.9 11.6 Hypothetical Protein
205990_s_at 4.6 5.5 12.1 36 55 28.1 11.3 7.7 5.1 2.6 3 3.3 7.4 50 10.1 46.7 WNT-5A
205767_at 5.2 10.6 6.1 53.5 169 87.2 22.1 5.2 4.9 10.4 9.4 4.8 8.4 234.4 10.9 94.8 Epiregulin
203835_at 5.9 5 2 18.1 54.6 38.6 7 4.3 4.8 4.8 7.7 4.7 16.4 26.2 3.7 48.7 CARP
207533_at 0.9 4 1.2 44.2 72.6 19.8 2.4 4.5 1.8 11.3 2.9 2.3 3.2 16.6 3.2 1.7 1-309
218880_at 11.1 23.5 12 53.1 152 94.9 26.3 20 25.7 12 26.1 26.3 34.9 161.6 27.4 86.1 Hypothetical Protein
210548_at 11.5 6.3 16.4 32 63.9 118.5 5.3 4.2 18.9 4.3 21 20.7 13.5 64.5 8.8 76.3 HMRP-2A
204698_at 1.2 4.9 5.9 16.6 114.6 43.9 2.5 1.4 1.3 2.7 2.2 1.2 1.9 44 3.5 10.8 ISG20
204879_at 1.8 2.6 1.1 7.4 72.8 76.5 44.9 4 8 1.5 3.6 15.7 2.1 10.8 29.9 111.6 T1A-2
41577_at 14.5 34.1 4 40 73.3 62.8 4.7 49.6 2.3 19.3 4.5 2.6 15.4 37.2 4.4 14.5 Hypothetical Protein
204156_at 22.8 26.1 2.4 45.8 58.6 73.2 26.5 25.3 14.6 23.3 2.1 26.7 15.9 55.8 16.9 40.7 EST
222326_at 4.5 14.9 11.2 18.2 105.2 57.6 7.7 10.1 5.9 7.2 14.9 7.2 8.3 99.1 5.9 45.7 EST
212823_s_at 7.3 41.9 14.2 39.9 69.1 101.6 19.1 32.8 24 26.7 5.5 30.1 32 52.6 5.2 42.9 Hypothetical Protein
206148_at 11 36.4 4.1 32.1 109 50.5 3.7 4.4 3.6 17.7 25.3 3.1 13.4 33.5 3.4 5.8 IL-3RA
209795_at 18.5 40.1 33.6 39.6 56.5 98.3 15.7 37.2 13.1 16.4 7.8 19.2 30.5 46.3 20.2 17.1 0069
215101_s_at 0.8 0.3 0.3 5.9 782.3 183.7 14.9 0.9 0.3 0.5 8.5 0.6 1 762.5 8.6 857.4 ENA-78
210773_s_at 19.8 35.3 15.1 47.6 129.3 40.7 18.4 16.2 18.5 26.7 11.7 9.9 14 101 25.4 96.5 Lipoxin A4R
203828_s_at 21.8 80.4 5.7 52.2 174.3 119.6 5.2 31.5 1.5 19.9 6.9 5.2 45.7 164.4 3.2 7.9 NK4
209339_at 35.2 75.1 22 62.6 81 95.4 72.1 57.2 56.7 14.5 6.4 40.7 72.1 88.5 43.3 44.5 hSIAH2
219423_x_at 10.5 28.5 28 21 60.7 59.6 24 29.1 13.6 18.2 5.4 6 35.8 31.9 21 21.4 TNFRSF12
218983_at 54.7 107.2 8.7 192.7 195.1 75.9 16.4 57.5 20.8 29.6 15.6 29.5 65.8 150.6 26 65.1 Complement Cir-like proteinase
218995_s_at 11.8 39.2 2.7 139.8 563.8 32.6 22.1 1.3 7.5 30 18.9 13.5 15.7 252.8 20.8 310.9 Endothelin-1
205146_x_at 4.5 29 1.7 19.8 31.4 36 7.3 8.5 21.1 3.2 3.7 23.2 29.8 20.2 6 22.1 AP&A3
204439_at 6 64.6 2.2 45.9 74.3 48.9 4.4 2.2 1.3 11.8 16.9 1.3 7.8 27.9 135.1 28.7 Hypothetical Protein
205001_s_at 32.1 44.6 5.4 40.8 66.4 56.3 3.8 41.7 6.4 1.9 30.3 1.7 45.2 37.8 28 46.3 Dead box, Y isoform
213173_at 20.6 19.5 1.9 27.1 42.5 24.8 20 18.9 15.1 15.4 1.3 16.8 18.8 34.7 15.2 30.1 Hypothetical Protein
209304_x_at 19.7 52.7 45.8 48.2 54.5 90.3 6.8 10.3 13.9 49.1 10.4 3.7 26.1 51.6 7.5 28.6 GADD45B
206187_at 4.3 25.9 19.5 13.3 41.1 82.6 24.6 18.2 28.3 5.8 9 12.6 15.4 31 16.8 35.2 Prostacyclin Receptor
216614_at 10.1 49.1 10.6 22.8 50.4 116.1 24 17.4 29 3.5 13.4 20.3 28.8 38.7 16.1 29.9 EST
209583_s_at 23.6 20.6 19.4 24.7 23.8 51.1 13.8 32 2.3 12.5 6.8 4.1 15.6 9.4 13.2 8.3 my033
204166_at 5.1 61.6 6.7 22.8 82.2 63.2 11.6 1 29.8 26.4 3.7 16.6 28.3 30.6 25.3 44.4 Hypothetical Protein
to 'O L ANIL MDP NIL MDP NIL MDP NIL MDP
210229_s_at 12.5 40.3 “!F 36.7 116.9 23.2 3.7 12.8 1.7 53 5.4 2.3 25.9 47.6 6.6 2.4 GM-CSF
210354_at 31.8 95.1 21.3 139.2 299.6 41.8 19 31.1 8.6 47.8 21.5 13 27 217.5 17.3 22 INF-gamma
207072_at 16.5 44.8 64.3 37.6 86.2 133.9 13.2 34.8 8.7 13 16.2 28.9 31.2 57.1 16.8 28.2 IL-18R-associated Protein
206341_at 11.1 38.6 1.4 52.5 141.6 13.7 7.6 9.4 0.9 21.8 11.6 4.5 7.7 97.4 6.8 5.4 IL-2R
214329_x_at 8.9 47.5 10.3 73.6 69.5 18.1 11.6 8.7 9 5.1 0.6 16.7 9.1 39.6 27.3 9.7 EST
205207_at 18.5 27.2 19.1 25.2 418.4 45.7 19.5 16.9 15.9 24.2 14 9.9 18.4 378.1 18.7 27.2 IL-6
203249_at 55.9 46.9 22.6 57.1 43.5 77.9 34.7 52.2 42.9 5.1 5.3 62 47.7 37.3 38.5 51 EST
212999_x_at 321.7 292.1 268.5 339 284.7 18.1 124.8 15.8 1 222 2.4 13.7 152.8 261.6 35.4 38.7 HLA-DQbetall
221807_s_at 6.7 50.8 9.5 28.6 38.2 25.8 19.4 15.7 23.6 5.6 4.2 19.9 45.1 34.4 25.7 50.7 Hypothetical Protein
204410_at 81.6 63.7 3.7 88.7 70 56.8 2 64.2 4.4 0.5 41.8 1.7 41.8 59.9 49.3 63 Translation initiation factor 1A
202661_at 8.2 35.9 26.9 19.7 28 47.9 25.1 31 31.8 2.3 2.1 41.6 27.9 36.6 16.9 28.3 Inositol 1,4,5-Triphosphate Receptor-2
214131_at 23.7 41.6 8.8 19.5 37.6 42 7.4 31.8 5.5 1.9 22.2 5.3 22.2 21.8 19.7 38.6 EST
209392_at 55.4 121.5 21.6 47.4 88.6 130.9 69.3 77.1 8.6 17.4 34 10 36.5 58.8 40 35.6 Autotaxin
210116_at 21.5 40.3 24.7 21.4 40.4 40.3 7.3 30.8 6 19.5 2.6 6.2 17.3 18.4 6.2 4.8 T cell signal transduction molecule SAP
214567_s_at 6.9 74.7 38.6 16.1 42.2 227.7 1.8 24.1 2.7 39.6 2.1 12.6 9.6 1.3 8.5 2.8 SCY-C2
217584_at 33.1 40 15.4 38 43.9 24.6 4.9 18.4 36.7 6 3.6 25 25.8 31.6 22.4 26.8 EST
213915_at 18.2 101.6 65.1 21.2 126.5 128.7 1.9 27.1 17.5 24.4 3.4 14 25.9 31.7 19.9 19.4 NKG7
211122_s_at 4.9 109.2 9.8 41.1 85.2 9.2 1.6 6.2 2.1 8.8 1 5.9 7.8 11.2 6.1 7.1 H174
214450_at 2 92.9 61.5 1.7 84.4 162.1 7.5 40.1 7.5 6.1 7.9 6.3 37.3 27.8 21.5 14.8 Cathepsin W
220005_at 26.2 67.2 13.9 44.7 24.8 40.7 3.3 27.1 0.9 1.8 8.3 7.7 17.5 0.9 1.7 2 GPR86
219725_at 1307.7 1026.1 1584.2 534.7 254.3 259.9 1110.3 872.3 1006.8 769.6 1441.8 951.7 940.8 540.7 982.9 749.2 TREM-2
220380_at 298.5 161.4 256.8 137.4 42 5.7 147.9 374 324.4 139.3 436.3 336 307.9 197.9 325.2 149.2 DNAse-llbeta
204141_at 506.1 250.6 605.1 224.4 114.1 45.6 559.5 1005.7 560.6 420.5 394.1 527.3 536.1 357.5 571.3 399.7 Tubulin-beta
201005_at 1250.6 654.6 1260.4 684.3 247.9 199 1014.6 572.9 1630.8 899.3 905.6 1321.4 1087.1 684.1 1084.8 861.7 CD9
202741_at 822.2 480.1 939.7 493.4 226.5 147.8 719.5 1047.2 772.2 673.2 1033.1 903.1 718.3 452.7 709.6 457.5 EST
219045_at 265.5 182 270.2 166 156.1 86.1 247.2 218.2 274.9 647.8 600.8 256.4 258 170.8 285 225.3 Hypothetical Protein
212949_at 902.3 394.1 400.9 454.1 123.8 3.4 558.8 665.8 689.2 631.4 1300.6 564.1 677.6 271.9 627.6 310.5 HCAP-H
201125_s_at 493.3 229.5 669.2 286.9 127.6 46.5 449.9 372.5 450.6 565.1 540.9 445.6 350 263.6 346.5 293.2 Integrin-betaS
212552_at 1075.1 857.5 1845.4 452.3 531.4 251.7 965.5 1615.2 1171.7 1125.2 1312.7 1100.3 1323.7 856.9 1316.2 985.6 Hippocalcin-like-1
217963_s_at 298.7 88.3 139.3 95.5 72.3 22.1 527.1 143.9 690.2 294.9 155.6 636 304.6 274 404.1 599.9 p75NTR-associated Cell Death Executor
210136_at 175.7 292 462.1 97.8 183.9 61.9 112.8 288.9 384.3 323.2 534.6 484.9 296.3 123.5 227.8 268.3 Myelin Basic Protein
203980_at 974.3 568.4 3451.8 502.9 75.3 10.4 1299.9 2373 92.7 1936.4 1533.4 88.6 1869.7 1479.3 1433.4 998.3 FABP4
201540_at 247.6 105.1 578.1 107.9 47.6 39.5 304.1 346.8 297.5 190 210.9 319.2 202.2 122.8 268.2 168.8 FHL-1
204580_at 343.2 167.4 305.6 287 83.7 27.2 664.6 1691.9 66.7 299.6 955.6 85.7 818.5 914.1 277.5 335.9 MMP12
208423_s_at 203.3 230.7 563.9 155.7 153.7 37.9 154.8 197.8 189.2 280.4 644.6 237.5 134.5 122.9 218.3 248.4 MSR1
202575_at 1130.5 793.6 274.3 631.4 284.1 12.9 731 422.4 1788 617.2 486.7 1528.5 795.6 579.8 827.7 734.1 CRABP2
to «o
ONNIL  _ MDP NIL MDP NIL MDP NIL MDP
220475_at 139.3 128 5 * 115.6 91.3 114.1 125.3 95.7 180.2 234.4 295.7 225.8 229.3 134 218.3 205.7 CNT3
211887_x_at 268.5 238.1 739.8 215.6 197.4 41.5 194.9 255.2 275.1 352.7 708.4 315.8 173.2 166.7 281.2 370.2 SR-A
218856_at 624.7 170.3 189.6 336 67.8 9.8 304.5 184.9 317.7 244.5 219.2 265.2 207.8 125.8 183.6 111.3 Hypothetical Protein
218885_s_at 652.7 278.8 249.5 491.3 117.2 14.3 459.9 550.9 502.3 340.7 246.7 498.5 577.4 288.9 608.4 276.2 Hypothetical Protein
2044M_s_at 444 214.2 106.9 264.6 63 2.6 518 329.4 114.8 320.7 464.6 123.5 270.7 181.1 232.2 140.6 SCL2A5
211470_s_at 149.2 98.1 91.8 102.6 78.2 5.7 60.5 120.1 38.2 250.2 280.2 55.5 83.6 76.9 191.9 131.3 SULT1C1
208168_s_at 1806.5 1206.7 871.4 2056.3 709.1 3.4 119.2 1114 1181.8 662.6 4793.7 961.4 1301 617.2 1256.6 901.5 Chitinase-1
210138_at 214 63.7 63.5 131.9 30.1 6.3 78.3 162.5 154.5 126 163.5 142.7 149.4 69.2 139.1 97.5 RGSZ1
202450_s_at 707.3 424.5 213.5 474 316.4 96.5 400.8 693.3 835.5 864.9 1673.1 795.5 1443.5 1203.6 1349.6 1119.9 Cathepsin K
221728_x_at 9 25.8 557.6 5.3 15.4 16.8 617.9 8.7 645 470.1 31.3 582.6 161.6 127.8 221.8 108.3 EST
204517_at 226.8 118.5 71.3 208.3 82.4 1.7 96.4 202.6 187.4 164 179.5 165.7 165.5 144.2 200 203.3 Cyclophilin 0
215856_at 82.6 48.1 80.5 128.9 56.7 15 52.7 194.4 220.4 131.5 345.2 269 203.8 191.3 137.3 151.9 EST
211748_x_at 315.3 270.9 67 245.2 249.5 21.1 72.4 190.4 772.8 580.1 235.1 476.3 527 361 416.4 495.2 Prostaglandin 02 Synthase
206881_s_at 3.8 69.8 255.7 2.8 217 47.5 193 478.4 380.1 306.8 452.8 381.2 460.6 370.5 360.6 240.1 LILRA3
219225_at 161.8 25.9 54.8 80.3 67 3 165.7 49.4 64.7 159.4 87.9 76.8 70.5 61.3 94.5 64.7 Hypothetical Protein
201058_s_at 149.7 22.8 96 78.4 110.7 1.9 60.9 206.5 103.6 58.9 232.8 76.9 192 109.7 146.1 91.6 MRLC-2
202134_s_at 134.1 21.9 66.3 111.6 53.5 3.1 45.8 93.9 114.9 119.8 133.3 98.5 88.6 85.2 107.3 68.3 TAZ
201904_s_at 93.9 19.3 18.1 18.8 32.1 4.6 14.8 46.7 101.5 62.8 86.3 91.7 89.8 26.3 55.8 28.5 HYA22
201474_s_at 81.3 16.7 108.9 38.4 75.2 3.4 119.7 72.2 157.5 71.1 126.3 129.8 152.2 69.9 91.4 76.8 CD49C
219263_at 67.9 21.2 20 52.9 27.3 0.3 96 46.2 82.8 57.9 64.4 68.3 63.7 53.4 59.4 69.3 Hypothetical Protein
211126_s_at 64.7 7.3 11.9 38.6 47.8 2.6 38.2 38.9 53.9 45.1 72.4 48.1 76.7 44.2 76.5 84.7 h-SmUM
204412_s_at 62.6 16.2 39.1 10.7 35.6 16.1 69.5 103 58.4 93.5 114.8 57.8 10.5 49.6 93.8 70.3 Neurofilament, Heavy Polypeptide
210402_at 53.1 18.9 4.3 12.9 38 1.8 26.7 66.6 59.4 33.6 34.8 61.7 35.6 25.7 164.7 67.3 ROMK1
201905_s_at 52.1 13.3 17 32.1 28.1 1.9 36.8 50.3 31.2 34.6 65.5 41.3 37.3 29.6 39.1 14.1 HYA22
204083_s_at 50.1 4.7 24.4 17.5 24.4 3.9 109 34.9 28 41.3 44.2 24.2 43.6 33.2 35.2 14.9 Tropomyosin-2
216604_s_at 49.2 73.9 204.6 26.6 69.1 2.2 56.3 43.4 62.5 117.2 136.6 62.6 130.3 36.3 93.4 141.4 SCL7A8
214040_s_at 30.1 25.5 40.1 3.7 58.5 39.5 59.5 3.8 110.8 156.8 104.3 95.6 51.8 23.2 34.3 44.8 Gelsolin
216603_at 29.7 48.4 73.7 11.8 49.7 2 25.7 12.5 41.7 65.9 108.9 37.6 63 19.1 45.3 81.8 SCL7A8
210298_x_at 29.1 3.7 74.2 13.1 19.7 2.3 58.8 29.9 63.1 22.1 32.7 76 34.7 14.7 54.8 35.1 FHL1
208422_at 26.8 22.6 339 16.6 18.9 1.8 18.3 63.9 22.3 35.4 274 20.9 28.1 19.3 22.5 27.8 MSR1
201015_s_at 24.5 2.4 2.7 6.2 27.9 44.6 21.5 25.7 64.2 58.5 51 57.3 47 20.4 39.8 19.3 Plakoglobin
215382_x_at 23.8 9.6 3.6 14.6 33.1 9.6 878.1 9 14.8 234.5 54.5 13.4 48.5 72.1 32.6 15.8 Tryptase
210084_x_at 13.1 3.7 4.2 6.3 5 2.7 872.6 3.7 3.6 233.5 47.4 5.1 51.8 68.8 14.5 5.6 Tryptase
202112_at 12.6 8.4 32.3 4.8 18.8 5.7 20.3 60.4 39.8 27.6 54.9 32.2 26.8 13.8 42.7 22.5 VWF
219271_at 9.8 3.7 14.1 3.3 5 2.6 9.7 43.6 29.7 22.4 57.8 20.5 34.3 16.2 24.3 20.6 Hypothetical Protein
203496_s_at 8.5 31.4 83.5 1 32.9 32.8 5.4 26.8 24.9 66.5 97.3 46.5 39.9 15.8 32.6 46.4 TRAP220
K )
■-JNIL  MDP NIL MDP NIL MDP NIL MDP
214218_s_at 7.6 12.1  368  14.9  13.9  6.9  313.1 11.6 287.2 251.3 11.9 329.4 101.4 80.3 129.3 53.2 EST
204163_at 6.4 31.3  8.3  3.6  28.1  5.3  7.2 2.2 38.6 75.5 62.7 36.8 23.3 13.6 19.7 49.8 EMIUN
203215_s_at 3.5 2.6  29.6  4.6  8.7  1.8  3.1 11.5 18.5 35.3 40.2 22.8 19.1 2.2 5.9 9.2 Myosin VI
to
'O
00Table A2.2: Normalised and Scaled Data
NIL MDP NIL MDP NIL MDP NIL MDP
-1.051 -0.767 -0.917 1.122 1.135 1.277 -1.912 -0.254 -1.069 -0.025 -0.469 -2.138 -1.659* 1.032 -0.501 0.81 MIP-ldeKa
0.04 0.358 -0.411 2.076 2.51 2.198 0.54 -0.011 0.552 0.911 0.315 0.571 0.457 2.453 0.32 2.482 TSG-6
0.512 0.723 -0.395 2.097 2.519 2.316 1.006 0.525 1.002 1.377 0.63 0.998 0.8 2.37 0.719 2.448 TSG-6
-0.099 0.922 0.248 2.341 2.821 2.89 0.785 1.136 0.861 1.808 1.883 1.036 0.991 2.522 1.31 2.764 IL-8
0.307 0.989 0.897 2.425 3.02 3.088 1.221 0.694 0.671 1.681 2.154 0.605 0.841 2.665 0.937 2.808 IL-1 beta
0.262 0.951 0.591 2.204 2.878 2.788 1.048 0.733 0.3 1.163 1.677 0.64 0.656 2.514 0.911 2.653 IL-1 beta
-0.35 0.75 0.039 1.365 1.655 1.684 0.368 0.553 -0.009 0.571 0.191 0.026 0.424 1.79 0.209 1.414 PDE-5
-1.462 -0.163 -1.997 0.919 0.847 1.475 -1.54 -1.363 -1.809 -0.146 -0.606 -1.709 -1.144 0.463 0.013 0.392 EBI-3
-0.041 0.361 0.002 1.046 1.755 1.442 -0.137 0.09 0.056 0.597 0.395 0.113 0.211 1.539 0.066 1.164 Hypothetical Protein
-0.334 0.016 -0.57 1.637 2.643 2.665 -0.51 0.077 0.196 0.545 0.636 0.127 0.126 2.334 0.507 2.421 IL-8
0.752 2.054 -0.432 2.453 2.831 2.744 0.576 0.384 -0.336 1.974 0.775 -0.387 0.79 2.471 0.184 1.511 100
-0.266 0.591 -0.012 0.848 1.359 1.201 0.119 0.125 -0.273 0.155 0.203 -0.303 0.077 1.405 -0.135 0.893 PDE-5
0.939 1.823 0.788 2.038 2.297 2.304 0.907 0.906 0.643 1.495 0.656 0.718 1.193 1.926 0.67 1.853 GTP Cyciohydrolase
-0.354 0.59 -1.856 1.097 1.096 1.644 0.033 0.112 -0.071 -0.175 -0.418 0.032 -0.09 0.556 0.259 0.407 TSC403 protein
-1.078 -0.202 -1.473 1.768 2.331 1.025 -1.814 -0.225 -1.394 -0.004 -1.127 -1.103 -1.032 2.326 -0.978 2.122 MIP-3alpha
-0.567 -0.16 -0.194 0.578 1.719 1.647 -0.137 -0.468 -0.347 -1.363 0.06 -0.765 -0.393 1.724 -0.206 0.915 IL-1alpha
0.573 1.416 0.05 1.558 2.154 1.929 -0.242 0.501 -0.207 0.886 0.437 -0.071 0.693 1.667 -0.068 1.163 CD38
-1.737 -0.914 -0.909 0.424 1.845 1.153 -0.639 -0.645 -1.598 -0.878 -0.596 -1.186 -0.898 1.842 -0.538 1.446 GRO-3
0.231 0.812 -0.387 1.71 1.779 0.901 -0.235 -0.082 -0.148 1.144 0.21 -0.608 0.511 1.246 -0.102 0.455 HM74
0.166 0.677 -1.086 0.761 1.314 1.019 -0.534 0.13 -0.085 0.464 -0.586 -0.296 0.163 0.927 0.102 0.587 Properdin
-0.29 -0.468 -0.628 1.379 1.788 0.228 -0.278 -0.416 -0.768 -0.91 -0.355 -0.224 -0.365 2.038 -0.425 1.841 COX-2
-1.362 -0.367 -1.593 0.317 2.407 1.897 0.907 -0.645 -0.827 -0.962 -0.426 -0.701 -0.171 2.07 0.321 2.244 Not Processed
-0.59 -0.011 -0.023 0.522 1.983 1.37 -0.309 -0.341 -0.546 -0.945 -0.386 -0.428 -0.193 1.852 -0.346 1.432 MIP-2alpha
0.526 1.068 -0.249 1.238 1.441 1.099 -0.024 -0.292 0.054 0.674 -0.297 0.2 0.466 0.811 0.654 -0.1 TRAIL
0.914 0.966 -2.408 2.005 2.57 1.132 1.024 0.522 0.733 0.993 0.854 0.75 0.625 2.274 0.37 2.096 InNbin-betaA
0.205 1.322 0.102 1.631 1.884 1.11 -0.639 0.233 -1.283 0.965 0.564 -1.298 0.453 1.39 -0.447 0.054 Ubiquitin-like protein FAT10
0.415 0.888 -1.437 1.098 1.456 0.94 -1.243 1.03 -1.112 1.08 -0.061 -1.676 0.777 1.238 -0.185 -0.054 Cl Esterase
-0.78 -0.042 -0.885 -0.14 2.245 1.962 -0.505 -0.741 -1.017 -0.802 -0.942 -0.925 -0.712 1.853 -0.403 1.053 Neutrophil-activating Protein-3
-0.615 1.461 -0.673 1.298 2.599 1.832 0.011 -0.818 -0.367 0.086 -0.164 -0.986 0.491 2.16 0.41 0.943 MCP-2
-1.655 -0.024 -0.697 0.603 2.005 0.699 -1.076 -0.373 -0.855 -0.587 -0.074 -1.865 -0.67 0.51 -0.425 1.217 PAI-2
0.052 1.166 0.822 0.905 1.91 2.023 0.789 0.646 0.757 0.504 0.434 0.567 0.822 1.387 1.603 1.47 Metallothionein-1 F
0.851 0.943 -1.959 1.122 1.197 1.087 -2.398 1.141 -2.252 -1.207 1.068 -0.997 0.735 0.955 0.641 1.081 DEAD-box Protein-3
0.822 0.836 -3.252 1.103 1.117 0.949 -3.04 0.928 -2.767 -2.925 0.446 -1.415 0.612 0.783 0.75 0.808 Eukaryotic Translation Initiation Fact
1.769 1.905 -0.644 1.733 1.953 2.212 -0.204 1.709 -0.307 -0.469 2.393 -0.293 1.781 1.715 1.688 1.949 40S ribosomal protein
0.1 2.276 1.534 1.115 2.715 2.816 1.581 1.466 0.439 0.968 1.901 0.387 1.536 1.346 0.983 0.899 MCP-1
to
V ONIL MDP NIL MDP NIL MDP NIL MDP
1.259 2.277 0.713 1.942 2.666 1.788 0.667 0.684 -0.02 1.35 0.998 0.193 1.322 2.067 0.227 0.587 MIG
0.492 2.524 0.314 2.085 2.549 1.89 0.888 0.32 0.109 1.072 0.571 -0.017 1.53 1.683 0.712 0.541 IP-10
0.138 0.774 0.082 0.033 0.831 3.197 -1.216 2.288 -0.597 -1.233 2.467 -0.986 1.56 2.285 -0.346 -1.4 HLA-DQalphal
-0.065 1.344 -0.741 0.402 1.364 1.239 -1.845 -1 -0.855 0.108 -0.273 -1.171 0.248 0.241 0.795 0.072 Sialoadhesin
0.174 1.219 1.177 0.621 2.033 0.936 0.962 0.494 -0.033 0.28 0.709 -0.721 0.359 0.59 0.603 0.385 MCP-3
-1.655 -1.731 -2.342 -0.311 0.317 0.037 -1.481 -1.47 -0.957 -1.675 -2.137 -2.014 -1.659 0.142 -1.486 -0.565 Hypothetical Protein
-1.012 -0.966 -0.662 0.18 0.396 -0.032 -0.699 -0.687 -0.946 -1.753 -1.924 -1.335 -0.749 0.339 -0.549 0.296 WNT-5A
-0.942 ■0.579 -1.141 0.395 1.095 0.709 -0.229 -0.907 -0.969 -0.767 -1.008 -1.103 -0.677 1.22 -0.506 0.733 Epiregulin
-0.87 -1.022 -1.923 -0.194 0.391 0.176 -1.034 -1.013 -0.98 -1.317 -1.168 -1.116 -0.295 -0.029 -1.112 0.322 GARP
-1.948 -1.153 -2.281 0.291 0.568 -0.26 -1.784 -0.988 -1.532 -0.708 -1.951 -1.558 -1.227 -0.289 -1.193 -1.751 1-309
-0.507 -0.11 -0.667 0.391 1.029 0.764 -0.107 -0.153 -0.037 -0.665 -0.189 -0.052 0.136 1.008 0.011 0.673 Hypothetical Protein
-0.487 -0.886 -0.449 0.116 0.489 0.91 -1.229 -1.026 -0.21 -1.395 -0.363 -0.2 -0.406 0.485 -0.626 0.599 HMRP-2A
-1.783 -1.034 -1.165 -0.241 0.853 0.26 -1.756 -1.641 -1.715 -1.726 -2.172 -1.96 -1.524 0.266 -1.143 -0.609 ISG20
-1.55 -1.407 -2.342 -0.68 0.57 0.624 0.268 -1.054 -0.693 -2.144 -1.777 -0.371 -1.467 -0.534 0.06 0.834 T1A-2
-0.354 0.109 -1.437 0.237 0.574 0.494 -1.313 0.355 -1.394 -0.327 -1.598 -1.482 -0.331 0.171 -1.015 -0.427 Hypothetical Protein
-0.094 -0.048 -1.795 0.31 0.435 0.595 -0.102 -0.022 -0.355 -0.193 -2.21 -0.042 -0.313 0.402 -0.26 0.211 EST
-1.025 -0.379 -0.716 -0.191 0.799 0.438 -0.968 -0.535 -0.864 -1.028 -0.638 -0.852 -0.683 0.729 -0.85 0.282 EST
-0.747 0.231 -0.55 0.235 0.538 0.809 -0.331 0.124 -0.076 -0.096 -1.437 0.032 0.086 0.368 -0.921 0.243 Hypothetical Protein
-0.512 0.148 -1.42 0.117 0.821 0.352 -1.481 -1 -1.142 -0.389 -0.214 -1.373 -0.41 0.111 -1.159 -0.993 IL-3RA
-0.214 0.205 0.054 0.231 0.412 0.788 -0.468 0.194 -0.416 -0.443 -1.157 -0.246 0.059 0.295 -0.16 -0.325 CD69
-2.016 -2.679 -3.252 -0.803 2.049 1.196 -0.505 -1.888 -2.539 -2.925 -1.088 -2.389 -1.89 1.893 -0.639 2.093 ENA-78
-0.175 0.13 -0.506 0.331 0.928 0.211 -0.357 -0.271 -0.222 -0.096 -0.832 -0.656 -0.385 0.74 -0.031 0.744 Lipoxin A4R
-0.12 0.614 -1.189 0.381 1.114 0.916 -1.243 0.101 -1.634 -0.305 -1.256 -1.054 0.289 1.018 -1.193 -0.802 NK4
0.155 0.574 -0.243 0.48 0.637 0.768 0.6 0.435 0.408 -0.53 -1.316 0.218 0.549 0.665 0.268 0.266 hSIAH2
-0.539 0.004 -0.074 -0.113 0.457 0.46 -0.171 0.057 -0.395 -0.369 -1.452 -0.965 0.15 0.083 -0.138 -0.186 TNFRSF12
0.408 0.784 -0.893 1.091 1.184 0.618 -0.438 0.438 -0.156 -0.023 -0.601 0.019 0.497 0.968 -0.018 0.501 Complement Cir-like proteinase
-0.472 0.191 -1.712 0.917 1.845 0.066 -0.229 -1.683 -0.729 -0.013 -0.447 -0.464 -0.32 1.263 -0.143 1.467 Endothelin-1
-1.025 0.014 -2.037 -0.145 0.047 0.131 -1.005 -0.632 -0.148 -1.605 -1.755 -0.129 0.046 -0.177 -0.841 -0.167 APB-A3
-0.86 0.486 -1.856 0.312 0.583 0.331 -1.36 -1.388 -1.715 -0.677 -0.537 -1.911 -0.719 0.007 0.906 -0.005 Hypothetical Protein
0.102 0.267 -1.227 0.248 0.513 0.423 -1.462 0.258 -0.819 -1.976 -0.069 -1.745 0.283 0.18 0.023 0.29 Dead box, Y isoform
-0.152 -0.22 -1.959 0.025 0.235 -0.113 -0.299 -0.185 -0.336 -0.488 -2.594 -0.329 -0.217 0.131 -0.319 0.024 Hypothetical Protein
-0.178 0.366 0.271 0.338 0.39 0.732 -1.055 -0.524 -0.383 0.337 -0.927 -1.264 -0.03 0.357 -0.716 -0.007 GADD45B
-1.051 -0.053 -0.327 -0.361 0.214 0.674 -0.154 -0.206 0.017 -1.182 -1.042 -0.507 -0.331 0.067 -0.263 0.121 Prostacyclin Receptor
-0.561 0.324 -0.754 -0.069 0.341 0.896 -0.171 -0.231 0.031 -1.541 -0.723 -0.212 0.026 0.193 -0.287 0.02 EST
-0.074 -0.188 -0.331 -0.025 -0.126 0.36 -0.559 0.11 -1.394 -0.636 -1.267 -1.201 -0.324 -0.614 -0.398 -0.771 my033
-0.953 0.458 -1.076 -0.069 0.646 0.499 -0.68 -1.829 0.046 -0.104 -1.755 -0.336 0.016 0.059 -0.034 0.264 Hypothetical Protein
lo
00 oNIL MDP NIL MDP NIL MDP NIL MDP
-0.439  0.206  -1.572  0.19  0.865  -0.157  -1.481  -0.403  -1.564  0.391  -1.452  -1.558  -0.034  0.311  -0.787  -1.538  GM-CSF
0.097  0.713  -0.265  0.914  1.451  0.228  -0.335  0.094  -0.652  0.318  -0.344  -0.487  -0.011  1.178  -0.247  -0.169  INF-gamma
-0.28  0.27  0.509  0.203  0.675  0.99  -0.59  0.157  -0.646  -0.608  -0.571  0.007  0.072  0.415  -0.263  -0.016  I L-18R-associated Protein
-0.507  0.182  -2.173  0.385  0.984  -0.501  -0.977  -0.576  -1.921  -0.24  -0.839  -1.143  -0.726  0.72  -0.77  -1.037  IL-2R
-0.634  0.304  -0.774  0.568  0.541  -0.319  -0.68  -0.619  -0.627  -1.274  -3.214  -0.332  -0.631  0.206  0.009  -0.675  EST
-0.214  -0.024  -0.342  -0.014  1.659  0.287  -0.316  -0.247  -0.307  -0.166  -0.688  -0.656  -0.229  1.493  -0.203  -0.038  IL-6
0.42  0.297  -0.224  0.43  0.25  0.635  0.087  0.384  0.251  -1.274  -1.467  0.478  0.314  0.172  0.202  0.35  EST
1.424  1.374  1.51  1.398  1.419  -0.319  0.984  -0.285  -1.862  1.41  -2.103  -0.455  0.978  1.283  0.155  0.18  HLA-DQbetall
-0.797  0.344  -0.831  0.055  0.169  -0.087  -0.32  -0.289  -0.085  -1.207  -1.654  -0.224  0.282  0.126  -0.025  0.346  Hypothetical Protein
0.637  0.477  -1.492  0.669  0.546  0.429  -1.912  0.499  -1.029  -2.925  0.189  -1.745  0.239  0.442  0.34  0.481  Translation initiation factor 1A
-0.681  0.139  -0.102  -0.148  -0.025  0.317  -0.14  0.092  0.083  -1.84  -2.21  0.232  0.008  0.161  -0.26  -0.014  Inositol 1.4.5-Triphosphate Receptor-2
-0.072  0.226  -0.885  -0.153  0.159  0.231  -0.995  0.106  -0.904  -1.976  -0.318  -1.042  -0.122  -0.134  -0.174  0.178  EST
0.415  0.858  -0.256  0.329  0.692  0.975  0.572  0.602  -0.652  -0.401  0.024  -0.649  0.161  0.432  0.223  0.128  Autotaxin
-0.128  0.208  -0.162  -0.103  0.204  0.204  -1.005  0.088  -0.855  -0.32  -2.038  -0.945  -0.265  -0.231  -0.822  -1.11  T cell signal transduction molecule SAP
-0.78  0.571  0.151  -0.258  0.231  1.337  -1.986  -0.049  -1.304  0.184  -2.21  -0.507  -0.6  -1.742  -0.645  -1.443  SCY-C2
0.12  0.203  -0.493  0.209  0.255  -0.119  -1.284  -0.2  0.163  -1.158  -1.777  -0.083  -0.037  0.078  -0.102  -0.047  EST
-0.223  0.752  0.517  -0.108  0.914  0.964  -1.948  0.017  -0.253  -0.16  -1.823  -0.441  -0.034  0.079  -0.168  -0.247  NKG7
-0.976  0.795  -0.809  0.252  0.668  -0.762  -2.069  -0.809  -1.445  -0.886  -2.805  -0.976  -0.719  -0.514  -0.831  -0.868  HI 74
-1.49  0.7  0.477  -1.479  0.662  1.115  -0.986  0.236  -0.729  -1.146  -1.147  -0.935  0.174  0.005  -0.125  -0.414  Cathepsin W
-0.014  0.509  -0.564  0.297  -0.1  0.211  -1.561  0.017  -1.921  -2.014  -1.107  -0.811  -0.258  -1.951  -1.548  -1.65  GPR86
2.229  2.115  2.753  1.645  1.349  1.423  2.516  1.959  2.025  2.294  3.029  2.167  2.014  1.697  2.019  2.01  TREM-2
1.381  1.025  1.479  0.907  0.228  -1.075  1.103  1.486  1.388  1.079  2.07  1.523  1.377  1.124  1.398  1.013  DNAse-llbeta
1.684  1.284  2.079  1.174  0.85  0.285  2.036  2.039  1.696  1.864  1.989  1.802  1.693  1.461  1.714  1.622  Tubulin-beta
2.203  1.85  2.503  1.779  1.333  1.249  2.453  1.724  2.296  2.405  2.656  2.37  2.097  1.831  2.074  2.096  CD9
1.962  1.667  2.387  1.602  1.277  1.054  2.212  2.062  1.876  2.199  2.762  2.134  1.86  1.506  1.836  1.705  EST
1.314  1.006  1.514  1.01  1.045  0.701  1.463  1.184  1.205  2.172  2.327  1.356  1.276  1.04  1.324  1.268  Hypothetical Protein
2.016  1.551  1.791  1.557  0.901  -1.413  2.035  1.808  1.812  2.154  2.946  1.843  1.827  1.305  1.767  1.466  HCAP-H
1.669  1.232  2.15  1.307  0.92  0.298  1.883  1.483  1.573  2.075  2.243  1.698  1.45  1.287  1.434  1.43  Integrin-betaS
2.116  2.009  2.86  1.554  1.808  1.402  2.418  2.304  2.11  2.565  2.054  2.256  2.209  1.959  2.182  2.179  Hippocalcin-like-1
1.382  0.67  1.05  0.71  0.566  -0.189  1.994  0.951  1.813  1.612  1.243  1.918  1.371  1.300  1.52  1.873  p75NTR-associated Cell Death Executor
1.077  1.374  1.80  0.722  1.147  0.485  0.013  1.341  1.484  1.677  2.233  1.75  1.355  0.855  1.100  1.376  Myelin Basic Protein
2.06  1.767  3.299  1.612  0.591  -0.682  2.626  2.519  0.684  2.951  3.078  0.699  2.406  2.271  2.23  2.187  FABP4
1.274  0.772  2.047  0.776  0.306  0.191  1.608  1.443  1.34  1.299  1.487  1.491  1.137  0.852  1.29  1.089  FHL-1
1.461  1.047  1.601  1.307  0.657  -0.053  2.156  2.33  0.409  1.623  2.699  0.679  1.935  1.996  1.309  1.514  MMP12
1.161  1.235  2.03  0.975  1.035  0.164  1.135  1.129  1.085  1.576  2.383  1.309  0.905  0.852  1.175  1.328  MSR1
2.145  1.963  1.525  1.736  1.418  -0.541  2.223  1.554  2.348  2.137  2.158  2.46  1.919  1.737  1.922  1.997  CRABP2
to
00NIL
HCt
MDP NIL MDP NIL NIL MDP
0.944 0.891 0.919 0.685 6.85 -0.189 0.987 0.723 1.058 1.449 1.758 1.277 1.209 0.901 1.175 1.211 CNT3
1.32 1.254 222 1.152 1.191 0.224 1.297 1.272 1.296 1.739 2.459 1.485 1.049 1.026 1.317 1.574 SR-A
1.805 1.057 1.266 1.393 0.526 -0.72 1.609 1.091 1.377 1.479 1.518 1.377 1.153 0.865 1.078 0.832 Hypothetical Protein
1.83 1.347 1.458 1.599 0.867 -0.473 1.898 1.702 1.634 1.715 1.613 1.767 1.736 1.339 1.75 1.393 Hypothetical Protein
1.609 1.192 0.865 1.263 0.48 -1.588 1.982 1.414 0.804 1.672 2.121 0.904 1.304 1.073 1.21 0.976 SCL2A5
0.983 0.732 0.758 0.749 0.615 -1.075 0.477 0.85 0.186 1.495 1.715 0.41 0.634 0.585 1.103 0.934 SULT1C1
2.414 2.21 2.335 2.377 1.987 -1.413 0.952 2.096 2.115 2.188 3.993 2.173 2.199 1.772 2.156 2.124 Chitinase-1
1.19 0.477 0.5 0.885 0.02 -1.009 0.658 1.019 0.971 1.007 1.283 0.994 0.965 0.525 0.922 0.75 RGSZi
1.876 1.595 1.349 1.58 1.485 0.775 1.802 1.831 1.92 2.377 3.148 2.056 2.258 2.153 2.196 2.258 Cathepsin K
-0.627 -0.055 2.022 -0.861 -0.397 -0.368 2.105 -0.619 1.775 1.944 -0.043 1.863 1.01 0.874 1.184 0.815 EST
1.224 0.843 0.581 1.133 0.647 -1.866 0.803 1.142 1.08 1.195 1.358 1.086 1.023 0.943 1.126 1.204 Cyclophilin C
0.644 0.312 0.666 0.872 0.415 -0.442 0.38 1.119 1.171 1.038 1.882 1.386 1.142 1.104 0.915 1.024 EST
1.413 1.33 0.537 1.222 1.337 -0.219 0.603 1.108 1.876 2.093 1.574 1.739 1.684 1.466 1.537 1.754 Prostaglandin D2 Synthase
-1.122 0.531 1.476 -1.208 1.25 0.312 1.29 1.623 1.477 1.64 2.1 1.601 1.607 1.481 1.456 1.307 ULRA3
1.03 0.507 0.397 0.615 -0.073 -1.495 1.183 0.353 0.482 1.175 0.785 0.611 0.537 0.455 0.705 0.497 Hypothetical Protein
0.985 0.803 0.789 0.602 -0.153 -1.793 0.482 1.153 0.747 0.467 1.567 0.612 1.108 0.787 0.95 0.712 MRLC-2
0.922 0.375 0.53 0.794 -0.178 -1.473 0.282 0.712 0.805 0.971 1.119 0.765 0.667 0.643 0.777 0.53 TAZ
0.718 0.074 -0.38 -0.173 -0.256 -1.215 -0.51 0.321 0.735 0.512 0.771 0.72 0.675 -0.027 0.41 -0.009 HYA22
0.635 0.575 0.878 0.215 -0.347 -1.413 0.955 0.565 0.982 0.6 1.076 0.935 0.975 0.53 0.687 0.603 CD49C
0.532 -0.022 -0.31 0.389 -0.198 -3.001 0.8 0.315 0.621 0.454 0.536 0.538 0.479 0.377 0.445 0.539 Hypothetical Protein
0.504 0.308 -0.673 0.217 -0.862 -1.588 0.155 0.219 0.379 0.277 0.63 0.322 0.585 0.269 0.587 0.663 h-SmLIM
0.485 0.135 0.16 -0.48 -0.365 -0.396 0.574 0.764 0.424 0.795 0.999 0.435 -0.549 0.335 0.701 0.548 Neurofilament. Heavy Polypeptide
0.391 0.173 -1.386 -0.378 -0.269 -1.829 -0.096 0.52 0.434 0.067 0.042 0.475 0.147 -0.04 1.017 0.521 ROMK1
0.38 -0.005 -0.423 0.117 -0.488 -1.793 0.129 0.363 0.072 0.088 0.549 0.227 0.174 0.04 0.21 -0.444 HYA22
0.357 -0.088 -0.17 -0.212 -1.136 -1.323 0.889 0.158 0.011 0.214 0.234 -0.103 0.263 0.106 0.152 -0.41 Tropomyosin-2
0.347 0.525 1.319 0.015 0.579 -1.698 0.427 0.28 0.463 0.956 1.139 0.484 0.887 0.157 0.699 0.98 SCL7A8
0.065 0.427 0.178 -1.056 -0.083 0.191 0.465 -1.082 0.784 1.163 0.923 0.746 0.361 -0.098 0.137 0.27 Gelsolin
0.058 0.331 0.604 -0.426 0.316 -1.76 -0.123 -0.416 0.235 0.546 0.957 0.169 0.472 -0.209 0.293 0.642 SCL7A8
0.046 -0.214 0.609 -0.37 -1.285 -1.668 0.457 0.072 0.468 -0.231 -0.008 0.604 0.132 -0.359 0.4 0.119 FHL1
-0.001 -0.238 1.673 -0.241 -0.158 -1.829 -0.361 0.497 -0.117 0.104 1.697 -0.194 0.012 -0.203 -0.099 -0.025 MSR1
-0.053 -0.009 -1.712 -0.776 -1.554 0.271 -0.248 -0.013 0.478 0.462 0.349 0.43 0.305 -0.172 0.22 -0.25 Plakoglobin
-0.07 0.092 -1.511 -0.311 -0.691 -0.734 2.351 -0.6 -0.347 1.449 0.402 -0.468 0.323 0.548 0.109 -0.374 Tryptase
-0.412 -1.022 -1.403 -0.767 -1.285 -1.564 2.347 -1.097 -1.142 1.446 0.29 -1.066 0.361 0.521 -0.346 -1.015 Tryptase
-0.434 -0.242 0.026 -0.915 -0.774 -1.075 -0.288 0.465 0.209 -0.073 0.408 0.073 -0.015 -0.395 0.26 -0.155 VWF
-0.578 -1.022 -0.554 -1.119 -1.285 -1.588 -0.806 0.283 0.044 -0.221 0.449 -0.206 0.126 -0.303 -0.056 -0.21 Hypothetical Protein
-0.66 0.088 0.692 -1.767 0.047 0.07 -1.216 0.011 -0.055 0.553 0.867 0.301 0.212 -0.318 0.109 0.292 TRAP220
to
sNIL MDP NIL  MDP NIL MDP  ^ NIL MDP
-0.724  -0.419  1.731  -0.3 -0.547 -0.95  1.629  -0.458  1.32  1.498  -0.818 1.511 0.744 0.609 0.881 0.376 EST
-0.823  -0.005  -0.926  -1.071 0.045 -1.122  -1.015  -1.388  0.192  0.643  0.514 0.156 -0.095 -0.403 -0.174 0.335 EMIUN
-1.169  -0.695  -0.035  -0.938 -1.505 -1.829  -1.605  -0.463  -0.222  0.102  0.158 -0.14 -0.208 -1.442 -0.85 -0.708 Myosin VI
K)
00 U )